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Summary 
 
Brain-selective kinases (BRSK1 and BRSK2) are serine/threonine kinase members 
of the AMPK-related family of protein kinases, the majority of which are regulated 
by the upstream kinase LKB1 whilst AMPK itself is regulated by CaMKK.  The 
BRSKs are highly expressed in brain and have been implicated in neuronal 
polarization and the regulation of neurotransmitter release. They have also been 
shown to be involved in the basal phosphorylation of tau at the Alzheimer‟s disease 
(AD) related residue, serine 262, and are highly expressed in areas of the brain 
affected by AD, namely the hippocampus and the cortex. I have utilised the model 
organism Drosophila melanogaster to investigate interactions between transgenically 
expressed human tau, human BRSKs and upstream regulators  
 
Selective over-expression of 0N4R human tau in the Drosophila eye resulted in a 
disruption of eye morphology. In contrast, over-expression of human wild type 
BRSK2 (B-WT) had no obvious effect on the eye. However, co-expression of both 
tau and B-WT resulted in a neurodegenerative phenotype more severe than tau alone. 
This enhancement of phenotype was not observed when BRSK2 was expressed that 
either lacked the activating phosphorylation site (non-phosphorylatable, B-NP) or 
that is unable to bind ATP (kinase dead, B-KD).  Co-expression of human tau and B-
WT significantly elevated tau phosphorylation at S262, suggesting that S262 is a key 
residue for tau-induced toxic phenotypes and the BRSK/tau interaction I observe.  In 
support of this, no phenotype was observed in flies expressing the S262A variant of 
human tau with or without B-WT. 
  
To establish the upstream kinases responsible for activating human BRSK2 in 
Drosophila I removed endogenous Drosophila LKB1 by RNAi. This prevented the 
enhanced degeneration of the eye caused by tau/B-WT co-expression, demonstrating 
that LKB1 is a key upstream regulator of BRSK2.  I also found that down regulation 
of the Drosophila CaMKK homologue, CG17698, by the same method, ameliorated 
B-WT induced eye degeneration implicating a calcium-dependent pathway in the 
regulation of BRSK.  Over-expression of human CaMKKα in the CG17698 RNAi 
background prevented the rescue seen with CG17698 RNAi.  Over-expression of 
cac1, a calcium channel subunit, in the presence of B-WT and human tau 
exacerbated the B-WT induced eye phenotype in a B-WT dependent manner, 
supporting the hypothesis that the human tau and B-WT interaction can be regulated 
in a calcium-dependent manner.   
 
Expression of total BRSK2, LKB1 and CaMKK were not altered in human post-
mortem AD brain tissue when compared to control.  However, with the exception of 
LKB1, due to limited reagents and time constraints I was unable to investigate the 
proportion of phosphorylated (and thus active) to total kinase. 
 
This study defines a novel Ca
2+
-dependent regulatory pathway to tau, which may 
contribute to AD and other tauopathies.   
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2naphthylgethylidene)malononotrile) 
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Dementia is the collective name for disorders affecting memory, thinking, emotion 
and behaviour.   Most people will experience some form of dementia in their life 
time.  With Alzheimer‟s disease (AD) accounting for nearly 60% of dementia cases 
and affecting more than 20 million people worldwide (Goedert and Spillantini, 2006), 
many people will have first-hand experience of this debilitating disease.    A small 
percentage of AD cases are familial (inherited) and are linked to genetic mutations, 
but the majority of AD cases have no known cause and as such are sporadic (Robakis, 
2010a).  A major report commissioned by Alzheimer‟s Research UK into the social 
and economic impact of dementia in the UK, states that dementia treatment and care 
costs the UK £23 billion a year (Luengo-Fernandez et al., 2010).  Another report 
commissioned by the Alzheimer‟s Society forecasts that 1.7 million people in the UK 
will have dementia by 2051 (Knapp et al., 2007).  Thus, research into the cause(s) of 
dementia and the development of treatments has never been more vital. 
 
 
1.1 A brief history of AD 
 
AD was first described in 1901 by Dr Alois Alzheimer, a German psychiatrist.  His 
patient was 51 year old Auguste D. who was presented to him by her distraught 
husband.  Dr Alzheimer was intrigued by her condition and followed her progressive 
mental decline until her death in 1906, when he made his findings public.  On 
November 3 1906 he made a presentation to the Meeting of the Psychiatrists of 
South West Germany describing his observation of „tangles‟ and „plaques‟ during his 
post mortem examination of Auguste‟s brain (Hardy, 2006) and in 1907 he published 
his findings.  The disease was given its name by Dr Alzheimer‟s senior colleague, 
Kreapelin, in 1910 after he heard Dr Alzheimer‟s statement: 
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“We must not be satisfied to force it into the existing group of well known disease 
patterns.”  
 
Many of the original references are in German, as referenced in Hardy (2006) but 
there is an English translation of Alzheimer‟s original 1907 paper (Alzheimer et al., 
1995). 
 
After its initial discovery, AD faded into the background until the 1960s, when 
Blessed, Tomlinson and Roth, a trio of researchers from Newcastle, realised upon 
post mortem examination of brain tissue that the „common‟ dementia they had been 
observing in elderly patients was in fact AD (Blessed et al., 1968; Tomlinson et al., 
1968; Tomlinson et al., 1970).  Their observations brought AD research back to the 
forefront of people‟s minds and it is largely down to this trio‟s rediscovery of the 
disease that advancements have been made in the understanding of AD in the last 50 
years.   
 
The next piece of the puzzle was put into place in the early 1980‟s, when it was 
discovered that the cerebral cortex of AD brain suffers a loss of the neurotransmitter 
acetylcholine, a vital chemical component of memory (Bartus et al., 1982).  This 
discovery was the basis for the development of the first drugs for mild to moderate 
AD, acetylcholinesterase inhibitors (AChEIs), which block the degradation of 
acetylcholine by acetylcholinesterase. 
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A major leap in understanding of AD pathology was made in the mid to late 1980‟s 
upon the discovery, by several groups, of two proteins whose conformation in the 
brain was abnormal; amyloid beta (Aβ) and the microtubule-associated protein, tau 
(Glenner and Wong, 1984; Masters et al., 1985; Grundke-Iqbal et al., 1986; Kosik et 
al., 1986; Goedert et al., 1988).  The discovery of these two proteins, and their 
recognition as the pathological species Alois Alzheimer had previously described, 
later split AD researchers into two „camps‟ – the baptists and the tauists.  The 
baptists believe in the amyloid cascade hypothesis, the principles of which state that 
genetic and environmental factors combine to cause the formation of aberrant 
fibrillar Aβ plaques (extracellular deposits composed predominantly of the Aβ1-42 
and Aβ1-40 peptides, see Figure 1.1), followed by tau tangles (composed of  
accumulations of hyperphosphorylated filaments of tau in a helical conformation, see 
Figure 1.1), the combination of which causes AD (Hardy and Allsop, 1991; Selkoe, 
1991; Hardy and Higgins, 1992).  The tauists believe that hyperphosphorylated tau is 
the toxic species in AD because the presence of hyperphosphorylated tau tangles in 
the brain correlates well with the severity of dementia (Tomlinson et al., 1970; 
Arriagada et al., 1992).  In addition, in the tauopathies (a spectrum of diseases that 
cause dementia), tau tangles but not Aβ plaques are present in the brain (Iqbal et al., 
2005).  
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Figure 1.1: Examples of Alzheimer’s disease pathology 
A: Antibody stained β-amyloid plaques in the frontal isocortex. B: Electron 
micrograph of paired helical filaments isolated from Alzheimer brain. C: 
Bielschowsky stain of multiple neurons in the CA1 region of the hippocampus 
showing dense neurofibrillary tangle formation 
1
. Scale bar 100µm applies to all 
panels.  
 
 
 
 
 
 
 
 
                                                 
1
 Images taken from: 
(A) http://www.nature.com/modpathol/journal/v21/n2/fig_tab/3800994f4.html#figure-title  
(B) http://www.mpasmb-hamburg.mpg.de/webpage_tau/figure9.gif 
(C) http://brain.oxfordjournals.org/content/122/4/741.full 
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Since these initial discoveries, it has been established that AD brains undergo huge 
global cell loss.  Brains from AD patients have approximately a 50% reduction in the 
size of the medial temporal lobe (Smith and Jobst, 1996) and also exhibit pan-
cerebellar atrophy (Apostolova and Thompson, 2008).  The medial temporal lobe is 
an area of the brain comprised of the hippocampus, subiculum, parahippocampal 
gyrus and amygdala – areas of the brain that are heavily affected by tau tangles 
(Arnold et al., 1991; Smith and Jobst, 1996).  Indeed, medial temporal lobe atrophy 
correlates with both the density of tau tangles in the pyramidal cell layer of the 
hippocampus and with the degree of memory impairment (Nagy et al., 1996).  In 
addition, cell loss from the hippocampus is usually very prominent (Smith and Jobst, 
1996).  Patients that undergo yearly temporal lobe-orientated x-ray computed 
tomography (CT), and more recently volumetric magnetic resonance imaging (MRI), 
scans during life have been demonstrated to have a rate of medial temporal lobe 
atrophy of up to 15% - more than 10 times higher than the approximately 1-1.5% 
yearly atrophy rate of age-matched control subjects (Jobst et al., 1992; Jobst et al., 
1994; Apostolova and Thompson, 2008).   
 
It has also been established that in the early stages of the disease, before any 
evidence of cell loss, Aβ accumulation or tau tangles, AD causes dramatic synaptic 
loss (Mucke et al., 2000; Selkoe, 2002; Brickman et al., 2009).  Indeed, synaptic 
deterioration in AD brain correlates strongly with the severity of symptoms (Selkoe, 
2002).  Studies of post-mortem human AD brain tissue have established that the 
synaptic failure in AD is mainly due to changes in synaptic structural plasticity such 
as reductions in the number and/or density of structures such as presynaptic boutons 
and dendritic spines (Masliah et al., 1994; Mucke et al., 2000).  Synaptic loss can be 
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detected in post mortem brain tissue simply by staining for synaptic markers such as 
synaptophysin and counting the number of synapses (Brickman et al., 2009).  
However, more recently, advances in brain imaging techniques have allowed the 
development of more sophisticated methods for determining synaptic loss in the 
brain.  Functional MRI (fMRI), which relies on the fact that any synaptic changes 
will affect the rate of oxygen consumption in the brain, has been used to investigate 
synaptic loss (Brickman et al., 2009).  Although fMRI can‟t directly measure oxygen 
consumption, it can measure correlates of oxygen consumption such as cerebral 
blood flow (CBF) and cerebral blood volume (CBV) (Small, 2003).   
 
1.2 The clinical symptoms of AD  
 
The clinical signs of AD are characterized by progressive cognitive deterioration 
beginning with mild memory loss, behavioural changes and a decrease in day to day 
activities.  Often the first sign of AD is forgetting simple things such as where one 
lives or where the milk is kept.  However, these symptoms can be put down to a 
number of different causes, such as stress and general old age.  This progressive 
impairment may continue for many months affecting first declarative memory 
(memory which stores facts (semantic) and experiences (episodic)) and then non-
declarative memory (Walsh and Selkoe, 2004).  Over a period of many years, a more 
serious form of dementia develops which usually presents with a variety of 
symptoms affecting multiple cognitive and behavioural aspects such as language, 
learning, reasoning, attention, problem solving, emotion and memory.  As there is no 
cure, death is inevitable and will usually be caused by a minor complication which 
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would not normally cause death in a healthy individual, such as pneumonia (Walsh 
and Selkoe, 2004). 
 
1.2.1 The relationship between the clinical symptoms and the pathology of AD 
 
 
There appears to be a close relationship between most of the identified pathological 
changes in AD brains and the severity of symptoms in life - with one notable 
exception: extracellular amyloid plaques.  Extracellular accumulations of A  were 
one of the two original pathological hallmarks of AD identified by Alois Alzheimer 
(Alzheimer et al., 1995).  However, it has now been established that the load and 
location of A  plaques in AD brain does not correlate with the severity of symptoms 
in life (Robakis, 2010a).   
 
In contrast, the load and location of tau tangles, level of cell death and synaptic 
degeneration are known to correlate very well with the severity of dementia suffered 
in life (Grober et al., 1999).  The correlation between tau tangle pathology and 
dementia gave rise to the original Braak scoring for post-mortem AD brain tissue 
(discussed further in section 1.3) (Braak and Braak, 1991; Braak and Braak, 1997). 
The first area of the brain to be affected by tau pathology and cell death is the 
transentorhinal cortex (TE) which is a relay station between the cortex and 
hippocampus which filters sensory input (Braak and Braak, 1991; Braak and Braak, 
1997; Taylor and Probst, 2008).  As the disease progresses the pathology becomes 
more extensive and begins to affect the hippocampus and nearby amygdala (Braak 
and Braak, 1991; Braak and Braak, 1997).  The hippocampi are located one on each 
side of the brain, in the temporal lobes and have been demonstrated to be critical in 
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the formation of new memories (Thompson, 1985).  One of the most important 
studies showing the involvement of the hippocampi in memory formation was patient 
H.M.  Patient H.M had both hippocampi and parts of the temporal lobes removed in 
order to treat severe epilepsy (Thompson, 1985; Bear et al., 2007).  Although the 
surgery was successful in treating his epileptic seizures, patient H.M was left with a 
complete inability to create new memories – although his very immediate short term 
memory was unaffected.  In addition, his memories from before the surgery were left 
intact, indicating that the hippocampi are not where memories are stored but are 
essential to the encoding of them (Thompson, 1985; Bear et al., 2007).  The 
amygdala are also located deep within the temporal lobes and are thought to be 
important for the regulation of emotion, and in particular fear (Bear et al., 2007).  
Pathology in the amygdala is likely to give rise to some of the behavioural symptoms 
observed in AD such as distress, apathy, aggression and fear.   
 
Whilst tangles, cell death and synaptic degeneration in the TE and hippocampus 
account for the memory deficits seen in AD patients, it is likely that pathology seen 
in the neocortex is responsible for symptoms affecting functions such as language, 
reasoning and attention (Nelson et al., 2009).  The neocortex comprises the outer 
layer of the brain and is responsible for many higher-order processes such as vision, 
sensation, voluntary movement, imagination, consciousness and hearing (Bear et al., 
2007).  In short, the neocortex is what makes humans what they are.  The progressive 
development of AD pathology and cell/synapse degeneration in the neocortex is 
undoubtedly responsible for such symptoms as dissorientation, lack of awareness and 
a general inability to perform daily tasks (Thompson, 1985).  However, not all areas 
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of the neocortex are affected: hearing, vision and voluntary movement appear to be 
well preserved in AD patients.    
 
 
1.3 Diagnosing AD 
 
The diagnosis of Alzheimer‟s disease is notoriously difficult as subjects may present 
with varying symptoms easily mistaken for other disorders.  There are several tests 
conducted in the clinic which are designed to assess the cognitive function of 
patients, the most well known being the mini mental state examination (MMSE).  
The MMSE consists of a brief 30 point questionnaire conducted over 10 minutes 
which is designed to test for cognitive impairment by asking the patient questions 
which probe his/her orientation to time/place, recall skills (short term memory), 
attention/registration, calculation and language amongst other aspects (Harvan and 
Cotter, 2006).  A score below 24 is indicative of mild cognitive impairment (MCI), a 
score of 10-20 points is considered as moderate impairment and a score of <9 points 
is classed as severe impairment (see Table 1.1).   
 
In addition to cognitive tests, patients with suspected AD may undergo brain scans to 
aid in the diagnosis.  As previously discussed, fMRI can be utilised to assess the 
degree of synaptic deterioration due to the relationship between CBV/CBF with the 
oxygen demands of the brain (Small, 2003; Brickman et al., 2009).  Additionally, 
positive emission topography (PET) scanning in combination with injection of the 
tracer 18
F
-2-fluoro-2-deoxy-Dglucose (FDG) allows the measurement of regional 
cerebral glucose metabolism (Herholz et al., 2007).  Glucose is the main energy 
supply in the brain and its metabolism is closely coupled to neuronal function both at 
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rest and during activation (Sokoloff, 1977).  Characteristic reductions in regional 
cerebral glucose metabolism have been identified in several areas of AD brains such 
as the posterior cingulate and precuneus (Herholz et al., 2007).  MRI and CT scans 
can be used to monitor the rate of atrophy in the brain.  Brain atrophy has been 
demonstrated to be vastly increased in AD brain when compared to age-matched 
controls (Jobst et al., 1992; Jobst et al., 1994; Apostolova and Thompson, 2008).  
Positive emission topography (PET) scanning in combination with tracers such as 
18
F-(2-(1-f6-[(2-[
18
F]fluoroethyl)(methyl)amino]-2-naphthylgethylidene) 
malononitrile) (
18
F-FDDNP), a molecule that binds to plaques and tangles, or 
Pittsburgh compound B, a compound that binds to Aβ aggregates, may also be used 
in order to visualise AD pathology in live brain (Small et al., 2006; Tolboom et al., 
2009).   Pittsburgh compound B has been shown to have high sensitivity when used 
to detect amyloid plaques in vivo, but there appears to be no increase in tracer signal 
during the progression of the disease, a disadvantage when trying to differentiate 
between subjects with MCI and AD (Engler et al., 2006; Herholz et al., 2007).  
However, despite having a weaker imaging signal than Pittsburgh compound B, use 
of 
18
F-FDDNP confers the ability to differentiate between control, MCI and AD 
groups (Small et al., 2006).      
 
Despite cognitive tests which can be carried out in life such as the MMSE, and the 
development of sophisticated brain scanning, a diagnosis of AD cannot be confirmed 
until the patient has died and a post-mortem is conducted.  Upon post-mortem 
examination, the brains of patients with suspected AD undergo an examination for 
the two classical hallmarks of AD pathology (A  and tau tangles) and, historically, 
were scored according to Braak stages.  Braak stage is a measure based on how many 
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tau tangles are present in the brain and their locations (Figure 1.2) (Braak and Braak, 
1991; Braak and Braak, 1997). The location and load of tau tangles is known to 
correlate well with the MMSE score given in life (Table 1.1) (Grober et al., 1999).  
In order for a post-mortem diagnosis of AD to be made, there must be both tau 
tangles and Aβ plaques in the brain, and so some brain banks have begun to stage 
brains according to a new Brain Net Europe Consortium Scheme method which also 
takes into account the presence of amyloid plaque pathology (Alafuzoff et al., 2008). 
 
More recently, a move has been made to attempt to identify biomarkers that could 
aid in the diagnosis of AD: since Aβ and tau are the two main pathological features 
of AD, much research has focussed upon these two proteins.  A number of groups 
have shown a strong inverse relationship between cerebrospinal fluid (CSF) Aβ1-42 
concentrations and cortical Aβ deposition (Fagan et al., 2006; Grimmer et al., 2009).  
Additionally, a number of studies have demonstrated that CSF total tau and 
phosphorylated tau levels are elevated in AD, presumably as a result of cell death 
and subsequent lysis (Sunderland et al., 2003; Buerger et al., 2009; Mattsson et al., 
2009).  Although CSF total tau has been shown to increase following acute stroke 
and head trauma (Blennow and Nellgard, 2004; Ost et al., 2006; Yao et al., 2008), 
CSF phosphorylated tau appears to be a more specific marker for AD and has been 
shown to correlate with NFT load in post-mortem studies (Itoh et al., 2001; Buerger 
et al., 2006).  However, both tau and Aβ species are found in the CSF of control 
populations and as such further characterisation of these proteins as potential 
biomarkers will be required in order to ensure sufficient sensitivity and specificity 
before they can be routinely utilised in the clinic (Fagan and Holtzman, 2010; 
Robakis, 2010b).   
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Diagnosis 
Braak 
Stage 
MMSE Symptoms 
Mild Cognitive 
Impairment 
(MCI) 
2-3 26-30 
Mild memory loss/impairment 
Normal cognitive abilities 
MCI is frequently a precursor to AD but 
does not lead to AD in all cases 
Mild AD 3-4 20-26 
Mild memory loss/impairment 
Slight decrease in cognitive function 
Mild behavioural changes 
Moderate AD 4-5 11-19 
Progressive memory loss 
Increasingly disorganised and confused 
thinking 
Increasing behavioural symptoms 
Need for assistance in everyday 
activities 
Severe AD 5-6 0-10 
Severe memory loss and dementia 
Agitation, aggression, paranoia and 
delusions 
Loss of motor skills 
Patients often require hospitalisation or 
long-term care 
 
Table 1.1: Correlation of Braak stage and MMSE scores. 
Braak stage and MMSE scores show an inverse correlation; a low MMSE score, 
based on decreasing cognitive ability, indicates severe dementia whereas a low 
Braak stage, based on the load and location of tau tangles, indicates mild cognitive 
impairment.  Table taken from http://www.tau-rx.com/quiz/tangles.html 
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Figure 1.2: Braak staging of human brain 
Braak staging is based upon the number and location of tau tangles in the brain.  In 
Stage I there are minimal tangles present in the trans-entorhinal cortex (yellow).  
Most of the aged population will achieve this stage.  As the Braak Stages increase 
the load of tau tangles in the trans-entorhinal cortex increases and tangles appear in 
the hippocampus (pink) and neocortex (blue).  From Braak Stage III, extensive cell 
death is visible in the brain, first in the trans-entorhinal cortex, then in the 
hippocampus and neocortex.  Tau tangles and cell death are accompanied with 
progressively significant memory problems culminating in severe dementia.  Images 
taken from http://www.tau-rx.com/quiz/tangles.html  
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1.4 Treatment of AD 
 
In the UK, there are currently four drugs licensed for the treatment of AD.  Three of 
them, Aricept, Exelon and Reminyl are all acetylcholineesterase inhibitors (AChEIs) 
designed to prevent the degradation of acetylcholine by inhibiting the action of 
acetylcholinesterase.  However, although the three drugs are effective in slowing 
cognitive decline, their efficacy is only seen in some patients, and ultimately their 
effects are limited to preserving simple daily activities and reducing the burden 
placed on caregivers (Rosler et al., 1999; Raskind et al., 2000; Rogers et al., 2000; 
Jacobsen, 2002).  Current National Institute for Health and Clinical Excellence 
(NICE) guidelines on anti-Alzheimer's drugs recommend that people with moderate 
AD should be prescribed Aricept, Reminyl or Exelon.  The fourth drug licensed in 
the UK for the treatment of AD is Ebixa (Memantine).  Ebixa is an uncompetitive N-
methyl D-aspartate receptor (NMDAR) antagonist which slows the rate of cognitive 
decline in patients with moderate to severe AD (Reisberg et al., 2003).  In addition, 
when administered to patients with moderate to severe dementia already receiving 
Aricept, Ebixa was associated with significantly better outcomes than placebo (Tariot 
et al., 2004).    However, treatment with Ebixa is not currently recommended as part 
of NHS care.  Instead, the guidelines emphasize the importance of further clinical 
studies with Ebixa.  Thus, there are currently no licensed drugs approved for the 
treatment of mild or severe AD. 
  
Due to the limited efficacy of currently licensed pharmaceuticals, there is 
considerable interest in developing new compounds for the treatment of AD.  
However, it is proving difficult to develop new agents that successfully pass through 
all the phases of clinical trials.  Compounds that have recently failed in phase III 
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clinical trials include Ginkgo Biloba (a widely used herbal treatment), Phenserine (a 
cholinesterase inhibitor reported to inhibit Aβ formation) and Tarenflurbil (a 
„selective Aβ42 lowering agent‟) (Sabbagh, 2009).  Only limited success has been 
seen with the first trials of Aβ vaccines, but there are currently at least 9 „second 
generation‟ Aβ vaccines in various clinical trial phases (Hock et al., 2003; Orgogozo 
et al., 2003; Bayer et al., 2005; Gilman et al., 2005; Lee et al., 2005; Lemere and 
Masliah, 2010).  Also in development are pharmaceutical compounds which target 
the formation of tau tangles (Bulic et al., 2009).  The most promising candidates at 
present are Rember and LMT-X which are being developed and tested by a small 
company called TauRX
2
.  Rember, based on methylthioninium chloride (better 
known as methylene blue), can block the formation of tau tangles and has been 
shown to be effective at dissolving tangles into tau monomers which can then be 
degraded by the cell.  Phase III clinical trials for this compound are currently being 
prepared.  LMT-X is a second generation derivative of Rember.  It has shown a 
strong effect on tau pathology in transgenic models and in pre-clinical and early 
clinical trials.    LMT-X is currently in phase III clinical trials.   
    
 
1.5 Theories for the cause of Alzheimer’s disease 
 
There are many theories as to the causative agent in AD.  Although much 
information has been gleaned from various animal models of AD, it is obvious from 
the literature that the scientific community is far from agreeing on a mechanism for 
the cause.  There are many different types of transgenic models including worms, 
                                                 
2
 http://www.taurx.com/tau.htm#clinicalres 
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fruit flies and mice, expressing many different combinations of genes, both 
endogenous and exogenous.  In the following section some of the most prevalent 
theories, such as the amyloid cascade hypothesis, will be summarised and because 
the experiments presented in this study were based upon the tau 
hyperphosphorylation theory, this hypothesis will be discussed in more detail.    
 
 
1.5.1 The amyloid cascade hypothesis 
 
As previously mentioned, the amyloid cascade hypothesis states that Aβ is the 
causative pathological agent in AD and that aberrant processing of the amyloid 
precursor protein (APP) leading to the production of Aβ, precedes formation of tau 
tangles.  It is thought that altered APP processing is influenced by genetic and 
environmental factors and that the combination of Aβ and subsequently tau 
pathology leads to AD (Hardy and Allsop, 1991; Selkoe, 1991; Hardy and Higgins, 
1992).   
 
Various Aβ species (oligomers, diffusible ligands and fibrillar) have been shown to 
be toxic when applied to neurons (Deshpande et al., 2006).  However, despite a 
strong amount of evidence supporting the amyloid cascade hypothesis, the quantity 
and formation of Aβ plaques do not correlate with the neurodegenerative decline 
observed in patients and it is still not clear whether Aβ plaques are the causative 
agent of the disease (Robakis, 2010a).  Furthermore, it is possible to detect Aβ 
plaque loads similar to those seen in AD in control individuals.  This strongly 
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suggests that fibrillar Aβ plaques do not cause neurodegeneration (Crystal et al., 
1988; Davis et al., 1999).   
 
1.5.1.1 APP processing 
 
Full length APP (APPFL) is a type I membrane protein consisting of a large 
ectodomain and a short cytoplasmic tail, the gene for which is on chromosome 21 
(Evin et al., 2003; Thinakaran and Koo, 2008).  The ectodomain can be shed from 
the membrane by way of two proteolytic pathways (Figure 1.3, adapted from Evin et 
al. (2003)).  The default pathway, termed the non-amyloidogenic pathway, involves 
the cleavage of APP within the Aβ sequence by α-secretases to produce sAPPα and 
an 83 amino acid membrane associated C-terminal fragment (αCTF or C-83) (Wilson 
et al., 2003).  C-83 can be further cleaved by either the γ-secretase/presenilin (PS) 
complex giving rise to a C-terminal fragment of the Aβ sequence, p3, and an APP 
intracellular domain (AICD), or by β-secretases giving rise to two N-terminally 
truncated variants of Aβ; Aβ11-40 and Aβ11-42 (Naslund et al., 1994).  Roles for AICD 
in transcriptional activation, the modulation of inositol triphosphate (IP3)-mediated 
calcium signalling and the suppression of neurogenesis have been proposed (Cao and 
Sudhof, 2001; Leissring et al., 2002; Ma et al., 2008).   
 
During the course of the amyloidogenic pathway, β-secretases cleave APPFL to 
release sAPPβ and a 99 amino acid membrane associated C-terminal fragment 
(βCTF or C-99) that contains the intact Aβ sequence (Evin et al., 2003).  Further 
cleavage of C-99 by the γ-secretase/PS complex, at a number of residues, allows the 
release of Aβ1-40 (the most common Aβ species), the less abundant but more 
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aggregating Aβ1-42 (which is the primary species found in Aβ plaques in AD brain) 
and AICD (Selkoe, 1999; Evin et al., 2003).   
 
Studies have identified α-secretases as zinc metalloproteinases and a number of 
proteins have been implicated as α-secretases, including members of the adamalysin 
family (Allinson et al., 2003).  β-secretase has been identified as an aspartyl protease, 
BACE (β-site APP-cleaving enzyme) of which there are two isoforms, BACE1 and 
BACE2 (Thinakaran and Koo, 2008).  The γ-secretase/PS complex has been 
identified to consist of four subunits: PS1 or PS2, nicastrin, PEN-2 and APH-1 
(Iwatsubo, 2004).     
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Figure 1.3:  Schematic of the proteolytic processing of amyloid precursor protein 
(APP) 
Full length APP (APPFL) can be processed by two pathways; the non-amyloidogenic 
and the amyloidogenic pathways.  The default is the non-amyloidogenic pathway 
whereby α-secretase cleaves within the Aβ domain to release sAPPα and an 83 
amino acid membrane associated fragment (αCTF or C-83).  Further cleavage of C-
83 by γ-secretase releases the C-terminal fragment of Aβ, p3, and a fragment termed 
the APP intracellular domain (AICD).  In the amyloidogenic pathway, β-secretase 
cleaves APPFL to release sAPPβ and a 99 amino acid membrane associated fragment 
(βCTF or C-99).  γ-secretase can cleave C-99 at a number of sites, giving rise to Aβ1-
40 or Aβ1-42 species and allowing the release of AICD.  Figure adapted from Evin et 
al. (2003).        
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1.5.1.2 Mutations in APP and the presenilins 
 
The amyloid cascade hypothesis was originally formulated on the basis that 
mutations in the APP gene (such as the London V717I mutation and the Swedish 
K670N and M671L mutations) or in the PS genes, affect the metabolism or 
production of Aβ1-42 and are a rare cause of early-onset familial AD (FAD) 
(Hashimoto et al., 2000; Eckert et al., 2010).  To date, only 10% of the known FAD-
related mutations affect APP itself, with the majority (~140) affecting the presenilins, 
mainly PS1 (Randall et al., 2010).  Despite the large variety of mutations found in 
APP and the presenilins, the vast majority result in an increased Aβ1-42:Aβ1-40 ratio 
which is suggestive of a toxic gain of function of Aβ1-42 (Kumar-Singh et al., 2006).  
However, mutations in presenilins have also been associated with familial 
frontotemporal dementia, a disease where degeneration occurs in the absence of any 
Aβ pathology (Zekanowski et al., 2006).  This would suggest that increased Aβ 
production and deposition are not the only consequences of presenilin mutations, and 
that the situation may be more complicated than it was first thought.   
 
 
1.5.1.3 Soluble Aβ 
 
More recently, it has been suggested that soluble Aβ species (as opposed to fibrillar 
Aβ which is found in extracellular Aβ plaques) may be important in the pathogenesis 
of AD.  APP is a protein that localises to the plasma membrane, but it can also 
localise to the Golgi network, ER and lysosomal, endosomal and mitochondrial 
membranes (Mizuguchi et al., 1992; Xu et al., 1995; Kinoshita et al., 2003).  Thus, 
should amyloidogenic APP cleavage occur at any of these locations, the liberated Aβ 
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would accumulate intracellularly.  However, although soluble Aβ species have been 
shown to accumulate intracellularly, they are also detected in the CSF of most people 
and there is little evidence that the intracellular concentration of these species 
correlates with cognitive decline (Robakis, 2010b).  Although this is a serious flaw in 
the theory that soluble Aβ species are the causative agents in AD, the effects of 
application of soluble Aβ to neuronal cells (see section 1.5.4), on mitochondria (see 
section 1.5.3) and at synapses (see section 1.5.1.4) make soluble Aβ species the 
subject of much interest and research.      
 
1.5.1.4 APP, long-term potentiation and NMDA receptors 
 
 
Long-term potentiation (LTP) has long been considered a neural correlate for 
memory.  It results from the simultaneous activation of pre- and post-synaptic 
elements of the synapse leading to an increase in chemical transmission that can 
persist for long periods of time, typically hours in vitro and weeks or months in vivo 
(Cooke and Bliss, 2006).  The increase in chemical transmission leads to the 
strengthening of synapses and it is this increase in strength that is thought to underlie 
memory formation.  In the majority of glutamatergic synapses in the brain, LTP is 
mediated by the NMDAR. 
 
A number of transgenic mouse models of AD have been constructed expressing wild 
type APP or APP with FAD-associated mutations either alone or in combination with 
other components of the APP processing pathway – most often mutated PS1 (Randall 
et al., 2010).  APP transgenic models show an age-dependent increase in Aβ plaques 
and multiple behavioural and neurophysiological changes but do not replicate the tau 
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pathology, neurodegeneration or cell death exhibited in AD (Gotz and Ittner, 2008).  
In electrophysiological studies on brain slices from many of these models, a deficit in 
basal synaptic transmission and/or LTP has been observed (Randall et al., 2010).  
However, this observation is not made consistently in all APP transgenic models or 
even in the same model by different laboratories (Chapman et al., 1999; Fitzjohn et 
al., 2001; Jolas et al., 2002; Jacobsen et al., 2006; Townsend et al., 2010).  These 
discrepancies are likely to depend on the combination of transgenes expressed in the 
various models.  Also, different methods for the preparation of brain slices from 
transgenic animals, different brain slice incubation conditions and varying induction 
protocols for LTP would be expected to contribute to the variable results and as such 
it is difficult to compare results across laboratories and models (Randall et al., 2010).  
Nevertheless, it has been shown robustly that over expression of APP can cause a 
deficit in LTP in transgenic animal models.  Whilst Aβ plaques are known to form 
extracellularly, and as such are unlikely to affect LTP per-se, intracellular soluble Aβ 
and/or other breakdown products of APP may contribute to the memory deficits seen 
in AD.  Indeed, a number of transgenic APP mouse models exhibit memory deficits 
as tested by the Morris water maze and a number of other experimental paradigms 
(Bryan et al., 2008).      
 
Recently a role has been proposed for APP in the trafficking of NMDAR from the 
endoplasmic reticulum to the cell membrane (Cousins et al., 2009).  However, it is 
not clear if the interaction between APP and NMDAR is direct, or mediated through 
a third protein.  It remains to be seen if APP is involved in the internalisation and/or 
recycling of NMDAR, but it could be hypothesised that if APP is cleaved at the 
membrane into Aβ1-42, this may have knock-on effects on the proper insertion, 
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internalisation and recycling of NMDAR leading to NMDAR-related excitotoxicity 
and possibly cell death.   
 
 
1.5.2 The hyperphosphorylated tau theory 
 
Tau was first described in a paper published in 1975 (Weingarten et al., 1975).  It 
was purified from porcine brain and was found to be present in combination with 
tubulin.  Weingarten et al (1975) described tau as an extremely heat stable protein 
required for the polymerization of 6S tubulin (in vitro).   
 
1.5.2.1 The expression and structure of tau 
 
 
Tau proteins are produced by alternative mRNA splicing of a single gene on 
chromosome 17 (Mi and Johnson, 2006).  Tau is mainly found within the brain 
where there are six isoforms ranging from 352 to 441 amino acids in length.  The 
isoforms differ by the presence of three (3R) or four (4R) 31-35 amino acid C-
terminal repeats encoding microtubule binding domains combined with zero, one or 
two N-terminal inserts caused by alternative splicing of exons 2 and 3 (Figure 1.4) 
(Mi and Johnson, 2006).  Due to the splicing in of exon ten, 4R tau has an extra 
microtubule binding domain and as such is known to bind to microtubules more 
effectively than 3R-tau, thereby stabilising them more effectively (Buee et al., 2000).  
This is an important feature of tau as the differential stabilising abilities of the 
various isoforms are likely to contribute heavily to the level of plasticity in the brain.  
Indeed, expression of tau isoforms is developmentally regulated and in foetal brain 
41 
 
only the shortest 3R isoform of tau is present.  However by adulthood, all six 
isoforms are present and the ratio of 3R to 4R tau is largely 1:1 (Buee et al., 2000; 
Takuma et al., 2003).  During early development the requirement for plasticity is 
naturally very high as the various brain regions and the connections between them 
form.  As such, exclusive expression of the weaker binding 3R tau is an advantage 
(Takuma et al., 2003).  In the adult brain one of two scenarios could exist: either 
expression of 4R tau reduces the ability of the brain to be plastic or, the reduced 
requirement for plasticity in a developed adult brain induces the expression of 4R tau 
isoforms.  Due to a high percentage of hydrophilic residues, tau normally exists as an 
unfolded protein (Jeganathan et al., 2008a). However when it aggregates into 
filaments and NFT it often adopts higher structures, in particular β-structure 
(Jeganathan et al., 2008a). 
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Figure 1.4  Exon organization of the six brain tau isoforms. 
Alternative splicing of exons 2, 3 and 10 is responsible for the formation of the six 
different brain isoforms.  Exons 2 and 3 are responsible for the N-terminal inserts 
termed 0N (exon 2 and 3 absent), 1N (exon 2 present) or 3N (exons 2 and 3 present).  
Exons 9, 10, 11 and 12 are responsible for the microtubule binding domains.  
Splicing in of exon 10 in 4R tau causes an extra microtubule binding domain.  Exons 
4a, 6 and 8 are present in peripheral nervous system (PNS) tau isoforms.   
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1.5.2.2 The physiological function(s) of tau 
 
 
Within neurons, tau is mainly localised to the axon where its primary function is to 
bind to and stabilise microtubules - the crucial tracks used for the intracellular 
transport of proteins, vesicles and organelles (Mandelkow et al., 2003).  This is a 
physiological process thought to be regulated at least in part by specific 
phosphorylation of tau.  In contrast, hyperphosphorylation of tau is thought to 
contribute to the pathological aggregation of tau into filaments and subsequently 
NFT, presumably through phosphorylation events distinct to those involved in the 
physiological function of tau (Burbank and Mitchison, 2006; Hanger et al., 2009).  
Tau has also been found localised to the ER, Golgi and plasma membranes and a role 
in src-family tyrosine kinase signalling has been proposed (Brandt et al., 1995; Farah 
et al., 2005; Farah et al., 2006; Pooler and Hanger, 2010).  Indeed, tau can be 
phosphorylated by members of the src-family of tyrosine kinases such as fyn (Lee et 
al., 2004).  In addition, it has been shown that tau can bind to the SH3 domain of fyn 
(Lee et al., 1998).  The binding of tau to the SH3 domain of fyn is likely to be 
mediated by tau‟s phosphorylation status; it has been demonstrated that 
phosphorylation of tau at threonine 231 decreases this binding (Zamora-Leon et al., 
2001; Reynolds et al., 2008).   
 
In addition to its role in microtubule stabilisation, tau is involved in neurite 
outgrowth and axonal transport.  Early studies demonstrated that suppression of tau 
expression in cerebellar neurons significantly decreased neurite outgrowth (Caceres 
and Kosik, 1990; Caceres et al., 1991) and it has been demonstrated that over-
expression of tau induced outgrowth (Yoshizaki et al., 2004).  However, tau 
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knockout (tau
-/-
) mice are viable and have no major neural phenotypes, suggesting 
that either tau is not an essential gene or that there is considerable redundancy 
between tau and the other microtubule-associated proteins, such as MAP1 (Harada et 
al., 1994; Dawson et al., 2001).  The latter situation was confirmed with tau
-/-
 
MAP1B
-/-
 double knockout mice in which the neural phenotypes of the double 
knockouts were exacerbated when compared to MAP1B
-/-
 mice (Takei et al., 2000).   
 
Tau has been shown to inhibit kinesin-dependent fast axonal transport via 
interference with the ability of the kinesin motors to attach to microtubules (Ebneth 
et al., 1998; Stamer et al., 2002).  In double transgenic mice over-expressing tau and 
the kinase GSK-3β, there was less impairment of axonal transport (Spittaels et al., 
2000).  This was related to a decreased affinity of tau for microtubules as a result of 
increased tau phosphorylation by GSK-3β (Mi and Johnson, 2006).  Thus, the 
involvement of tau in kinesin-dependent fast axonal transport is likely to be mediated 
by phosphorylation.     
 
1.5.2.3 Pathological aspects of tau  
 
1.5.2.3.1 Mutations in the tau gene and the involvement of tau in tauopathies. 
 
Although tau present in AD brain is generally not mutated, many mutations of the tau 
gene have been reported and they generally fall into one of two categories: the first 
category, including missense and deletion mutations in the coding region of tau, 
produce tau with an altered function.  These mutations influence tau‟s tendency to 
aggregate into filaments and also its ability to bind to microtubules (Hasegawa et al., 
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1998).  The second category of mutations mainly affects the splicing of exon ten 
(Grover et al., 1999).  The inclusion of exon ten gives 4R tau its extra microtubule 
binding domain, and is often associated with an increased ratio of 4R:3R tau.  
Mutated tau is strongly associated with FTDP-17, a familial form of dementia in 
which there are tau tangles (comprised of hyperphosphorylated tau) but no amyloid 
plaques present in the brain.  In FTDP-17 brain, tau depositions the same as those 
seen in AD are observed, however tangles can be detected at younger age and this is 
associated with the onset of cognitive symptoms.     
 
In progressive supranuclear palsy, tau inclusions consist of 4R isoforms only 
(Sergeant et al., 1999).  However, in AD, inclusions have 3R and 4R tau isoforms, 
while in Pick‟s disease only 3R isoforms are found in the aggregates (Sergeant et al., 
1997; Buee et al., 2000).  This would suggest that neither form of tau is more toxic 
than the other but that toxicity may arise from altered ratios of 4R:3R tau.  Taking 
into account that tau isoform expression is developmentally regulated, it is probable 
that isoforms have different functions within the cell.  Indeed different tau isoforms 
have differential effects on microtubule transport
 
(Vershinin et al., 2007).  Our 
understanding of the effect of altering 4R:3R ratios will increase as more information 
becomes available on the different functions of different isoforms.   
 
Apart from the differences in the composition of tau inclusions described above, to 
date there is no evidence that tau inclusions found in AD and in the tauopathies are 
different i.e. they all consist of accumulations (hence tangles) of 
hyperphosphorylated tau filaments which have a helical structure.  Although AD and 
the tauopathies are clinically and pathologically different diseases, the strong 
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association between tau tangle load and cognitive symptoms, and the development of 
a similar dementia to AD in the tauopathies (in the absence of Aβ plaques), forms the 
basis of the „tauists‟ belief that tau tangles in themselves must be pathogenic.   
 
 
1.5.2.3.2 Phosphorylation. 
 
It was not until 1984 that it was shown that phosphorylation can regulate tau‟s 
binding to microtubules (Lindwall and Cole, 1984).  It was found that 
phosphorylated tau promotes significantly less polymerization of microtubules than 
dephosphorylated tau.  In AD and tauopathies, mutant forms of tau become 
hyperphosphorylated, often within their microtubule binding domains, and 
subsequently have a reduced ability to bind to microtubules (Iqbal et al., 2005; Marx, 
2007).   
 
„Normal‟ tau has 2-3 mol of phosphate attached per mol of the protein (Iqbal et al., 
2005).  However, AD tau contains 9-10 mol of phosphate per mol of protein 
(Ksiezak-Reding et al., 1992; Kopke et al., 1993).  It remains unclear if 
hyperphosphorylation of tau is due to a decrease in the activity of one or more tau 
phosphatases, an increase in one or more tau kinases, or simply by tau becoming a 
better substrate (e.g. through a change in conformation of tau or via mis-localisation 
of tau or a tau kinase/phosphatase).  Indeed, it could be a combination of all three.  
What is clear is that tau found in the aggregated filaments which form the basis of 
NFTs in the somatodendritic compartment of the cell is phosphorylated on many 
residues that are not phosphorylated in healthy neurons and at a much higher 
stochiometry (Hanger et al., 2009).  These filaments may be straight or helical in 
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structure and typically come in pairs (Mandelkow et al., 2007).  There are a number 
of ways in which the presence of NFTs in neurons may cause cell loss.  NFTs are a 
physical barrier in the cell which have been reported to compromise cellular 
functions including distribution and number of organelles and proteasome activity 
(Gendron and Petrucelli, 2009).  In addition, the sequestration of tau into NFTs 
causes destruction of the microtubule network and consequently affects axonal 
transport and synaptic integrity.  
 
Tau is phosphorylated by many kinases (these include GSK-3β, PAR-1/MARK, cdk5 
and PKA to name but a few).  To date, 40 residues on tau have been reported to be 
phosphorylated either in vivo or in vitro (Hanger et al., 2009).  Phosphorylation 
within the microtubule binding domains of tau is reported to have a large effect on 
the ability of tau to bind to microtubules (Biernat and Mandelkow, 1999).  In 
particular, phosphorylation at serines 262 and 356 has a dramatic effect on binding 
(numbering based on the longest human tau isoform) (Biernat and Mandelkow, 1999; 
Biernat et al., 2002; Hanger et al., 2009).  However, it has also been shown that 
phosphorylation in the regions flanking the repeat domains can affect microtubule 
binding (Cho and Johnson, 2003).  It is also postulated that phosphorylation at some 
residues may cause conformational changes in tau, making the protein either 
inaccessible to phosphatases or simply a better substrate for additional kinases, or 
affecting tau‟s biological function (Jeganathan et al., 2008b; Fischer et al., 2009).   
 
Tau kinases can be broadly divided into two subgroups; the proline-directed kinases 
(which phosphorylate tau at serine/threonine-proline motifs) and the non proline-
directed kinases (which phosphorylate tau within KXGS motifs found in the 
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microtubule-binding domains; S262, S293, S324 and S356).  Two of the most 
heavily characterised proline-directed kinases are GSK-3β and cyclin-dependent 
kinase 5 (cdk5).  These kinases phosphorylate tau at a large number of common 
residues.  Although increases in the brain expression and/or activation of GSK-3β 
have not been consistently observed in AD, increased GSK-3β expression (as 
detected by indirect ELISA) is associated with all stages of neurofibrillary pathology 
in AD brains (Pei et al., 1997). Additionally, over-expression of GSK-3β in cells 
causes a dramatic change in tau phosphorylation at a number of residues such as 
pS202/T205 (Lovestone et al., 1996; Wagner et al., 1996). Treatment of cells with 
the selective GSK-3β inhibitor lithium decreases tau phosphorylation at the 
aforementioned sites (Lovestone et al., 1996).  These findings implicate tau as an in 
vivo substrate for GSK-3β and suggest that abnormal phosphorylation of tau by 
GSK-3β may be involved in the pathogenesis of AD.  It has been suggested that prior 
phosphorylation of tau by cdk5 may enhance its subsequent phosphorylation by 
GSK-3β (Ishiguro et al., 1993).  This is suggestive of cdk5 playing a regulatory role 
in tau phosphorylation.  cdk5 is specifically activated in neurons by p35, a protein 
that can be cleaved by calpain to form the smaller and more stable activator of cdk5, 
p25 (Lee et al., 2000).  This cleavage of p35 into p25 could lead to prolonged 
activation of cdk5.  Indeed, p25 immunoreactivity is high in AD brain, staining 
neurons and NFTs, whereas p25 immunoreactivity in control brain is very low 
(Patrick et al., 1999).  In addition, Aβ has been demonstrated to increase the cleavage 
of p35 to p25, which could represent a link between Aβ pathology and tau 
hyperphosphorylation (Lee et al., 2000; Town et al., 2002).  Similar to GSK-3β, cdk5 
has been shown to associate with all stages of neurofibrillary pathology in AD brain 
and over-expression of cdk5 and p25 in cell lines leads to increased tau 
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phosphorylation (Pei et al., 1998; Cruz et al., 2003).  However, inhibition of cdk5 in 
primary neurons led to increased tau phosphorylation and some studies have found 
that up regulation of p25 increases cdk5 activity but does not alter tau 
phosphorylation (Kerokoski et al., 2002; Morfini et al., 2004).  This is an issue that 
remains to be resolved.  
 
Of the non proline-directed kinases, PAR-1 (which is also known as MARK4 in 
mammals but will be referred to as PAR-1 in this thesis), a member of the AMPK-
related family of protein kinases, has been the focus of much research.  It has been 
shown to phosphorylate tau at two serine residues: S262 and S356 (Mandelkow et al., 
2004).  Phosphorylation at these residues has a large effect on the microtubule-
binding properties of tau and it has been suggested that phosphorylation at KXGS 
motifs may be a pre-requisite for phosphorylation at other residues.  Indeed, PAR-1 
has been implicated as the initiator of a phosphorylation cascade involving GSK-3β 
and cdk5 (Nishimura et al., 2004).  In addition to PAR-1, other non proline-directed 
kinases that have been shown to target tau in the KXGS motifs are PKA, CaMKKII 
and p70S6K (Mandelkow et al., 2007). 
 
Tau can also be phosphorylated on tyrosine (Y) residues, of which there are five in 
the tau molecule (Y18, Y29, Y197, Y310 and Y394).  Kinases that have been 
implicated in tyrosine phosphorylation of tau include c-Abl, Fyn, Syk, and tau-
tubulin kinase 1 (Lee et al., 2004; Derkinderen et al., 2005; Lebouvier et al., 2008).  
Tau from AD brain has been shown to be tyrosine phosphorylated in some cases and 
treatment of cultured neurons with Aβ induces tyrosine phosphorylation of tau 
(Williamson et al., 2002).   
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Besides protein kinases, protein phosphatases (PPs) also play an important role in the 
regulation of the phosphorylation status of tau.  Phosphatases that have been 
demonstrated to dephosphorylate tau in vitro include PP1, PP2A, PP2B and PP5 (but 
not PP2C).  All of these phosphatases have been shown to dephosphorylate tau at a 
number of serine and threonine residues.  However, the activity of PP2A towards tau 
has been demonstrated to be ~70% higher than the other phosphatases (Liu et al., 
2005a; Rahman et al., 2006).  Thus, PP2A is considered to be the „main‟ tau 
phosphatase and it is of interest that its activity is decreased in AD brain (Liu et al., 
2005a). 
 
It is becoming clear that no one specific kinase or phosphatase is responsible for the 
abnormal tau phosphorylation in AD and indeed the literature suggests that there 
may be a hierarchy among the tau kinases with phosphorylation by one kinase being 
a pre-requisite for phosphorylation by the next (Nishimura et al., 2004; Mi and 
Johnson, 2006; Bertrand et al., 2010). 
 
1.5.2.3.3 Tau and axonal transport 
 
 
Neurons are some of the largest cells in humans and the vast majority of their overall 
cellular volume consists of the axon.  Protein synthesis does not occur in axons and 
as such a process known as fast axonal transpost (FAT) takes place in order to enable 
the anterograde transport of essential components (e.g. membrane proteins, 
mitochondria and synaptic vesicles) from their sites of synthesis in the cell body to 
synaptic locations along the axon (Morfini et al., 2009).  This process is essential for 
proper synaptic function and is facilitated by a group of molecular motor proteins 
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known as kinesins (Wagner et al., 1989).  In addition, neuronal maintenance requires 
the reciprocal transport of signalling complexes and degradation products from the 
synapses to the cell body.  Retrogade FAT is carried out by another type of motor 
protein, dynein (Morfini et al., 2009). 
 
In normal differentiated neurons tau is confined to axons.  However it has been 
demonstrated in a number of neuronal cell types (e.g. hippocampal neurons, N2a 
neuroblastomas) that expression of tau results in its miss-sorting from axons into the 
somatodendritic compartments (Thies and Mandelkow, 2007).  This observation has 
also been made in post mortem human AD brain and transgenic mouse models of 
AD expressing human tau (Terry et al., 1991; Polydoro et al., 2009).  Expression of 
tau in primary cortical neurons leads to the inhibition of anterograde FAT due to 
interference between tau and kinesins (Stamer et al., 2002).  The interference in 
anterograde FAT seen upon tau expression in hippocampal neurons can be relieved 
by phosphorylation of tau by kinases such as PAR-1, resulting in the detachment of 
tau from microtubules (Thies and Mandelkow, 2007).  This suggests that the 
relationship between FAT and tau is closely associated with the phosphorylation 
status of tau.   
 
1.5.2.3.4 Tau and synaptotoxicity 
 
 
In addition to inhibiting FAT, expression of tau in cultured hippocampal neurons 
caused drastic changes in dendritic spine morphology leading to synapse loss, 
disintegration of processes and cell death (Thies and Mandelkow, 2007).  Expression 
of human tau in lamprey central neurons induces formation of tau filaments similar 
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to the straight filaments of tau seen in post mortem AD brain tissue.  Filament 
formation in these neurons was associated with a progressive loss of dendritic 
synapses and microtubules (Hall et al., 2000).  In support of a detrimental effect of 
tau on synapses, it has been demonstrated that aged htau transgenic mice (in which 
the mouse tau gene is replaced by non-mutated human tau) exhibit an age-dependent 
perturbation in basal synaptic transmission and LTP in the CA1 region of the 
hippocampus, an area that develops tau tangles in an age-dependent manner in this 
model (Polydoro et al., 2009).          
 
1.5.2.3.5 Other post-translational modifications of tau 
 
There are a number of other post-translational modifications of tau found in tangles 
(Buee et al., 2000; Gong et al., 2005; Gendron and Petrucelli, 2009).  A number of 
proteases and caspases capable of cleaving tau, along with their sites of action, have 
been identified and the resulting fragments appear to have a higher propensity for 
aggregation when compared to full length tau 
 
(Wang et al., 2009b; Hanger and Wray, 
2010).  It has been shown that increased phosphorylation of tau inhibits tau cleavage 
by caspases (Guillozet-Bongaarts et al., 2006).  In addition, application of Aβ to 
cultured hippocampal neurons induced the formation of a 17kDa tau fragment as a 
result of caspase-3 and calpain activity, and transfection of chinese hamster ovary 
(CHO) cells with a tau fragment of this molecular weight led to cell death (Canu et 
al., 1998; Park and Ferreira, 2005).  More recently, a different group demonstrated 
that transfection of CHO cells or primary hippocampal neurons with the 17kDa 
fragment of tau did not cause cell death and that the calpain-induced fragment was 
detectable in both human AD and control brains (Garg et al., 2010).  Thus it is not 
53 
 
currently clear if the cleavage of tau is part of a normal physiological process or of 
the cell‟s attempt to rid itself of pathological tau isoforms.  Whatever the 
contribution of cleavage in tau pathology, it is of interest that tau fragments exhibit 
strong aggregation properties and are capable of seeding the aggregation of both 
cleaved and full length tau
 
(Wang et al., 2009b).  This could also have implications 
for current drugs being developed to dissolve NFTs.    
 
Glycosylation (the reaction between the amino group of an amino acid side chain and 
the carboxyl end of reducing sugars) of AD tau but not control tau has been 
demonstrated (Wang et al., 1996).  It is postulated that glycosylation is a process that 
precedes tau phosphorylation: tau isolated from AD brain that was not yet 
hyperphosphorylated was already glycosylated, whereas tau purified form normal 
control brain was not glycosylated (Liu et al., 2002).  In addition, it would seem that 
aberrant glycosylation induces tau hyperphosphorylation in a site-specific manner 
both by promoting phosphorylation and inhibiting dephosphorylation (Gong et al., 
2005).  In contrast, O-GlcNAcylation (a common post-translational modification 
whereby O-linked-β-N-acetylglucosamine transferase (OGT) catalyses the transfer of 
GlcNAc from UDP-N-acetylglucosamine to serine or threonine residues of nuclear 
and cytoplasmic proteins) of tau has been shown to correlate negatively with tau 
phosphorylation at most sites (Liu et al., 2004; Liu et al., 2009).   
 
It is known that tau in PHFs and NFTs is ubiquitinated, whereas control tau is not.  
Ubiquitination is considered as a label targeting short-lived, abnormal or damaged 
proteins for ATP-dependent degradation and removal through the ubiquitin-protease 
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system (Lace et al., 2007).  As such, ubiquitination of tau in PHFs or NFTs may 
represent a failed attempt by the cell to rid itself of toxic tau species.   
 
The role of these additional post-translational modifications of tau in the 
pathogenesis of AD and/or the tauopathies is not yet fully understood, but in addition 
to failed attempts by the cell to rid itself of pathological tau species, it has been 
proposed that they may be involved in the attempted adaptation of tau function(s) to 
different cellular locations (Lace et al., 2007).              
 
 
1.5.3 The mitochondrial cascade (or metabolic) theory  
 
This hypothesis states that genetic inheritance determines mitochondrial function and 
durability, durability dictates how mitochondria change with age, and AD pathology 
and symptoms develop when mitochondrial change/impairment rises above a certain 
level (Swerdlow and Khan, 2004).  Reduced brain metabolism is a well documented 
abnormality in AD which appears before the ability to detect functional impairment 
by neuropsychological testing (Blass, 2000).  Significant changes in the number, size 
and structure of mitochondria have been reported in AD neurons (Hirai et al., 2001).   
In addition to damage to the structure of mitochondria, several mitochondrial DNA-
encoded enzymes have been shown to be altered in AD, most notably cytochrome c 
oxidase, which is at the terminal end of the electron transport chain (ETC) and 
attaches its acquired electrons to oxygen in order to generate water and not reactive 
oxygen species (ROS) (Zhu et al., 2006; Swerdlow and Khan, 2009).  Deficiencies in 
mitochondrial oxidative phosphorylation lead to an increase in ROS, which is present 
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in the very early stages of AD, and the degree of impaired mitochondrial oxidative 
phosphorylation in AD brains correlates with the level of neurodegenerative decline 
(Rhein and Eckert, 2007).  Additionally, mitochondria play a role in buffering 
cytosolic calcium within cells.  When mitochondria are damaged this ability is 
compromised.  However, it would appear that increased cytosolic calcium in 
neurodegenerative disease is upstream of mitochondrial calcium buffering deficits 
(Mattson, 2007).   
 
Another prominent change in AD brain is synaptic loss and this is postulated to be 
important for the pathogenesis of AD (Selkoe, 2002).  Under normal physiological 
conditions, the brain is highly metabolically active and consequently neurons need 
many mitochondria; especially at synapses, where synaptic transmission demands a 
constant supply of ATP (Sheehan et al., 1997; Isaacs et al., 2006).  It has been 
proposed that aberrant mitochondrial distribution from an even distribution to a peri-
nuclear distribution could be responsible for the synaptic loss seen in AD neurons 
(Wang et al., 2009a).       
 
Potentially compounding these metabolic defects, in vitro Aβ can inhibit enzymes of 
the mitochondrial respiratory chain such as cytochrome c oxidase, and its toxicity 
appears to be mediated through effects on mitochondria; mitochondrial DNA 
depleted NT2 cells are resistant to Aβ-induced toxicity (Cardoso et al., 2001; Crouch 
et al., 2005).  Additionally, it has been demonstrated that the expression of APP 
(wild-type or mutant) in cultured neurons dramatically increases the percentage of 
fragmented mitochondria (Wang et al., 2008).  Fragmented mitochondria arise as a 
result of mitochondrial fission, which is a process that allows the sequestration and 
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elimination of mitochondria that have been damaged irreversibly (Chen et al., 2005; 
Chen et al., 2007).  Mitochondrial fragmentation is also known to be an early event 
in apoptosis (Frank et al., 2001).  Over-expression of APP also results in a profound 
loss of mitochondrial fusion (Wang et al., 2008), a process that allows the exchange 
of mitochondrial proteins and DNA.  Fusion enables mitochondria that have 
undergone damage to mitochondrial DNA to replenish their stores of oxidative 
phosphorylation-related proteins, thus lowering the effect of the mitochondrial DNA 
defect (Wang et al., 2009a).  
 
Tau has also been shown to affect mitochondrial function.  In transgenic mice over-
expressing a mutant version of human tau (P301L), respiratory chain components 
and antioxidant enzymes were dysregulated (David et al., 2005).  Additionally, in 
triple transgenic mice carrying human tau (P301L mutation), APPSW (Swedish 
mutation) and mutated PS2 (N141I), tau was shown to specifically dysregulate 
enzymes related to complex I of the oxidative phosphorylation system (Rhein et al., 
2009).  Furthermore, expression of a cleaved version of tau in cells (mimicking 
cleavage of tau by caspases) resulted in mitochondrial fragmentation and elevated 
ROS levels (Quintanilla et al., 2009).   Interestingly, it would appear that the 
detrimental effects of tau on mitochondrial function are reciprocal; inhibition of 
complex I of the oxidative phosphorylation system in cultured neurons led to miss-
sorting of tau from axons to the cell body, retrograde transport of mitochondria and 
cell death (Escobar-Khondiker et al., 2007).     
 
Although it is clear that Aβ, APP and tau can exert detrimental effects on 
mitochondria, the cause of the early metabolic and mitochondrial defects observed in 
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AD remains elusive.  That said, the correlation between impaired mitochondrial 
function and cognitive decline is an interesting subject that warrants further 
investigation and impaired mitochondrial function may prove to be a useful early 
indicator of AD.   
 
 
1.5.4 The calciumopathy model  
 
The calciumopathy model for AD was originally proposed by Khachaturian in 1987 
and states that as humans age, their capacity for buffering calcium becomes impaired 
leading to a dysregulation of calcium homeostasis which if sustained, may provide a 
trigger for age-associated changes in the brain (Khachaturian, 1987).   
 
A number of studies have shown that elevated cytosolic calcium concentration, 
through plasma membrane calcium channels or release of calcium from endoplasmic 
reticulum (ER) stores (mediated by IP3 and ryanodine receptors), increases the 
production of intracellular Aβ (Querfurth and Selkoe, 1994; Pierrot et al., 2004; 
Pierrot et al., 2006).  Conversely, increasing cytosolic calcium concentrations by 
inhibition of the sarco/ER calcium-ATPase (SERCA) pumps with thapsigargin, 
results in decreased Aβ production (Buxbaum et al., 1994).  This suggests that the 
effects of calcium on APP processing (and the production of Aβ) may be different 
depending on the source of the calcium ions.   Whilst the effect of calcium on the 
processing of APP and production of Aβ remains unclear, there is strong evidence 
that the reciprocal situation is true; that Aβ has a detrimental effect on calcium 
signalling.  It has been shown by a number of groups that application of Aβ to 
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cultured cells increases cytosolic calcium though the formation of cation-selective 
ion channels by Aβ and via IP3 and ryanodine receptor-mediated release of calcium 
from ER stores (Arispe et al., 1993; Mattson et al., 1993; Goodman and Mattson, 
1994; Kawahara and Kuroda, 2000; Ferreiro et al., 2004).   
 
Although mutations in presenilins account for less than 10% of all AD cases (Selkoe, 
2004), presenilins have also been implicated in the calciumopathy theory; mutations 
in the PS1 or PS2 genes alter the γ-secretase cleavage pathway leading to increased 
Aβ production.  Additionally, every mutation of PS1 and PS2 that has been studied 
alters calcium signalling (LaFerla, 2002).  It remains unclear as to the exact 
mechanism by which presenilins affect calcium signalling, but a number of studies 
have shown that both PS1 and PS2 are involved in the destabilisation of IP3-mediated 
calcium release from ER stores (Guo et al., 1996; Begley et al., 1999; Leissring et al., 
1999a; Leissring et al., 1999b; Leissring et al., 2000).  Indeed, ER calcium stores are 
diminished in presenilin deficient cells, indicating that presenilins play an important 
role in the regulation of ER calcium homeostasis (Leissring et al., 2002).     
 
In addition to the calcium-dependent effects mediated by Aβ and the presenilins, tau 
phosphorylation can be regulated by calcium-dependent mechanisms.  
Calcium/calmodulin-dependent kinase II (CaMKII) phosphorylates tau at S262 and 
S356 (Litersky et al., 1996).  Additionally, calpain, a calcium-activated protease, can 
indirectly activate another tau kinase, cdk5 (Kusakawa et al., 2000).  Furthermore, 
the calcium/calmodulin-dependent phosphatase calcineurin (also known as PP2B), 
has been shown to be able to dephosphorylate tau - albeit to a much lesser extent 
than the main tau phosphatase, PP2A (Liu et al., 2005a).  These data indicate a role 
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for calcium-activated kinases and phosphatases in the regulation of tau 
phosphorylation.  More recently, it has been shown that treatment of neurons with 
amyloid proteins led to miss-sorting of tau from axons to dendrites, local elevation of 
intracellular calcium levels, tau phosphorylation at a number of residues and 
increased expression and/or activation of tau kinases such as PAR-1 and brain 
selective kinase 1 (BRSK1) (Zempel et al., 2010).   
 
It remains to be seen if altered calcium signalling is a causative agent in AD, but it 
cannot be ignored that calcium signalling has been shown to be altered before the 
development of symptoms in patients who later develop either familial or sporadic 
AD, and as such may represent an early indicator of AD (Ito et al., 1994; 
Etcheberrigaray et al., 1998).   
 
 
1.6 The AMPK-related family of protein kinases 
 
 
The AMPK-related family of protein kinases were initially identified by their 
sequence homology to the catalytic domain of the prototypical member of the family, 
AMP-activated protein kinase (AMPK) (Figure 1.5).  AMPK is a kinase that consists 
of three subunits (α, β and γ) and is involved in the regulation of cellular energy 
homeostasis and cellular polarity.   The α subunit is where the serine/threonine 
kinase domain resides.  This domain also contains a C-terminal regulatory domain.  
The β subunit is thought to enable the binding of the α and γ subunits to form a 
complex.  The γ subunit is where AMP and ATP bind to the AMPK complex 
(Carling, 2004).  AMPK is activated by a decrease in the cellular ratio of ATP:ADP 
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which leads to a large increase in the concentration of AMP.  Increased intracellular 
concentrations of AMP activate AMPK which then initiates ATP conserving 
mechanisms by switching off any ATP depleting processes that are not essential for 
immediate survival and activating ATP generating pathways (Carling, 2004; Hardie, 
2004).  These complex actions of AMPK are effected through direct and indirect 
phosphorylation by AMPK of downstream targets.  In addition to its essential role in 
energy sensing mechanisms, AMPK has recently been implicated in cellular polarity 
in epithelial cells and Drosophila (Hardie, 2007; Lee et al., 2007).  The Drosophila 
homologue of AMPK is SNF1A.  SNF1A-null mutant Drosophila are lethal and 
exhibit severe polarity and mitotic defects which can be rescued with a 
phosphomimetic mutant of non-muscle myosin regulatory light chain, a target that is 
directly phosphorylated by AMPK (Lee et al., 2007). 
 
In a complex with STE20-related adaptor (STRAD) and mouse protein 25 (MO25), 
the tumour suppressor master kinase LKB1 has been shown to phosphorylate 14 of 
the 22 AMPK-related family members (including AMPK) on T-loop serine/threonine 
residues, causing their activation (Hawley et al., 2003).  AMPK has also been shown 
to be regulated by the Ca
2+/
calmodulin dependent kinase-β (CaMKKβ), and, to a 
much lesser extent, CaMKKα (Hawley et al., 2005).  Although much is known about 
the regulation and function of AMPK, the regulation and functions of other members 
of the AMPK-related family of kinases appears to be quite diverse.  These functions 
include the regulation of tumour invasion (NUAK1/2) (Legembre et al., 2004; 
Suzuki et al., 2004), regulation of gene expression through phosphorylation of CRE-
binding protein (SIK1) (Katoh et al., 2004) and the regulation of cell proliferation 
(QSK) (Bettencourt-Dias et al., 2004).  None of the AMPK-related kinases appear to 
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be activated by the same pharmacological stimuli as AMPK, such as phenformin or 
AICAR, implying that members of this family are activated and/or regulated by 
different stimuli to AMPK itself (Lizcano et al., 2004; Sakamoto et al., 2004).  This 
is likely to be because the AMPK-related kinases do not have an AMP binding 
domain.   
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Figure 1.5  The AMPK-related family of protein kinases 
Dendrogram revealing the level of relatedness between the human AMPK-related 
family of protein kinases, a family that is largely regulated by the tumour supressor 
kinase LKB1(greyed out are non-LKB1 substrates). The diagram shows that there 
are two isoforms of BRSK (1 and 2) in the human genome and that they are closely 
related to AMPKα1 and AMPKα2, the prototypical members of this family of protein 
kinases.  Adapted from Alessi et al. (2006). 
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1.6.1 AMPK-related kinases as tau kinases 
 
It is of interest that at least three members of this family (AMPK, PAR-1 and BRSK) 
have been reported as tau kinases and that these kinases have (at least partially) 
overlapping functions.   
 
Probably the more familiar of the three, in terms of being a tau kinase, is the 
aforementioned PAR-1.  PAR-1 was originally identified in a screen to identify 
determinants of early embryonic polarity in C.elegans and was later identified as part 
of an evolutionarily-conserved group of proteins required for cell polarity in 
mammals, worms, frogs and flies (Kemphues et al., 1988; Biernat et al., 2002; Hurov 
and Piwnica-Worms, 2007).  PAR-1 has been implicated in the phosphorylation of 
tau by a number of groups (Drewes et al., 1997; Biernat et al., 2002; Mandelkow et 
al., 2004; Nishimura et al., 2004; Wang et al., 2007a; Chatterjee et al., 2009).  It is 
known that PAR-1 is able to phosphorylate tau within the KXGS motifs, at S262 and 
S356, and that this has a dramatic effect on the microtubule binding properties of tau 
(Mandelkow et al., 2004).  In addition, work in Drosophila melanogaster has shown 
that PAR-1 can exacerbate a human tau-induced degenerative eye phenotype, and 
that PAR-1 may instigate endogenous (fly) and exogenous (human) tau 
hyperphosphorylation by initiating a phosphorylation cascade which includes GSK-
3β and cdk-5 (Shulman and Feany, 2003; Nishimura et al., 2004).  Following this, it 
was shown by Wang et al (2007a) that LKB1 lies upstream of PAR-1 and acts as an 
activator of PAR-1 via phosphorylation at T408.   
 
In addition to PAR-1, AMPK itself has been implicated as a tau kinase in vitro 
(Vingtdeux et al., 2010a; Thornton et al., 2011) and recent data from a post-doctoral 
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researcher in the laboratories of Prof. Bruno Frenguelli and Dr Kevin Moffat 
indicates that this is also the case in vivo in Drosophila (Dr Alessia Galasso, personal 
communication).  AMPK has been shown to phosphorylate tau on a number of sites 
including S262/S356 and S396.  Because patients with diabetes appear to have an 
increased risk for AD, it was considered a concern that the most widely used 
pharmacological agent for treating type-2 diabetes, Metformin, is an AMPK activator 
(Kroner, 2009).  However, it has recently been demonstrated that in addition to 
activating AMPK, metformin, reduces tau phosphorylation via activation of PP2A 
(Kickstein et al., 2010).   Additionally, activation of AMPK has recently been 
implicated in the mediation of autophagy (Egan et al., 2011) and in the degradation 
of Aβ peptides, presenting a perplexing situation whereby both activation and 
inhibition of AMPK could be detrimental (Vingtdeux et al., 2010b; Vingtdeux et al., 
2011).  Thus it is of vital importance that further research is conducted into the 
capacity of AMPK as a tau kinase and its potential involvement in the degradation of 
Aβ species.       
    
 
1.7 Brain selective kinases (BRSKs) 
 
BRSKs are evolutionarily conserved serine/threonine kinase members of the AMPK-
related family of kinases which have orthologues in mouse (SAD-B and SAD-A), 
C.elegans (SAD-1), Drosophila (CG6114) and Ascidians (HrPOPK-1).  For clarity, 
mammalian orthologues will be referred to as BRSK1 and 2 throughout this thesis.  
Northern and Western analyses have demonstrated that BRSKs are highly expressed 
in the brain with lower expression in the testis and the pancreas (Lizcano et al., 2004; 
Kishi et al., 2005; Hezel et al., 2008). 
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1.7.1 Physiological function(s) of BRSKs 
 
 
1.7.1.1 BRSKs and neuronal polarity 
 
Crump et al (2001) identified the C.elegans orthologue of the BRSKs, SAD-1, and 
showed that it regulates presynaptic differentiation and axonal polarity (Crump et al., 
2001).  Work by Crump et al (2001) on SAD-1 reported that mutant worms showed 
axons that failed to terminate properly indicating a deficiency in the signals which 
control this process.  Worms over-expressing SAD-1 had axons which either 
terminated prematurely or were miss-directed.  As a result of these observations 
Crump et al suggest that one of the functions of SAD-1 is to signal to the axons to 
stop elongating.  In support of these findings, Hung et al (2007) indicate that SAD-1 
directly interacts with the C.elegans homologue of Neurabin-1, NAB-1, to confer 
axonal identity in C.elegans dorsal and ventral GABAergic motor neurons (Hung et 
al., 2007).  Additionally, Kim et al (2008) show that SAD-1 is required for 
establishment, but not maintenance, of neuronal polarity in the same C.elegans motor 
neurons (Kim et al., 2008).  Consistent with the observations made, SAD-1 has a 
kinase domain which is related to the kinase domain of the aforementioned 
embryonic polarity determinant, PAR-1.  
 
Single and double knockout mice have been made for the murine homologue genes 
of BRSK 1 and 2, SAD-B and SAD-A respectively, to investigate their functions in 
neuronal polarity (Kishi et al., 2005).  Kishi et al (2005) found that single knockout 
mice were healthy and fertile and that lack of one kinase had no compensatory effect 
on the expression of other.  However, the double knockout mice died within two 
hours of birth and had little response to tactile stimulation, suggesting a neural 
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phenotype.  Examination of the embryonic (E19) nervous system of these mice 
showed normal formation of the brain, spinal cord and peripheral nervous system, 
although double knockout animals had visibly thinner cortices when compared to 
littermate control animals.  In addition, the double knock out animals had severely 
decreased thalamo-cortical projections and the neurons of the forebrain lacked 
polarity with many of them exhibiting starburst morphology and failing to form 
distinct axons and dendrites.  This confirmed that BRSKs were involved in the 
establishment of forebrain neuronal polarity, more specifically in the processes that 
confer distinct axonal and/or dendritic identity.   
 
1.7.1.2 BRSKs and synapses 
 
Presynaptically, sad-1 mutant worms had a more diffuse distribution of synaptic 
vesicles than wild type animals at both neuron to neuron and neuromuscular 
synapses (Crump et al., 2001).  In addition, inhibition of SAD-1 activity during the 
development of DD-type motor neurons disrupted synaptic organisation, an effect 
which was rescued upon expression of SAD-1 after development (Kim et al., 2008).  
SAD-1 has been shown to co-localise with SNT-1, a synaptic vesicle protein, and 
UNC-10, an active zone protein, indicating that SAD-1 is present presynaptically and 
is associated with active zones and vesicle pools in C.elegans (Hung et al., 2007).  In 
support of SAD-1 being involved in presynaptic differentiation, mammalian BRSK1 
has also been implicated at the synapse where it was found to localise to, and 
associate with, synaptic vesicles in mouse hippocampus and cerebellum (Inoue et al., 
2006).  In addition, it has been suggested that BRSK1 plays a role in 
neurotransmitter release in cultured rat primary hippocampal neurons by 
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phosphorylation of the active zone protein RIM1 (Inoue et al., 2006).  However, 
Crump et al (2001) suggest that sad-1 does not regulate all aspects of presynaptic 
development as other mutants (rpm-1 and syd-2) identified in the same screen exhibit 
defects in neurons where SAD-1 has little or no effect.  sad-1 and syd-2 double 
mutants exhibit an additive phenotype, showing that both genes function in different 
aspects of synapse development.       
   
1.7.1.3 BRSKs and tau phosphorylation 
 
Because the phosphorylation status of tau regulates its interactions with microtubules 
(Weingarten et al., 1975; Lindwall and Cole, 1984; Barghorn et al., 2000; Makrides 
et al., 2004; Wang et al., 2007b) and local variations in the organisation of 
microtubules affect neuronal polarisation (Mandell and Banker, 1996; Arimura et al., 
2004), Kishi et al (2005) chose to look at whether BRSKs phosphorylate tau.  They 
found that BRSKs are involved in the basal phosphorylation of tau at S262 - a crucial 
residue that must be phosphorylated in order for NFTs to form and a residue that is 
also targeted by PAR-1.  In cortical brain slices, immuno-staining for tau 
phosphorylated at S262 showed a decrease in pS262 in BRSK double knockout mice 
when compared to wild type animals (Kishi et al., 2005).  There was no difference in 
the amount of total tau detected.   
 
1.7.1.4 BRSKs as checkpoint kinases 
 
In addition to roles in presynaptic differentiation, the establishment of forebrain 
neuronal polarity and an involvement in the basal phosphorylation of tau, BRSK1 
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has been identified as a potential checkpoint kinase at the G2/M transition of the cell 
cycle (Lu et al., 2004).  This was discovered because BRSK1 exhibits homology 
with the fission yeast kinase Cdr2, which along with Wee1 protein kinase, is 
involved in the regulation of mitosis (Breeding et al., 1998).  In vivo, BRSK1 
phosphorylates Cdc25-C on Serine 215 (Lu et al., 2004).  In HeLa cells, BRSK1 was 
activated upon DNA damage induced by UV or methyl methane sulphonate and was 
subsequently translocated to the nucleus.  This led to arrest of the cell cycle at the 
G2/M transition which could be prevented by treatment with caffeine. It was 
suggested that these effects on BRSK and the cell cycle arrest were mediated by 
ataxia-telangiectasia mutated (ATM) or Rad3-related (ATR) protein kinases, both of 
which are inhibited by caffeine (Lu et al., 2004).  In support of this, the BRSK1 
sequence contains two consensus phosphorylation sites for ATM or ATR, although 
there is currently no evidence that BRSKs are targeted by ATM or ATR.  
 
 
1.7.2 Regulation of BRSKs 
 
 
Like AMPK and PAR-1, BRSKs can be regulated by the master kinase LKB1 
through phosphorylation of a conserved threonine residue in their T-loop (T189 in 
BRSK1 and T174 in BRSK2) (Lizcano et al., 2004).  It has been suggested that 
LKB1 is constitutively active: under conditions which are known to cause activation 
of AMPK, no increase in LKB1 activity is seen (Alessi et al., 2006).  However, 
Shelly et al (2007) have evidence that phosphorylation of LKB1 at a PKA site (S431) 
elevates the activity of LKB1.  When they mutated the PKA site, so that it was no 
longer an active site, the increase in LKB1 activity was not seen (axonal 
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differentiation was prevented) (Shelly et al., 2007).  This view is supported by 
Barnes et al (2007) who state that LKB1 is required for axonal polarization, having 
first been activated by phosphorylation at S431 by PKA (Barnes et al., 2007).  In 
contrast to the work of Shelly et al (2007) and Barnes et al (2007), a splice variant of 
LKB1 which lacks S431 has been reported which activates BRSK1/2 and AMPK to 
the same level as wild type LKB1 (Fogarty and Hardie, 2009).  Recently, it was 
demonstrated that BRSKs act downstream of LKB1 in the establishment of axonal 
identity; phosphorylation of BRSKs was decreased in the cortices of LKB1 knockout 
mice and the ability of over-expressed LKB1 to induce the formation of multiple 
axons was reduced upon BRSK knockdown (Barnes et al., 2007).   
 
In a similar manner to AMPK (Hawley et al., 2005), unpublished data shows that 
BRSK activity in brain slices is STO-609 sensitive (Prof. Bruno Frenguelli, personal 
communication).  STO-609 is a relatively specific inhibitor of CaMKK and as such, 
this result suggests that BRSKs are regulated in a calcium dependent manner.  Indeed, 
in mammals, there are two isoforms of  CaMKK, α and β, both of which are highly 
expressed in the brain regions where BRSKs are expressed (Vinet et al., 2003).  
More recently, it was shown that CaMKKα is an upstream activator of BRSK1 in 
vitro (Fujimoto et al., 2008).  This could provide a link between deregulated BRSK 
activity, tau phosphorylation and aberrant calcium metabolism.  In contrast, Bright et 
al showed that CaMKKβ does not activate the BRSKs (Bright et al., 2008), yet it 
does strongly activate AMPK (Hawley et al., 2005; Woods et al., 2005). 
 
It has also been reported that BRSK2 is directly activated by PKA via 
phosphorylation at T260 (Guo et al., 2006).  This could implicate another signalling 
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pathway in the control of the BRSKs.  However, PKA activation of BRSKs is not via 
the T-loop threonine residue and it has been reported that PKA has no effect on 
BRSK activation, so this is an issue that remains unresolved (Bright et al., 2008). 
 
 
1.8 Drosophila melanogaster as a model for neurodegeneration 
 
A process which is pathogenic in humans can be studied in Drosophila providing it 
can be mimicked in a way that shows sufficient correlation of the features of the 
disease in man (Sang and Jackson, 2005).  The fundamental processes of membrane 
trafficking, the cytoskeleton, gene expression regulation, cell signalling and neuronal 
connectivity are comparable in flies and man.  The lack of redundancy within the fly 
genome can simplify genetic analysis of processes within the fly: processes which 
when studied in humans can be difficult due to two or more copies of some genes.  A 
case in point is the presence of only one BRSK homologue in the Drosophila 
genome; CG6114.  Arguably the main advantage of using Drosophila as a model, is 
that large numbers of flies can be manipulated, mutagenized and screened in a 
relatively short time period, allowing insights to be made into disease mechanisms.  
These experiments would be impractical or even impossible to carry out in a 
mammalian system over a similar time period (Sang and Jackson, 2005).  Perhaps 
one of the most useful tools for Drosophila geneticists is the GAL4/UAS miss-
expression system which allows the over-expression of a gene of choice in a wide 
range of developing and adult tissues in the fly (Brand and Perrimon, 1993).    
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1.8.1 The eye 
 
The eye is often the focus of Drosophila research as the adult animal is highly 
tolerant of disruption to basic biological processes in this organ, and it is extremely 
easy to identify eye phenotypes, with many being visible to the naked eye.  
Additionally, under laboratory conditions, where the flies are kept in vials or bottles, 
the eye is not required in order to ensure the survival of the fly (Sang and Jackson, 
2005).  Using the eye-specific driver, GMR-GAL4, the eye has long been utilised for 
the analysis of developmental patterning and proliferation (Freeman, 1996).  It has 
been shown by a number of groups that expression of 4R human tau isoforms 
(mainly 0N4R and 2N4R) in the Drosophila eye causes a degenerative phenotype 
which is visible as a rough surface of the eye with disordered and fused lenses, 
implying disorganization of the ommatidia (photoreceptor clusters) (Shulman and 
Feany, 2003; Nishimura et al., 2004; Steinhilb et al., 2007a; Steinhilb et al., 2007b; 
Chatterjee et al., 2009; Iijima-Ando et al., 2010).  Shulman and Feany (2003) 
reported that the observed eye phenotype changes with the level of human tau 
expression, signifying that the model could be used as a sensitive marker for genetic 
interactions with tau that influence its toxicity. 
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Aims of the thesis 
 
Whilst the cause of AD remains elusive, it is apparent that tau pathology in the brain 
correlates well with the severity of symptoms in life.  In addition, the tauopathies are 
a spectrum of diseases which appear to be caused by aberrant tau protein.  Because 
of the central role of tau phosphorylation in the pathogenesis of tau and the formation 
of tau tangles, understanding tau phosphorylation is of the utmost importance.  As 
discussed, three members of the AMPK-related family of protein kinases, including 
AMPK itself, have been implicated as tau kinases.  BRSKs have been implicated in 
the basal phosphorylation of tau and unpublished data suggests that they are 
regulated in a calcium-dependent manner, via CaMKK.  Thus, the aim of my thesis 
was to investigate the interaction between human BRSKs and 0N4R tau using the 
Drosophila eye as a model, and to further explore the upstream regulation of BRSKs.  
More specifically, the aims of my thesis were: 
  
1. To transgenically express various mutated forms of human BRSK in the 
Drosophila eye and observe the effect this has on human tau-induced toxic 
eye phenotypes. 
2. To determine if human BRSKs are capable of phosphorylating human tau in 
vivo. 
3. To establish the upstream kinases responsible for BRSK activation. 
4. To investigate the potential for BRSKs to be regulated in a calcium 
dependent manner in vivo.  
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5. To investigate the expression levels/activity of BRSK and its upstream 
activators in human post-mortem brain tissue from AD patients and control 
subjects. 
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2| Materials and Methods 
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All chemicals and reagents were supplied by Sigma Aldrich, UK unless otherwise 
stated. 
 
2.1 Maintenance of Drosophila stocks 
2.1.1 Preparation of Sussex fly food 
 
Drosophila stocks were held at 25°C or 18°C in bottles or vials containing Sussex fly 
food.  Sussex fly food was prepared by mixing 518g maize flour, 471g sugar, 93g 
yeast and 28g agar into 5L water and boiling for 10 minutes in order to kill the live 
yeast.  The food was cooled prior to the addition of 75ml Nipagen M (10% w/v in 
ethanol) in order to prevent fungal growth, mixed well and poured into bottles and 
vials.  Once set, the food was supplemented with live yeast.  
 
 
2.1.2 Drosophila melanogaster lines used in this work 
 
See Appendix 1. 
 
 
2.2 Analysis of adult fly phenotypes 
2.2.1 Expression of exogenous and endogenous genes in the Drosophila 
melanogaster retina 
 
Over-expression of exogenous (human) and endogenous genes in the retina was 
achieved using the UAS-GAL4 expression system with the eye specific glass 
multiple repeat (GMR) driver (Brand and Perrimon, 1993). 
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2.2.2 Scanning electron microscopy 
 
Female flies were fixed overnight in 4% paraformaldehyde (PFA) made in phosphate 
buffered saline (PBS, 0.1M sodium phosphate pH 7.3, 0.1M sodium chloride) at 4˚C.  
Flies were then dehydrated using an acetone series (10%, 30%, 50%, 70%, and 90%), 
incubated on a rotator in 1ml of solution for 15 minutes at room temperature.  Flies 
were transferred to 100% acetone stored over a molecular sieve (dry acetone), for at 
least 2 days at 4˚C.  Flies were attached to stubs using double-sided tape, sputter 
coated in gold (or gold and palladium) for 60 seconds and imaged using a Zeiss 
Supra55 VP SEM at 150X magnification. 
 
2.2.3 Quantitative Edge Detection (QED) 
 
Software for assessing the level of ommatidial disruption in adult fly eyes (QED) 
was developed in collaboration with Dr John Aston and Mr Quentin Caudron from 
the Statistics Department at Warwick University.  The software was written in 
Matlab by Mr Quentin Caudron with contributions from Dr John Aston, Prof Bruno 
Frenguelli, Dr Kevin Moffat and I.  A full description of QED (written by Mr 
Quentin Caudron) is supplied in Appendix 2.  Briefly, QED processes SEM images 
and on the basis of sharp differences in contrast, uses edge detection to identify the 
edges of ommatidia.  The programme then measures the roundness of each 
ommatidia along with the distance to the six nearest neighbours of the central 
ommatidia and the angles to the six nearest neighbours of the central ommatidia.  For 
the purpose of this study, only data for the roundness measure (termed ommatidial 
distortion) has been used as it is a more sensitive measure, sampling hundreds of 
times per image as opposed to once per image for the distance and angle measures.  
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Once all the images of a genotype have been analysed, QED plots the distribution of 
the ommatidial roundness measures for the eye and then proceeds to measure the 
width of the distribution plot – this is termed the dispersion coefficient.  Dispersion 
coefficients from QED were collected and transferred to GraphPad software (version 
4) in order to produce cumulative plots of ommatidial distortion (dispersion 
coefficients) versus fly count (in percent of total). 
 
 
2.2.4 Resin embedding 
 
Heads of female flies were dissected on sylgard plates immersed in PBS in order to 
remove the proboscis and air sacks.  Heads were then fixed overnight in 2% 
gluteraldehyde: 2% paraformaldehyde made in PBS, at 4˚C.  Flies were dehydrated 
using an acetone series (10%, 30%, 50%, 70%, 90% and dry acetone, twice) 
incubated on a rotator in 1ml of solution for 30 minutes at room temperature.  Heads 
were embedded in Durcupan resin by following the next steps.  1 hour incubation in 
3 parts dry acetone: 1 part number 1 Durcupan ACM mixture (11.4g component A, 
10g component B, 150µl component D) at room temperature with rotation.  1 hour 
incubation in 2 parts dry acetone: 2 parts number 1 Durcupan ACM mixture at room 
temperature with rotation.  Overnight incubation in 1 part dry acetone: 3 parts 
number 1 Durcupan ACM mixture at room temperature with rotation.  The following 
day, two 2 hour incubations in number 1 Durcupan ACM mixture at 50°C followed 
by a 2 hour incubation in number 2 Durcupan ACM mixture (11.4g component A, 
10g component B, 350µl component C, 150µl component D) at 50°C.  Heads were 
transferred individually into moulds containing a thin layer of number 2 Durcupan 
ACM mixture that had been pre-baked at 70°C for 2-3 hours to prevent the heads 
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from sinking.  The wells were filled with number 2 Durcupan ACM mixture and the 
heads were orientated.  The moulds were baked at 70°C for 2 days to fully set the 
resin. 
 
2.2.5 Resin sectioning 
 
Resin blocks were trimmed to a trapezoidal shape using a razor blade and 2.5µm 
sections were cut using a Leica 2065 Supercut Rotary Microtome.  The sections were 
placed on drops of sterile water on superfrost slides (VWR) and allowed to dry on a 
heated block at 80-82°C. 
 
 
2.2.6 Toluidine-blue staining 
 
After sectioning, slides were stained with toluidine blue for the visualisation of the 
structure of photoreceptor cells.  For this, a solution of 1% toluidine blue and 1% 
borax in water was prepared.  The solution was re-used and filtered through a 0.2µm 
filter prior to each use.  Slides were stained for 30 seconds on a heated block at 80-
82°C, rinsed under tap water and allowed to dry on a heat block.  Once dry, slides 
were mounted in a mixture of dibutyl phthalate and xylene (DPX).  Sections were 
visualised and imaged under brightfield light on an epifluoresence microscope at 
100X magnification. 
.   
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2.3 DNA manipulations 
2.3.1 DNA isolation 
2.3.1.1 Small scale preparation of plasmid DNA 
 
DNA was isolated using the QIAprep Spin Miniprep Kit (Qiagen) according to 
manufacturer‟s manual. 
 
2.3.1.2 Large scale isolation of plasmid DNA 
 
DNA was isolated using either the Qiagen Plasmid midi or Hi-Speed maxi kit 
according to manufacturer‟s instructions. 
 
 
2.3.1.3 Preparation of genomic DNA from Drosophila melanogaster 
 
Genomic DNA was prepared according to the method written by E. Jay Rehm 
(Berkeley Drosophila Genome Project) which was accessed online at: 
 
http://www.fruitfly.org/about/methods/inverse.pcr.html 
 
Briefly, 30 flies were homogenised in 400µl of buffer A (100mM Tris-HCl pH7.5, 
100mM EDTA, 100mM NaCl, 0.5% SDS) using a mechanical pestle and incubated 
at 65°C for 30 minutes.  800µl Lithium Chloride/Potassium Acetate (LiCl/KAc) 
solution (2.5 parts 6M LiCl: 1 part 5 M KAc) was added and the tube was incubated 
on ice for 10 minutes before centrifugation for 15 minutes at full speed in a bench-
top microcentrifuge (room temperature).  1ml of supernatant was transferred to a new 
tube avoiding any floating debris and 600µl isopropanol was added.  The tube was 
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re-centifuged as above and the supernatant discarded.  The pellet was washed with 
70% ethanol and air dried before re-suspending in 100µl sterile water.  
 
 
2.3.2 Determination of DNA concentration 
 
DNA concentration and purity was measured using a NanoDrop ND-1000 
spectrophotometer (Thermo Scientific) and associated NanoDrop 1000 3.6.0 
software.  Purity was assessed by the 260nm/230nm and the 260nm/280nm ratios, 
with a ratio below 1.8 indicating a high level of organic contaminants or proteins in 
the DNA preparation respectively. 
 
 
2.3.3 Restriction digestion of DNA 
 
This was done in a total reaction volume of between 10 and 100μl using enzymes 
and buffers supplied by Invitrogen or Fermentas, according to manufacturer‟s 
instructions.  Enzyme was at 1/10 of the total volume.  100ng-5μg DNA was used.  
Digests were incubated over night in a 37°C water bath. 
 
 
2.3.4 Separation of DNA fragments according to size 
 
Method based on Maniatis et al (1982) – book 5, chapter 1, pages 150-162 
Fragments of DNA were separated according to their size by electrophoresis in 
agarose gels as previously described (Maniatis et al., 1982).  For ease of loading, 
DNA was mixed with loading buffer containing 30% glycerol, 0.1% bromophenol 
blue and 0.1% xylene cyanol at a ratio of 1 part loading buffer to 5 parts DNA.  Gels 
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were run at 150V until the dye front had migrated ¾ of the way along the gel.  For 
visualisation of DNA fragments on a UV transilluminator, ethidium bromide or 
RedSafe DNA stain (Chembio) were incorporated into the gel at 0.5μg/ml. 
 
 
2.3.5 Purification of DNA from agarose, salts and impurities 
 
This was done using QIAquick Gel Extraction (Qiagen) or Gene Clean II (Q Bio 
Gene) kits according to manufacturer‟s instructions. 
 
2.3.6 Subcloning of DNA fragments to plasmid vectors 
2.3.6.1 Ligation of DNA fragments to plasmid vectors 
 
Ligations were performed over night at room temperature using a 3:1 or 10:1 molar 
ratio of insert to vector with T4 DNA ligase (Invitrogen), according to 
manufacturer‟s instructions.  Vector was pre-treated with Bacterial Alkaline 
Phosphatase (Invitrogen) according to manufacturer‟s instructions in order to prevent 
self-ligation. 
 
 
2.3.6.2 Transformation of Escherichia coli and selection of colonies 
 
Following 2.3.6.1, chemically competent E.coli (high efficiency or subcloning 
efficiency, both New England Biolabs) was transformed with ligation mixture 
according to manufacturer‟s instructions.  Transformed cells were identified using 
antibiotic selection plates. 
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2.3.7 Bacterial strains 
 
Escherichia coli DH5α derivative (high efficiency, New England Biolabs) genotype:  
araD139 Δ(ara-leu)7697 fhuA lacX74 galK (Φ80 Δ(lacZ)M15) mcrA galU recA1 
endA1 nupG rpsL Δ(mrr-hsdRMS-mcrBC) 
 
Escherichia coli DH5α derivative (subcloning efficiency, New England Biolabs) 
genotype:  fhuA2 Δ(argF-lacZ)U169 phoA glnV44 Φ80Δ (lacZ)M15 gyrA96 recA1 
relA1 endA1 thi-1 hsdR17 
 
 
2.3.8 Media Preparation 
2.3.8.1 Luria-Bertani (LB) Broth 
 
LB broth was prepared by mixing 10g NaCl, 10g tryptone and 5g yeast extract into 
1L H2O.  This was autoclaved and cooled prior to use.  Where antibiotics were used, 
the antibiotics were added after autoclaving.  Ampicillin was used at a final 
concentration of 100µg/ml and kanomycin at a final concentration of 25µg/ml. 
 
 
2.3.8.2 LB agar plates 
 
LB broth (see 2.2.7.1.) with 15g/L agar.  Autoclaved and cooled before pouring into 
petri dishes to set.  Where antibiotics were used, the antibiotics were added after 
autoclaving.  Ampicillin was used at a final concentration of 100µg/ml and 
kanomycin at a final concentration of 25µg/ml. 
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2.3.9 Amplification of DNA using Polymerase Chain Reaction (PCR) 
2.3.9.1 Primer design 
 
Sense and antisense primers were designed to gene sequences using Clone Manager 
Suite software.  The software scores potential primer sequences on the basis of a set 
of criteria including annealing temperature, GC content, primer length, melting 
temperatures, hairpins, stability, runs of bases and dimers.  Primers which satisfied 
the criteria were ordered from Invitrogen (Custom oligonucleotide service).  See 
Appendix 3 for a list of primers used in this study. 
 
 
2.3.9.2 PCR conditions 
 
PCR reactions were carried out using the following basic conditions for a 50µl 
reaction: 
 
5µl 10X PCR buffer (Invitrogen) 
1.5µl 50mM MgCl2/MgSO4 (depending on whether standard taq or pfx enzymes 
were being used) 
1.5µl 10mM dNTPs (ATP, CTP, GTP, TTP) (Invitrogen) 
5µl of each primer (final concentration of 0.005µg/µl) 
x µl DNA (1ng for plasmid and up to 500ng for genomic) 
0.4µl polymerase – either taq or pfx (both Invitrogen) 
Water to 50µl 
 
 
An Eppendorf thermocycler was used for all reactions with the following basic 
conditions: 
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1. Initial denaturation: 5 minutes, 94°C 
2. Denature: 15 seconds, 94°C 
3. Anneal primers: 30 seconds, 55°C  
4. Extend DNA: 30 seconds per kb of product, 72°C 
5. Repeat steps 2-4 for 35 cycles 
6. Final Extension: 10 minutes, 72
o
C 
 
If the PCR was unsuccessful using the basic conditions above, two approaches were 
taken in order to optimise the conditions.  Firstly, the magnesium concentration of 
the reaction was altered.  Magnesium is a cofactor for enzymes and altering its 
concentration may enhance the stringency of the polymerase.  Secondly, the 
annealing temperature was altered in order to customize the reaction conditions for 
that particular set of primers.  
 
 
2.3.10 Sequencing DNA 
 
Using primers designed as described in 2.3.9.1 and plasmid DNA prepared as 
described in 2.3.1.1 or 2.3.1.2.  50-500ng DNA and 5.5pmol primer were typically 
used in a total volume of 10ul.  Sequencing was carried out by Molecular Biology 
Services, Biological Sciences, Warwick University on an ABI Prism Genetic 
Analyser 3130xl, the data from which was collected using ABI Prism 3130xl Genetic 
Analyser Data Collection Software version 3.0 and edited using ABI Prism 
Sequencing Analysis Software version 5.2.   
 
85 
 
2.4 Protein manipulations 
2.4.1 Analysis of samples from Drosophila melanogaster 
2.4.1.1 Protein extraction from Drosophila melanogaster 
 
Lysis buffer contained 50mM tris(hydroxymethyl)aminomethane-hydrochloric acid 
(Tris-HCl pH 7.5), 0.1mM ethylene glycol tetra-acetic acid (EGTA), 1mM ethylene 
diamine tetra-acetic acid (EDTA), 1% (v/v) Triton X-100, 1mM Sodium 
Orthovanadate (Na3VO4), 50mM Sodium Fluoride (NaF), 5mM Sodium 
Pyrophosphate (Na4P2O7), 0.27M Sucrose, 0.1% (v/v) -Mercaptoethanol and 
„Complete‟ protease inhibitor cocktail (Roche, three tablets per 50ml).  NaF and 
Na4P2O7 were included in order to inhibit serine/threonine protein phosphatases.  
Na3VO4 was included in order to inhibit protein tyrosine phosphatases.   EDTA was 
used to chelate Mg
2+
 ions which are essential co-factors required for kinase activity.  
Proteinase inhibitor cocktail tablets were used to inhibit serine, cystein, metallo and 
aspartyl proteinases.  EGTA was included in order to chelate Ca
2+
 ions which are 
important signalling molecules.  This combination of chelators and inhibitors made 
certain that proteolysis, phosphatase and protein kinase activity was insignificant in 
the produced lysates. 
 
 
In order to minimise the effect of tau and BRSK2 expression during eye development, 
all western blots were conducted on flies which had been reared according to the 
method described by Iijima-Ando et al (2010).  Briefly, flies were crossed and reared 
until eclosion at 18°C in order to minimise GAL4 activity.  Once flies had eclosed 
they were aged at 25°C for 7 days in order to activate GAL4 expression.  After aging, 
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fly heads were dissected and subsequently lysed in 2ul lysis buffer per head with the 
aid of a mechanical pestle.  Lysates were spun in a microcentrifuge at 13000rpm for 
20 minutes at 4°C and the supernatant removed.  The pellet of cell debris was 
discarded and the amount of protein in the lysate was determined via the Bradford 
Assay.  Sodium dodecyl sulphate (SDS) loading dye was then added to the lysates 
which were subsequently heated at 70°C for 10 minutes before snap freezing in 
liquid nitrogen and storing at -80°C. 
 
 
2.4.1.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
SDS-PAGE was performed using the BioRad mini system. Protein extracts were 
thawed and heated at 70˚C for 10 minutes.  Following a brief centrifugation to collect 
the samples at the bottom of the tubes, samples along with Bench Mark Pre-Stained 
Protein Ladder (Invitrogen) were loaded onto SDS-PAGE gels which constituted of 
10% resolving gel and 4% stacking gel (see tables 2.1 and 2.2 for gel compositions).  
SDS containing loading dye ensured all proteins had an equal mass to charge ratio 
therefore, the distance travelled through the gel was directly related to a proteins size, 
with smaller proteins migrating faster than larger ones.  Electrophoresis was carried 
out using running buffer containing (per 1L of distilled water) 1g SDS, 3g Tris and 
14.4g Glycine, at a voltage of 100V for 20 minutes for stacking which was then 
increased to 150V for 30-45 minutes.  Proteins were transferred to nitrocellulose 
using a constant current of 200mAmp for 2 hours.  Transfer buffer contained (per 1L 
of distilled water) 3g Tris, 14.4g Glycine and 20% (v/v) methanol.   
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 10% 
d.water 4.1ml 
Lower buffer 3.1ml 
30% acrylamide 3.7ml 
10% SDS 110ul 
TEMED 11ul 
20% APS 55.3ul 
 
Table 2.1 Composition of lower (resolving) gel.   
Lower buffer consisted of 1.5M Tris at pH 8.8 
 
 
 
 
 
 
Table 2.2 Composition of upper (stacking) gel.   
Upper buffer consisted of 0.5M Tris at pH 6.8 
 
 
2.4.1.3 Immunoblotting  
 
Membranes were blocked with either 5% (w/v) skimmed dried milk in PBS or 5% 
(w/v) bovine serum albumin (BSA) in PBS for 1 hour at room temperature with 
agitation.  Membranes were incubated in various primary antibodies diluted in 1% 
(w/v) skimmed dried milk in PBS.  Primary antibodies were applied at 4°C, with 
rotation, overnight (see Table 2.3 for primary antibodies used in this study).  
Following three 10 minute washes in PBS containing 0.05% Tween-20 (PBST) to 
remove any unbound or non-specific primary antibody, membranes were incubated 
with horseradish peroxidase (HRP) conjugated secondary antibodies (Thermo 
Scientific, all used at 1:1000) diluted in 1% (w/v) dried skimmed milk in PBS for 1 
 4% 
d.water 2.8ml 
Upper buffer 1.2ml 
30% acrylamide 830ul 
10% SDS 50ul 
TEMED 5.3ul 
20% APS 50ul 
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hour at room temperature with agitation (see Table 2.4 for secondary antibodies used 
in this study).  Membranes were washed with two 10 minute washes of PBST to 
remove any unbound or non-specific secondary antibody followed by one 10 minute 
wash in PBS to remove residual Tween-20 (which can cause a high background 
signal).  Membranes were then incubated with enhanced chemoluminescence (ECL) 
reagent (GE Healthcare) for one minute before exposing film to the membranes and 
developing the film.  Developed films were scanned using a flat bed scanner and 
densities of bands were measured using Scion image software.   
 
 
2.4.2 Analysis of samples from post-mortem human brain tissue  
 
This work was carried out in the lab of Dr Diane Hanger, MRC Centre for 
Neurodegeneration Research, Institute of Psychiatry, King's College London under 
the supervision of Dr Wendy Noble and Dr Diane Hanger.  Post-mortem frontal 
cortex tissue from clinically and pathologically confirmed human AD patients and 
age-matched control subjects was provided by the MRC Neurodegenerative Diseases 
Brain Bank at the Institute of Psychiatry, King‟s College London, UK.  Written 
consent was obtained from each subject and/or their families for the purpose of this 
study.  This study was conducted according to the principles expressed by the 
Declaration of Helsinki. 
 
2.4.2.1 Protein extraction from human post-mortem brain tissue 
 
Human cortex tissue was homogenized on ice at 200 mg/mL (w/v)  in modified 
radioimmunoprecipitation assay buffer (mRIPA) containing 50mM Tris-HCl pH8, 
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150mM Sodium Chloride (NaCl), 2mM EGTA, 1mM phenyl methane sylfonyl 
fluoride (PMSF), 10mM NaF, 1mM Na3VO4, 1% nonidet P-40, 0.5% sodium 
deoxycholate (C24H39O4Na), 0.1% SDS and „Complete‟ protease inhibitor cocktail 
lacking EGTA and PMSF (Roche, three tablets per 50ml) using a polytron 
mechanical homogeniser.  PMSF is a serine protease inhibitor, nonidet P-40 is a 
detergent used for solubilising membranes, sodium deoxycholate is an ionic 
detergent useful for disrupting and dissociating protein interactions; it is more severe 
than nonidet P-40 and was included to ensure complete lysis.  Homogenates were 
centrifuged at 13000rpm for 30 minutes and the supernatant was removed.  
Supernatants were mixed 1:1 with 2x SDS loading dye.  5ul of each sample 
(approximately 10ug protein) was run on a 10% SDS-PAGE gel and immunoblotted 
with neuron specific enolase (NSE) primary antibody and a fluorescent conjugated 
secondary antibody.  Membranes were scanned and quantified (see section 2.4.2.2) 
and subsequent loading was normalised for NSE signal.  NSE was chosen for 
normalisation in order to control for the loss of neurons in AD samples. 
 
2.4.2.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
and immunoblotting 
 
SDS-PAGE and immunoblotting was carried out essentially as described in sections 
2.4.1.2 and 2.4.1.3 with the following exceptions: 
 
 The apparutus used was the Novex system and all gels consisted of 10% 
stacking gel and 4% resolving gel. 
 SeeBlue Plus2 Pre-Stained Standard (Invitrogen) was used as a molecular 
weight marker. 
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 A gel-to-gel loading control was included in order to facilitate normalisation 
of samples across membranes.  This was necessary as the size of the data set 
necessitated splitting the samples over three gels. 
 Membranes were blocked in either 5% (w/v) dried skimmed milk in PBS or 
Odyssey blocking buffer (made according to manufacturer‟s instructions) for 
1 hour at room temperature with agitation – see Table 2.3 for further details. 
 Due to poor signal, some primary antibodies were diluted in Odyssey 
blocking buffer – see Table 2.3 for further details. 
 Fluorescent conjugated secondary antibodies (see Table 2.4. for details) were 
used followed by scanning of membranes on an Odyssey infrared scanner and 
quantification of band intensities using Odyssey software (version 3).  
Membranes were then re-blocked and re-probed for the appropriate loading 
control and scanned and quantified as before.  
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2.4.3 Primary antibodies used in this study 
Antibody Source Species Application Blocking Dilution 
Incubation 
time 
pS262 
tau 
Invitrogen 
Rabbit 
polyclonal 
Drosophila 5% milk 
1:1000 
in 1% 
milk Overnight 
4°C 
Human 5% milk 
1:1000 
in 1% 
milk 
T46 
(total 
tau) 
Abcam 
Mouse 
monoclonal 
Drosophila 5% milk 
1:1000 
in 1% 
milk 
Overnight 
4°C 
BRSK2 
N-term 
Kind gift 
of Dr C 
Sutherland 
Sheep 
polyclonal 
Drosophila 5% milk 
1:1000 
in 1% 
milk Overnight 
4°C 
Human 
Odyssey 
block 
1:500 in 
odyssey 
block 
BRSK2 
C-term 
Kind gift 
of Dr C 
Sutherland 
Sheep 
polyclonal 
Human 5% milk 
1:1000 
in 1% 
milk 
Overnight 
4°C 
Actin Abcam 
Rabbit 
polyclonal 
Drosophila 5% BSA 
1:2500 
in 1% 
milk 
Overnight 
4°C 
NSE Dako 
Mouse 
monoclonal 
Human 5% milk 
1:10000 
in 1% 
milk 
1hr room 
temperature 
LKB1 
Kind gift 
of Dr C 
Sutherland 
Sheep 
polyclonal 
Human 
Odyssey 
block 
1:500 in 
odyssey 
block 
Overnight 
4°C 
pLKB1 Abcam 
Rabbit 
polyclonal 
Human 
Odyssey 
block 
1:500 in 
odyssey 
block 
Overnight 
4°C 
CaMKK 
Kind gift 
of Dr J 
Hastie 
Sheep 
polyclonal 
Human 5% milk 
1:1000 
in 1% 
milk 
Overnight 
4°C 
Total tau Dako 
Mouse 
monoclonal 
Human 5% milk 
1:20000 
in 1% 
milk 
Overnight 
4°C or 1hr 
room 
temperature 
PHF1 
Kind gift 
of Prof P 
Davies 
Rabbit 
polyclonal 
Human 5% milk 
1:200 in 
1% milk 
Overnight 
4°C 
 
Table 2.3 Primary antibodies used in this study.   
A table showing the primary antibodies used, their source, species and application, 
the appropriate block, the dilution and the incubation time and temperature. 
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2.4.4 Secondary antibodies used in this study 
 
Antibody Source Species Application Dilution Incubation 
anti-
rabbit-
HRP 
Thermo 
Scientific 
Rabbit Drosophila 
1:1000 in 
1% milk 
1hr room 
temperature 
anti-
mouse-
HRP 
Thermo 
Scientific 
Mouse Drosophila 
1:1000 in 
1% milk 
1hr room 
temperature 
anti-
sheep-
HRP 
Thermo 
Scientific 
Sheep Drosophila 
1:1000 in 
1% milk 
1hr room 
temperature 
anti-
rabbit 
800 
Rockland Goat Human 
1:5000 in 
1% milk 
1hr room 
temperature 
anti-
sheep 
680 
Invitrogen Sheep Human 
1:5000 in 
1% milk 
1hr room 
temperature 
anti-
mouse 
800 
LICOR Mouse Human 
1:5000 in 
1% milk 
1hr room 
temperature 
anti-
mouse 
680 
Invitrogen Goat Human 
1:5000 in 
1% milk 
1hr room 
temperature 
 
Table 2.4 Secondary antibodies used in this study.   
A table showing the secondary antibodies used, their source, species and application, 
the appropriate block, the dilution and the incubation time and temperature. 
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2.4.5 Recombinant BRSK2 degradation assay 
 
Recombinant BRSK2 protein (10ng/µl) was incubated at 37°C in a water bath.  At 0, 
1, 2, 4 and 8 hours a 15µl aliquot was removed, placed on ice and SDS sample buffer 
was added.  Equal amounts of protein from each timepoint were analyzed by SDS-
PAGE as described in section 2.4.1.2. 
 
2.4.6 Calpain Assay 
 
Method adapted from Patzke and Tsai (2002).  Briefly, in calpain reaction buffer 
(100mM imidazole, 5mM L-cystein and 5mM calcium chloride, pH 7.5) 100ng 
purified recombinant BRSK2 protein was incubated with increasing concentrations 
of Calpain-2 (Calbiochem) in the presence or absence of the calpain inhibitor, 
calpeptin (Calbiochem).  Reactions were incubated at 30°C (in a water bath) for 1 
hour.  Reactions were terminated by the addition of SDS sample buffer and equal 
amounts of the reactions were analyzed by SDS-PAGE as described in section 
2.4.1.2.  
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3| Cloning of human and 
Drosophila gene 
sequences into the 
Drosophila expression 
vector, pUAST. 
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3.1 Introduction 
 
 
In order to investigate the effect of co-expression of various human genes (BRSK1, 
BRSK2, CaMKKα, LKB1) and endogenous Drosophila CG6114 (the Drosophila 
homologue of BRSK) with human tau in the Drosophila eye, flies which were 
capable of expressing the genes were constructed.  This was achieved by cloning the 
genes into the Drosophila expression vector, pUAST.  pUAST is a Drosophila 
vector that confers GAL4 inducibility (Brand and Perrimon, 1993).  In the following 
sections are schematics for the cloning of BRSK1, BRSK2, CaMKKα, LKB1 and 
CG6114 into the pUAST vector.  This chapter serves as a record of the cloning and 
subsequent transgenic flies used in this thesis.   
 
Two methods were utilised for the cloning of human gene sequences into pUAST.  
The first method (used for BRSK1, BRSK2 and CG6114 constructs) involved the 
use of restriction enzymes to release the gene of interest from the construct and 
ligation of this fragment into pUAST which had been digested with the same 
enzymes (or enzymes which were isocaudomers).  The second method (used for 
CaMKKα and LKB1 constructs) utilised PCR in order to amplify the sequences.  
This method was used as cloning of the CaMKKα and LKB1 genes required the 
insertion of a Kozak sequence, which was absent from the mammalian CaMKKα and 
LKB1 clones,  upstream of the gene in order to ensure that the gene was recognised 
and able to be expressed and functional in Drosophila.  Although there is a 
consensus Kozak sequence for use in Drosophila, the BRSK2 Kozak sequence was 
chosen as the BRSK2 transgenic flies had already been proven to be expressing and 
functional.   
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Prospective clones were confirmed with restriction enzyme digests and sequencing, 
and subsequently the DNA was sent to Best Gene Inc. for transgenesis.  Please see 
Appendix 3 for a list of primers used in this work. 
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3.2 BRSK1 
 
Four pCMV5.BRSK1 constructs (kind gifts of Prof. Dario Alessi, University of 
Dundee) were available for cloning; wild type (B-WT), constitutively active (B-CA), 
kinase dead (B-KD) and non-phosphorylatable (B-NP), see Table 3.1 for a list of the 
amino acid and DNA codon changes.  B1-CA has a conserved threonine (T) residue 
in the T-loop mutated to glutamic acid (E) in order to mimic phosphorylation.  In B1-
WT, this threonine residue requires phosphorylation by an upstream kinase in order 
for BRSK to become active.  B1-NP has the same threonine residue mutated to 
alanine (A), which prevents the residue from becoming phosphorylated and thus 
causes BRSK to be inactive.  Recombinant B1-CA and B1-NP constructs were tested 
using in vitro kinase assays in order to show that the mutations resulted in a 
functional change (Lizcano et al., 2004).  B1-KD has an aspartic acid (D) residue 
mutated to alanine which prevents BRSK from utilising ATP in order to 
phosphorylate other proteins, rendering BRSK KD.  The B1-KD construct has also 
been tested using in vitro kinase assays and has been confirmed to be inactive 
(personal communication, Prof Dario Alessi).   
 
 
Construct Amino acid change DNA codon change 
B1-CA T189E ACC to GAG 
B1-KD D174A GAC to GCC 
B1-NP T189A ACC to GCC 
 
Table 3.1  BRSK1 amino acid and DNA codon changes.  
Mutations made in wild type BRSK1 to produce B1-CA, B1-KD and B1-NP 
constructs. 
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BRSK1 genes were released from the pCMV5 plasmids via restriction enzyme digest 
with EcoRI and BamHI, yielding a fragment (2376bp) containing the BRSK1 gene.  
The Drosophila vector, pUAST, was linearised using EcoRI and BglII and 
subsequently treated with bacterial alkaline phosphatase (BAP) to prevent re-ligation.  
BglII and BamHI are isocaudomers, and as such recognise slightly different 
sequences (AGATCT and GGATCC respectively) but produce the same sticky ends.  
The purified BRSK1 fragments were ligated to the linearised pUAST to create 
pUAST.BRSK1. 
 
Restriction enzyme digest of possible clones were designed so that digestion of a 
positive clone with EcoRI and XbaI would release a 2403bp fragment and digestion 
with XhoI would yield a 959bp fragment (see Figure 3.2 for an example digest) – 
fragments which would differ in size from those produced by digestion of either 
empty pUAST vector or pCMV5.BRSK1. 
 
Having verified the clones by restriction enzyme digest, the DNA was sequenced 
using primers 1 a), 1 b) and 1 c) to confirm the ligation and maintenance of the 
mutation sites. 
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. 
Figure 3.1  Schematic for cloning of BRSK1 into pUAST.   
A. pCMV5.BRSK1 constructs were digested with EcoRI and BamHI to release a 
2376bp fragment containing the BRSK gene.  pUAST plasmid was linearised with 
EcoRI and BglII. 
B. The BRSK1 fragment and the linearised pUAST were ligated to create 
pUAST.BRSK1. 
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Figure 3.2 Enzyme digest of pUAST.BRSK1 clones.   
Agarose gel containing ethidium bromide in order to stain DNA fragments.  Lanes 2, 
4, 6, 8, 10 and 12 digested with EcoRI and XbaI (to yield a 2403bp fragment from 
positive clones).  Lanes 3, 5, 7, 8, 9, 11 and 13 digested with XhoI (to yield a 959bp 
fragment from positive clones).  pUAST and pCMV5.BRSK1 included as controls. 
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3.3 BRSK2 
 
 
As with BRSK1, four pCMV5.BRSK2 constructs (kind gifts of Prof. Dario Alessi, 
University of Dundee) were available for cloning; B2-WT, B2-CA, B2-KD and B2-
NP, see Table 3.2 for a list of the amino acid and DNA codon changes.  Recombinant 
B2-CA and B2-NP constructs have previously been tested using in vitro kinase 
assays in order to confirm that the mutations resulted in functional changes (Lizcano 
et al., 2004).  The B2-KD construct has also been tested using in vitro kinase assays 
and has been confirmed to be inactive (personal communication, Prof Dario Alessi).  
 
 
Construct Amino acid change DNA codon change 
B2-CA T174E ACC to GAA 
B2-KD D159A GAC to GCC 
B2-NP T174A ACC to GCC 
 
Table 3.2  BRSK2 amino acid and DNA codon changes.   
Mutations made in wild type BRSK2 to produce B2-CA, B2-KD and B2-NP 
constructs. 
 
 
 
BRSK2 genes were cloned in a similar way to BRSK1.  Enzyme digestion of 
pCMV5.BRSK2 plasmids with EcoRI and NotI released a fragment (2077bp) 
containing the BRSK2 sequence.  pUAST, was linearised using EcoRI and NotI and 
BAP treated.  The two DNA fragments were then ligated to create pUAST.BRSK2.  
 
As with BRSK1, restriction enzyme digest of possible clones were designed so that 
digestion of a positive clone with EcoRI and NotI would release a 2077bp fragment 
and digestion with SmaI would yield a 3640bp fragment (see Figure 3.4 for an 
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example digest) - fragments which would be different in size from those resulting 
from digestion of either empty pUAST vector or pCMV5.BRSK2. 
 
 
Having verified the clones by restriction enzyme digest, the DNA was sequenced 
using primers 2 a), 2 b) and 2 c) to confirm the ligation and maintenance of the 
mutation sites. 
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Figure 3.3  Schematic for cloning of BRSK2 into pUAST.   
A. BRSK2 constructs were digested with EcoRI and NotI to release a 2077bp 
fragment containing the BRSK gene.  pUAST plasmid was linearised with EcoRI and 
NotI. 
B. The BRSK2 fragment and the linearised pUAST were ligated to create 
pUAST.BRSK2. 
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Figure 3.4 Enzyme digest of pUAST.BRSK2 clones.   
Agarose gel containing ethidium bromide in order to stain DNA fragments.  Lanes 2, 
4, 6, 8, 10 and 12 digested with EcoRI and NotI (to yield a 2077bp fragment from 
positive clones).  Lanes 1, 3, 5, 7, 8, 9, and 11 digested with SmaI (to yield a 3640bp 
fragment from positive clones).  pUAST and pCMV5.BRSK2 included as controls. 
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3.4 Genotyping the BRSK transgenic flies 
 
 
Upon receipt of the BRSK flies, it was important to confirm that BestGene Inc. had 
used the correct DNA for transgenesis and that the mutation sites in the BRSK 
isoforms had been maintained.  This was done by genomic PCR using primers 3 a) 
and 3 b) to amplify a fragment of 492bp from BRSK1 genomic DNA and primers 4 a) 
and 4 b) to amplify a 990bp fragment from BRSK2 genomic DNA. Subsequently, 
primer 3 a) was used for direct sequencing of the BRSK1 PCR products and primer 5 
a) was used for sequencing the BRSK2 products.  Figure 3.5 shows the results for 
BRSK1 flies and Figure 3.6 the results for BRSK2 flies. 
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Figure 3.5  BRSK1 genotyping.   
Sequences from genotyping of B1-WT, B1-NP, B1-KD and B1-CA transgenic flies.  
Highlighted in red in the B1-WT sequence, are the two possible mutation sites; GAC 
(aspartic acid, on the left) and ACC (threonine, on the right).  B1-NP is wild type for 
the GAC site but has an ACC to GCC mutation (threonine to alanine).  B1-KD has a 
GAC to GCC mutation (aspartic acid to alanine) and is wild type for the ACC site.  
B1-CA is wild type for the GAC site and has an ACC to GAG mutation (threonine to 
glutamic acid). 
107 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  BRSK2 genotyping. 
Sequences from genotyping of B2-WT, B2-NP, B2-KD and B2-CA transgenic flies.  
Highlighted in red in the B2-WT sequence, are the two possible mutation sites; GAC 
(aspartic acid, on the left) and ACC (threonine, on the right).  B2-NP is wild type for 
the GAC site but has an ACC to GCC mutation (threonine to alanine).  B2-KD has a 
GAC to GCC mutation (aspartic acid to alanine) and is wild type for the ACC site.  
B2-CA is wild type for the GAC site and has an ACC to GAA mutation (threonine to 
glutamic acid). 
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3.5 BRSK transgenic line assessment and selection 
 
 
Due to the redundancy exhibited between BRSK1 and 2 in mammals, most of the 
experiments in this thesis have been conducted using BRSK2.  However, in order to 
gain some insight into whether BRSK1 and 2 were capable of performing the same 
function in Drosophila, BRSK1 lines were also assessed for their eye phenotype 
during the selection of BRSK2 lines. 
 
BLASTp showed that BRSK2 has slightly higher sequence identity with CG6114 
than BRSK1 (maximum score of 585 with 88% coverage for BRSK2 and maximum 
score of 572 with 77% coverage for BRSK1). 
 
All BRSK1 and BRSK2 lines were crossed to a line carrying the GMR::GAL4 driver 
on the second chromosome and the 0N4R isoform of human tau on the third 
chromosome and the resulting eye phenotypes were scored according to the scale 
demonstrated in Figure 3.7. 
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Figure 3.7  Light microscope images of fly eyes to demonstrate the scale used for 
phenotypic scoring. 
The scale used for phenotypic scoring of fly eyes was as follows: 0 – Not rough, 1 – 
Slightly rough, 2 – Very rough, no signs of necrosis, 3 – Very rough, signs of 
necrosis, 4 - Very rough, signs of necrosis, eye very small.  Scale bar 100µm applies 
to all panels. 
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Tables 3.3 and 3.4 show the phenotypic scoring for BRSK1 and BRSK2 flies 
respectively. 
 
 
Fly 
no. 
BRSK1 WT 
Line No. 
BRSK1 KD Line 
No. 
BRSK1 
NP 
Line No. 
BRSK1 CA Line 
No. 
2 3 5 6 7 8 10 6 7 3 4 5 1 2 
1 3 3 3 3 3 3 4 2 2 2 2 2 2 2 
2 3 3 4 3 2 4  2 2 2 3 2 2 2 
3 3 2 4 3 2 3  2 2 2 2 2 2 2 
4 3 3 3 2 3 3  2 3 2 2 2 2 2 
5 3 2 3 3 3 3  2 2 3 2 3 3 2 
6 2 2 4 2 3 4  2 2 3 2 2 2 2 
7 2 2 4 3 3 4  2 2 2 2 2 2 3 
8 3 3 4 3 2 3  2 2 2 2 2 2 2 
9 2 3 3 2 3 3  2 2 2 2 2 2 2 
10 3 3 4 3 3 3  2 2 2 2 3 2 3 
 
Table 3.3  Phenotypic scoring of BRSK1.   
BRSK1 lines were crossed to GMR;tau and the resulting eye phenotypes scored 
according to the previously described scale. 
 
 
 
Fly 
No. 
BRSK2 WT 
Line No. 
BRSK2 KD 
Line No. 
BRSK2 NP 
Line No. 
BRSK2 CA 
Line No. 
1 2 3 4 5 1 3 4 5 7 9 1 2 3 4 6 8 4 5 7 8 10 
1 3 3 3 4 3 3 2 2 2 3 2 2 2 3 2 2 3 3 3 3 3 2 
2 3 3 3 3 3 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3 2 
3 2 3 3 2 3 3 2 2 2 2 2 2 3 2 2 2 2 2 2 2 2 2 
4 2 2 3 3 4 2 2 2 2 2 2 2 2 2 2 3 2 2 3 2 3 2 
5 3 2 2 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 3 2 2 2 
6 2 3 2 3 4 2 2 2 2 2 2 2 3 2 2 2 2 2 2 2 2 3 
7 3 4 2 2 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
8 4 4 3 3 3 2 3 2 3 2 2 2 2 3 2 2 2 2 2 2 2 2 
9 4 4 3 3 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
10 3 3 4 3 3 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 
 
Table 3.4  Phenotypic scoring of BRSK2.   
BRSK2 lines were crossed to GMR;tau and the resulting eye phenotypes scored 
according to the previously described scale. 
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Comparison of the scoring for the BRSK1 and BRSK2 flies, showed that the mutated 
isoforms of BRSK were capable of producing a similar phenotype, with B-WT 
isoforms (BRSK1 and BRSK2) having a consistently higher score than either B-NP, 
B-KD or B-CA.  However, this was a surprising result in that B-CA did not appear to 
have a higher score than B-NP or B-KD.  This suggested that the B-CA mutation 
may not be functional in the transgenic flies. 
 
From the phenotypic scoring in Table 3.4, the BRSK2 lines selected for further use 
were B2-WT line 5, B2-NP line 4, B2-KD line 4 and B2-CA line 5, henceforth 
referred to as B-WT, B-NP, B-KD and B-CA respectively.  BRSK2 lines were 
selected on the basis that the flies exhibited a robust and reproducible phenotype.  All 
lines selected had the BRSK2 insertion on the 3
rd
 chromosome in order to minimise 
any chromosome-specific expression effects.     
 
In addition, with a view to conducting experiments with BRSK and 0N4R human tau 
in the nervous system, B-WT (line5) and CG6114 RNAi (CG6114 is the Drosophila 
homologue of human BRSKs) were crossed to a number of neuronal GAL4 drivers 
(elav::GAL4 which expresses in the CNS, tub::GAL4 which expresses everywhere 
that tubulin is expressed, cha::GAL4 which expresses in cholinergic neurons, 
d42::GAL4 which expresses in motor neurons and 0k-6::GAL4 which expresses in a 
subset of motor neurons).  However, over-expression of B-WT or knock-down of 
CG6114 using the aforementioned neuronal drivers was lethal at the embryonic stage 
and so these experiments were not pursued. 
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3.6 BRSK2 expression  
 
 
In order to ascertain that the lack of phenotype in the B-NP and B-KD flies was in 
fact due to the mutations they carried and not due to a lower level of expression, 
western blots were carried out on lysates from each of the four selected BRSK2 lines.  
Figure 3.8 shows that the expression level of total BRSK2 in the four lines was not 
significantly different (n=3 0.59±0.10 for B-WT, n=3 0.74±0.13 for B-NP, n=3 
0.64±0.12 for B-KD and n=3 0.61±0.02 for B-CA, p=0.63 one way anova). 
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Figure 3.8  Western blots for BRSK2 and actin.   
Quantification of western blots to show BRSK2 expression normalised to actin.  One 
way anova analysis showed that expression was not significantly different (n=3 
0.59±0.10 for B-WT, n=3 0.74±0.13 for B-NP, n=3 0.64±0.12 for B-KD and n=3 
0.61±0.02 for B-CA, p=0.63 one way anova).  Representative western blots shown.   
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3.7 CaMKK alpha 
 
 
The cloning of CaMKKα into pUAST was done by Mrs Ellie Tucker under my 
supervision.  
 
One of the upstream regulators of mammalian BRSK identified in the literature is 
calcium/calmodulin dependent kinase kinase alpha (CaMKKα).  CaMKKα acts on 
BRSKs by phosphorylating the conserved T-loop threonine residue (T189 in BRSK1 
and T174 in BRSK2), leading to the activation of BRSKs (Fujimoto et al., 2008). 
 
 
In order to insert the BRSK2 Kozak sequence at the start of the CaMKK α gene,   
primers were designed to amplify the gene sequence via PCR.  Primer 6 b) was used 
to engineer an EcoRI restriction enzyme site upstream of the BRSK2 Kozak 
sequence, onto the 5‟ end of the antisense strand and primer 6 a) was used to insert a 
NotI restriction enzyme site onto the 3‟ end of the sense strand.  This approach 
allowed the successful PCR of the CaMKKα gene, downstream of the BRSK2 kozak 
sequence and the insertion of two different restriction enzyme sites allowed the 
subsequent restriction enzyme digestion and directional cloning of the PCR fragment 
into pUAST linearised with EcoRI and NotI.  Figure 3.9 shows a schematic of the 
cloning of CaMKKα. 
 
Restriction enzyme digest of possible clones were designed so that digestion of a 
positive clone with EcoRI and NotI would release a 1561bp fragment containing 
CaMKKα (see Figure 3.10 for an example digest). 
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Having verified the clones by restriction enzyme digest, the DNA was sequenced 
using primers 7 a) and 7 b) in order to confirm the ligation before being sent for 
transgenesis.  However, it should be noted that the full CaMKKα insert was not 
sequenced. 
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Figure 3.9  Schematic for cloning of CaMKKα into pUAST.   
A. CaMKKα was amplified using PCR primers 6 a) and 6 b) and subsequently 
restriction enzyme digested using EcoRI and NotI.  pUAST plasmid was linearised 
with EcoRI and NotI. 
B. The CaMKKα fragment and the linearised pUAST were ligated to create 
pUAST.CaMKKα. 
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Figure 3.10 Enzyme digest of pUAST.CaMKKα clones.   
Agarose gel containing ethidium bromide in order to stain DNA fragments.  Lanes 2, 
3, 4, 5, 6 and 7 digested with EcoRI and NotI (to yield a 1561bp fragment from 
positive clones).  Lane 3 shows a negative clone, lanes 2, 4, 5, 6 and 7 show positive 
clones. 
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3.8 LKB1 
 
Another regulator of mammalian BRSKs identified in the literature is LKB1, which 
has the same mode of action on BRSK as CaMKKα (Lizcano et al., 2004).  LKB1 is 
a master kinase of the AMPK family of protein kinases.   
 
LKB1 was cloned using the same method as was used for CaMKKα: primer 8 b) was 
used in order to engineer an EcoRI restriction enzyme site upstream of the BRSK2 
Kozak sequence onto the 5‟ end of the antisense strand and primer 8 a) was used to 
insert a NotI restriction enzyme site onto the 3‟ end of the sense strand.  As for 
CamKKα, this approach allowed the successful PCR of the LKB1 gene, downstream 
of the BRSK2 Kozak sequence and the insertion of two different restriction enzyme 
sites allowed the subsequent restriction enzyme digestion and directional cloning of 
the PCR fragment into pUAST linearised with EcoRI and NotI.  Figure 3.11 shows a 
schematic of the cloning of LKB1. 
 
 
Due to the presence of only a few colonies on the transformation plates, 
pUAST.LKB1 was sequenced using primers 9 a) and 9 b) without being restriction 
enzyme digested.   
 
LKB1 transgenic flies were not used for any experiments in this thesis, but the 
cloning is included here as a record of how the LKB1 transgenic flies were 
constructed. 
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Figure 3.11  Schematic for cloning of LKB1 into pUAST.   
A. LKB1 was amplified using PCR primers 8 a) and 8 b) and subsequently restriction 
enzyme digested using EcoRI and NotI.  pUAST plasmid was linearised with EcoRI 
and NotI. 
B. The LKB1 fragment and the linearised pUAST were ligated to create 
pUAST.LKB1. 
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3.9 CG6114 
 
CG6114 is the Drosophila homologue of BRSKs and was cloned in order to 
ascertain if CG6114 was capable of interacting with human tau in the same way that 
is seen for other Drosophila kinases such as shaggy (GSK3-β homologue) and PAR-
1. 
 
Figure  3.12 shows a schematic for the cloning of CG 6114 into pUAST. 
 
As with previous clones, restriction enzyme digests were designed so that digestion 
of a positive clone with EcoRI and XbaI would release a 2548bp fragment and 
digestion with XhoI would release fragments of 578bp and 1162bp in length (see 
Figure 3.13 for an example digest). 
 
Having verified the clones by restriction enzyme digest, the DNA was sequenced 
using primers 10 a) and 10 b) in order to confirm the ligation before being sent for 
transgenesis. 
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Figure 3.12  Schematic for cloning of CG6114 into pUAST.   
A. pOT2.CG6114 was digested with EcoRI and BglII resulting in a 2533bp fragment 
containing CG6114.  pUAST plasmid was linearised with EcoRI and BglII. 
B. The CG6114 fragment and the linearised pUAST were ligated to create 
pUAST.CG6114. 
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Figure 3.13 Enzyme digest of pUAST.CG6114 clones.   
Agarose gel containing ethidium bromide in order to stain DNA fragments.  Lanes 2, 
4, 6, 8, 10 and 12 digested with EcoRI and XbaI (to yield a 2548bp fragment from 
positive clones).  Lanes 1, 3, 5, 7, 8, 9, and 11 digested with XhoI (to yield 578bp and 
1162bp fragments from positive clones).   
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3.10 Discussion 
 
This chapter serves as a record of the construction of transgenic flies carrying human 
BRSK1, BRSK2, LKB1 and CaMKKα and endogenous Dosophila CG6114.   
 
Phenotypic analysis showed that BRSK1 and BRSK2 isoforms produce similar 
phenotypes when expressed with GMR::GAL4 and the 0N4R isoform of human tau.  
B-WT enhanced the tau induced eye phenotype, whilst B-NP, B-KD and B-CA did 
not (both isoforms).  This suggests that B-CA may not be fully constitutively active 
in the Drosophila model.  In addition, over-expression of human B-WT or knock-
down of the Drosophila homologue, CG6114, using a number of neuronal drivers 
was lethal at the embryonic stage. 
 
Selected BRSK2 transgenic lines (B-WT5, B-NP4, B-KD4 and B-CA5) were 
confirmed to have similar BRSK expression levels by western blot, indicating that 
there was no significant position effect of the transgenes in these flies. 
 
Having verified that the BRSK2 flies were expressing and that the protein was 
functional, the BRSK2 Kozak sequence was used in the construction of CaMKKα 
and LKB1 transgenic flies in order to ensure that those proteins were also expressed 
and functional in Drosophila. 
 
In Chapter 4, I present data utilising the selected human BRSK2 transgenic flies in 
combination with human 0N4R, S2A and S262A tau in order to further assess 
interactions between BRSK2 and tau and to identify the amino acids that are 
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important for these interactions.  I also discuss the data produced with the UAS-
CG6114 transgenic flies. 
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4| Interactions between 
human BRSK2 isoforms 
and human tau in the 
Drosophila eye. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
126 
 
4.1 Introduction 
 
 
At the beginning of this project, little was known about the potential for BRSKs as 
tau kinases.  It had been reported that tau phosphorylation at S262 was reduced in 
BRSK double knockout mice and that the double knockout mice had a severe neural 
phenotype which led to death within two hours of birth (Kishi et al., 2005).  However, 
no further exploration had been made into the possibility of BRSK being a direct tau 
kinase.  BRSK was an interesting candidate as a tau kinase due to its mainly neuronal 
expression and its close relation to PAR-1, another member of the AMPK family of 
protein kinases, which is a well defined tau kinase and has been studied extensively 
in both mammalian and Drosophila models of AD (Nishimura et al., 2004; Thies and 
Mandelkow, 2007; Wang et al., 2007a; Zempel et al., 2010). 
 
Four different tau lines were used in this chapter (0N4R tau, R406W tau, S2A tau 
and S262A tau, for a schematic see Figure 4.1).  R406W tau is the 0N4R isoform of 
tau carrying an R406W mutation (numbering based on the longest human isoform of 
tau); a mutation that is associated with fronto-temporal dementia with Parkinsonism 
linked to chromosome 17 (FTDP-17) (Bunker et al., 2006).  R406W tau was used as 
a control in some of the experiments in this chapter as S2A tau was constructed by 
mutating S262 and S356 in R406W tau to alanine (Nishimura et al., 2004).  S262 and 
S356 are located within KXGS motifs in microtubule binding domains 1 and 4 
respectively.  S262A tau is the 0N4R isoform of tau carrying a S262A mutation 
(Iijima-Ando et al., 2010).  The tau lines were genotyped in order to confirm isoform 
identity and mutation status.  This work is shown in Appendix 4 along with western 
blots to show the tau expression level.  
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Flies expressing human tau (0N4R), BRSK2 (WT, NP, KD, CA) or co-expressing 
both genes (under the control of the GMR-GAL4 driver) were assessed qualitatively 
using SEM, and quantitatively using QED software in order to compare the scale of 
ommatidial distortion.  The use of QED allowed me to unambiguously determine the 
effect various manipulations had on the phenotype of the eye.  Semi-thin resin 
sections of eyes were produced in order to view the effect of human tau and BRSK2 
co-expression on the internal cellular structure of the eyes.  The S262A tau line 
(carrying a S262A mutation) was utilised in order to assess the contribution of this 
site to the BRSK-tau phenotype and this was followed with western blots on lysates 
from flies expressing 0N4R tau or 0N4R tau with BRSK isoforms in order to 
elucidate if BRSK was capable of phosphorylating tau.  Finally, the S2A tau line 
(carrying S262A/S356A mutations) was utilised in order to assess the additional 
contribution of S356 to the BRSK-tau eye phenotype.  
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Figure 4.1: Schematic of tau isoforms. 
Scheme showing the four tau isoforms used in this chapter: 0N4R, R406W, S2A and 
S262A along with the relative positions of the R406W, S262A and S356A mutations.  
In pink are the C-terminal repeats (microtubule binding domains).   
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4.2 Results 
 
4.2.1 Expression of BRSK2 isoforms in the Drosophila eye 
 
 
In order to ascertain whether expression of human BRSK2 caused an eye phenotype, 
four different isoforms of BRSK2 were expressed.  Visual inspection of SEM images 
of the eyes showed that expression of wild type (B-WT), non-phosphorylatable (B-
NP), kinase dead (B-KD) or constitutively active (B-CA) BRSK was not detrimental 
to the eye (Figure 4.2) when compared to wild type (CS) eyes or eyes expressing the 
GAL4 driver alone (GMR).  
 
Figure 4.3 shows a cumulative distribution plot produced by quantification of the 
SEMs using software designed for this purpose at Warwick University (QED).  QED 
is a software package that was written in Matlab in order to quantify the level of 
ommatidial distortion in SEMs (described in the Methods section and in Appendix 2).  
Having processed a number of images per genotype, I have produced a cumulative 
graph for the distortion coefficients for each genotype, with 0 corresponding to no 
ommatidial distortion and 1 corresponding to maximal ommatidial distortion on the 
x-axis and the cumulative fly count on the y-axis (in percent of total).  Quantification 
of the ommatidial distortion using QED confirmed that eyes expressing BRSK2 
isoforms were the same as those of the GMR driver.   
 
Looking at the range of distortion coefficients (DCs) produced by QED for each 
genotype gives an indication as to the variability of the phenotypes; a wide DC range 
would indicate a genotype with a varied phenotype whilst a narrow DC range would 
indicate a genotype with little phenotypic variation.  Figure 4.4 shows the images 
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with the lowest and highest DCs for the genotypes analysed in Figure 4.2; it is 
possible to see that there is little variation in the phenotypes and that the DC ranges 
are very similar for each of the genotypes (CS: 0.15-0.26, GMR: 0.22-0.29, B-WT: 
0.18-0.35, B-NP: 0.19-0.25, B-KD: 0.20-0.31 and B-CA: 0.19-0.28).   
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Figure 4.2: SEM images of flies expressing human BRSK2 isoforms.   
Scanning electron micrographs showing that expression of human B-WT, B-NP, B-
KD or B-CA isoforms under the control of the GMR-GAL4 driver (GMR) did not 
cause an eye phenotype.   Scale bar 100µm applies to all panels. 
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Figure 4.3: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies expressing human BRSK2 isoforms and GMR.   
Quantitative analysis of flies expressing BRSK2 isoforms using QED showed that 
expression of BRSK2 isoforms did not cause an eye phenotype.  CS n=18, GMR 
n=11, B-WT n=21, B-NP n=12, B-KD n=10 and B-CA n=12. 
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Figure 4.4: SEM images of flies expressing BRSK2 isoforms with the lowest and 
highest DCs.   
Images of flies expressing GMR, B-WT, B-NP, B-KD or B-CA.  The range of DCs for 
the BRSK expressing flies overlapped with that of the GMR flies. DCs are shown on 
the images.     Scale bar 100µm applies to all panels. 
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4.2.2 Co-expression of human BRSK2 isoforms with human 0N4R tau 
 
 
It is well known that expression of human tau in the fly eye causes a degenerative 
„rough eye‟ phenotype when visualised externally with SEM (Wittmann et al., 2001; 
Shulman and Feany, 2003; Steinhilb et al., 2007a).  In order to test the hypothesis 
that human BRSK2 would interact with and phosphorylate human tau in Drosophila, 
UAS-0N4R tau and UAS-BRSK2 (B-WT, B-KD or B-NP) were expressed in the eye 
(Figure 4.5).   
 
This manipulation caused a drastic exacerbation of the tau phenotype, demonstrating 
for the first time, that human 0N4R tau and BRSK2 are able to interact in-vivo in 
Drosophila.  Further to this, it is reasonable to conclude that there is an endogenous 
Drosophila kinase capable of phosphorylating and activating BRSK2.  This indicates 
that intact signalling cascades, composed of both human and Drosophila genes and 
proteins can be observed in the fly.   
 
Expression of B-KD or B-NP with 0N4R tau had no effect on the previously 
observed degenerative tau phenotype, demonstrating that the exacerbation seen upon 
B-WT co-expression with 0N4R tau was not simply due to expression of exogenous 
proteins.  Further to this, quantification of western blots for BRSK2 expression 
(shown in Chapter 3, Figure 3.7) demonstrates that the lack of exacerbation in the 
flies expressing 0N4R tau with B-NP or B-KD was not due to a lack of BRSK2 
expression.  
 
Figure 4.6 shows a cumulative distribution plot produced for the flies of the 
genotypes in Figure 4.5.  As in Figure 4.3, expression of B-WT (green line) had little 
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or no effect on the ommatidial structure of the eye when compared to GMR (black 
line).  Expression of 0N4R tau caused a degenerative phenotype which can be seen 
by the shift of the tau curve (red line) further towards 1.  However, co-expression of 
B-WT with 0N4R tau caused a dramatic exacerbation of the 0N4R tau phenotype as 
can be seen in the large shift to the right of the blue line.  This was not the case with 
B-KD as this line overlies that of the 0N4R tau flies.  B-NP appeared to exhibit an 
intermediate phenotype which was not visually evident from the SEMs. 
 
Figure 4.7 shows the images from the two extremes of the cumulative distribution 
plot for flies expressing tau, T + B-WT, T + B-NP and T + B-KD; the images with 
the lowest and highest DCs for each genotype are shown (the images for GMR and 
B-WT flies were shown in Figure 4.4 and so have not been repeated here).  Tau flies 
had a DC range that was higher than that of the GMR flies (0.31-0.55 and 0.22-0.29 
respectively) and correlated with the appearance of a tau-induced degenerative 
phenotype.  Co-expression of B-WT with Tau gave a range of 0.40-0.99.  This was 
visible in the images – the eye with the lowest DC showed signs of B-WT 
enhancement of Tau, with a smaller eye size and a slightly altered shape.  The eye 
with the highest DC was very degenerated and had almost no ommatidial structure, 
hence a DC of 0.99.  Tau + B-NP and Tau + B-KD flies had ranges of 0.33-0.64 and 
0.29-0.72 respectively.  These ranges were lower than that of the Tau + B-WT flies 
and this could be seen in the images; flies of these two genotypes looked more like 
the Tau flies. 
 
Semi-thin 2.5µm resin sections of eyes from flies of the genotypes shown in Figure 
4.5 were produced in order to investigate the underlying cellular morphology of the 
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eyes.  Figure 4.8 shows that expression of the GMR driver caused no phenotype; 
hexagonally packed ommatidia are visible, each one containing seven rhabdomeres 
(R8 is not visible).  Expression of B-WT did not alter this structured phenotype, 
whereas expression of 0N4R tau caused marked disruption to the cellular structure.  
This was manifested as holes where some cells had died at an early stage of 
development (arrow), merged ommatidia (*) and an incorrect number of 
rhabdomeres (arrowhead).  This phenotype was exacerbated upon co-expression of 
B-WT, with very few detectable ommatidia and an obvious increase in 
disorganisation.  The effects caused by B-WT were not visible in the sections from 
eyes co-expressing 0N4R tau and B-NP or B-KD. 
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Figure 4.5: SEM images of flies co-expressing human 0N4R tau with human 
BRSK2 isoforms.   
Expression of 0N4R human tau under the GMR::GAL4 driver caused a degenerative 
eye phenotype (Tau).  This was dramatically enhanced upon co-expression of human 
B-WT (Tau + B-WT).  Enhancement was not seen in eyes expressing NP or KD 
isoforms of human BRSK2 (Tau + B-NP and Tau + B-KD).   Scale bar 100µm 
applies to all panels. 
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Figure 4.6: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies co-expressing human 0N4R tau and BRSK2 
isoforms.   
Quantitative analysis of flies co-expressing 0N4R tau and human BRSK2 isoforms 
under the control of the GMR-GAL4 driver showed that expression of B-WT 
enhanced the 0N4R tau induced ommatidial distortion (T + B-WT).  Enhancement 
was not seen with B-KD (T + B-KD), whereas B-NP produced an intermediate 
phenotype (T + B-NP).  GMR n=11, Tau n=20, B-WT n=21, T + B-WT n=17, T + B-
KD n=17 and T + B-NP n=12.  
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Figure 4.7: Scanning electron micrographs of flies co-expressing 0N4R tau and 
BRSK2 isoforms with the lowest and highest DCs.   
Tau flies had a DC range that was 0.31-0.55, values which were higher than those of 
the GMR flies (GMR and B-WT flies were shown in Figure 4.3).   Co-expression of 
B-WT with Tau gave a range of 0.40-0.99 indicating a more severe phenotype.  Tau 
+ B-NP and Tau + B-KD flies had ranges of 0.33-0.64 and 0.29-0.72 respectively.  
These ranges were lower than that of the Tau + B-WT flies – this is clear upon visual 
examination of the images.  DCs are shown on each image.   Scale bar 100µm 
applies to all panels. 
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Figure 4.8: Semi-thin 2.5µm resin sections of eyes co-expressing human 0N4R tau 
with human BRSK2 isoforms.   
GMR and B-WT eyes had a very regular sub-cellular structure consisting of 
hexagonally packed ommatidia, each containing 7 rhabdomeres (R8 was not visible).  
Expression of 0N4R human tau under the GMR-GAL4 driver caused a degenerative 
eye phenotype manifested as an incorrect number of rhabdomeres (arrowhead), 
merged ommatidia (*) and absent cells (arrow).  This was enhanced upon co-
expression of human B-WT with very little sub-cellular structure visible in the 
sections.  Enhancement was not seen in eyes co-expressing B-NP or B-KD.   Scale 
bar 25µm applies to all panels. 
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4.2.3 Co-expression of constitutively active human BRSK2 with human 0N4R 
tau 
 
 
In addition to B-WT, B-NP and B-KD, I made B-CA flies in which the T-loop 
threonine had been mutated to glutamic acid in order to mimic phosphorylation at 
this residue (T174) and produce a constitutively active version of BRSK2 (Lizcano et 
al., 2004).  However, co-expression of B-CA with tau did not cause the enhancement 
of the tau phenotype seen with B-WT (Figure 4.9).  This result was not expected, as 
B-CA should be able to reproduce the phenotype seen with B-WT.  Western blots for 
BRSK expression (Chapter 3, Figure 3.7) demonstrated that this negative result was 
not due to a lack of B-CA expression.    
 
QED analysis (Figure 4.10) of flies of the genotypes shown in Figure 4.9 
demonstrated that expression of B-CA (blue line) had little effect on the ommatidial 
structure of the eye when compared to GMR (black line).  Additionally, QED 
confirmed that co-expression of B-CA with 0N4R tau (brown line) did not reproduce 
the enhancement that was seen with co-expression of B-WT with tau (Figure 4.6), a 
result that indicates that the T174E mutation in B-CA was not sufficient to render the 
kinase constitutively active in this model.   
 
The DC range for the tau flies was 0.31-0.55 and the range for the flies co-expressing 
tau and B-WT was 0.40-0.99 (Figure 4.7), flies co-expressing tau with B-CA had a 
DC range of 0.39-0.50 (Figure 4.10), indicating that Tau + B-CA flies had a 
phenotype that was very similar to that of the tau flies.   
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Figure 4.9: SEM images of flies co-expressing human 0N4R tau with 
constitutively active BRSK2.   
Expression of B-CA did not affect the eye phenotype (B-CA).  Expression of 0N4R 
human tau under the GMR-GAL4 driver caused a degenerative eye phenotype which 
was not enhanced upon co-expression of human B-CA (T + B-CA).  Scale bar 100µm 
applies to all panels. 
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Figure 4.10: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software and images of flies with the lowest and highest DC for 
flies co-expressing human 0N4R tau and constitutively active BRSK2. 
Quantitative analysis of flies co-expressing 0N4R tau and human B-CA under the 
control of the GMR-GAL4 driver showed that expression of B-CA did not enhance 
the 0N4R tau induced ommatidial distortion.  GMR n=11, B-CA n=12, Tau n=20 
and T + B-CA n=8.  The range of DC for T + B-CA flies was 0.39-0.50.  Scale bar 
100µm applies to all panels. 
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4.3 Co-expression of CG6114 and human tau 
 
 
Having shown an interaction between B-WT and tau, I wished to explore if CG6114, 
the Drosophila homologue of mammalian BRSKs, was also capable of interacting 
with human tau. 
 
Over-expression of CG6114 alone resulted in a phenotype similar to that seen upon 
expression of human B-WT (Figures 4.11, 4.12 and 4.13).  Over-expression of 
CG6114 with tau did not enhance the tau-induced eye phenotype, demonstrating that 
there is not sufficient conservation between some part of the BRSK-tau pathways 
between humans and Drosophila despite there being 88% sequence identity between 
CG6114 and human BRSK2.  Figure 4.14 shows that the residues that were mutated 
in the human BRSK proteins (both isoforms), and the residues immediately 
surrounding the mutation sites, are conserved in CG6114, suggesting that the same 
kinases which activate the human B-WT would also be capable of activating 
CG6114.   
 
It should be noted that a potential weakness of QED analysis is that it over-estimates 
the degree of ommatidial distortion in control flies.  For example, Figure 4.14 shows 
that the GMR CG6114 eye with the highest DC had a value of 0.28 and the T + 
CG6144 eye with the lowest DC had a value of 0.31.  These numbers are fairly close, 
but the phenotypes are very different as one eye expresses tau and the other doesn‟t.  
The reason for this discrepancy is that in the control eyes there are many bristles, and 
these have an effect on the QED analysis.  Depending on the angle that the bristles 
intersect the ommatidia, some ommatidia may be registered by QED as two smaller 
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ones because a bristle is lying across the middle.  This is generally not a problem in 
eyes which express tau as they do not have many bristles.  
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Figure 4.11: SEM images of flies co-expressing human 0N4R tau with CG6114. 
Expression of 0N4R human tau under the GMR-GAL4 driver caused a degenerative 
eye phenotype which was not enhanced upon over-expression of CG6114 (T + 
CG6114).  Over-expression of CG6114 alone (GMR CG6114) resulted in a 
phenotype similar to that seen with expression of human B-WT.  Scale bar 100µm 
applies to all panels. 
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Figure 4.12: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies co-expressing human 0N4R tau and CG6114. 
Quantitative analysis of flies co-expressing 0N4R tau and CG6114 under the control 
of the GMR-GAL4 driver showed that over-expression of CG6114 slightly 
ameliorated the 0N4R tau induced ommatidial distortion.  Expression of CG6114 
alone caused a phenotype similar to that seen with expression of human B-WT.  
GMR n=11, Tau n=20, GMR CG6114 n=7, T + B-WT n=17, T + CG6114 n=12 and 
B-WT n=21.  
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Figure 4.13: Scanning electron micrographs of flies over-expressing CG6114, with 
or without tau, with the lowest and highest DCs.   
Over-expression of CG6114 gave a DC range of 0.20-0.28.  Tau + CG6114 flies had 
a range of 0.31-0.48, which was slightly lower than the DC range of flies expressing 
tau alone (0.31-0.55).  DCs are shown on each image.   Scale bar 100µm applies to 
all panels. 
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Figure 4.14: Alignment of human BRSK1 and 2 sequences with CG6114 sequence 
showing conservation of mutated sites.   
Alignment of the sequences for human BRSK isoforms with CG6114 shows that the 
amino acids around the mutation sites are fully conserved between human BRSKs 
and CG6114.  Red arrows indicate the amino acids mutated in kinase dead (D) or 
non-phosphorylatable (T) human BRSK. 
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4.4 S262A 
 
 
Data presented by Kishi et al (2005) indicated that BRSKs are involved in the 
phosphorylation of tau at S262, and so I decided to investigate how important S262 
was to the B-WT enhancement of the tau-induced eye phenotype.  In order to do this 
I utilised a version of 0N4R tau which carries a S262A mutation (a kind gift of Dr 
Koichi Iijima).   
 
Expression of S262A tau caused no eye phenotype (Figure 4.15), and further to this, 
mutation of S262A almost completely prevented the exacerbation seen upon co-
expression of B-WT.  This suggests that the phenotype seen upon tau expression, and 
the enhancement seen with B-WT, is directly linked to the ability of tau to be 
phosphorylated at S262.   
 
Figure 4.16 shows the cumulative distribution plot for flies expressing S262A tau ± 
B-WT and flies expressing the relevant controls; GMR, B-WT and 0N4R tau ± B-
WT.  It clearly shows that expression of S262A tau had no effect on the ommatidial 
structure of the eyes.  The cumulative curve closely overlays that of the GMR flies: 
demonstrating that the S262A mutation is sufficient to prevent the formation of tau-
induced eye phenotypes.  Co-expression of S262A tau with B-WT had a small effect 
on eye phenotype - there was a difference visible between the cumulative curves for 
S262A and S262A + B-WT flies.  This may suggest that there are other sites in tau 
which are important for the enhancement seen with B-WT.   
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The DC range of the S262A flies (Figure 4.17) was 0.21-0.30, indicating that this 
phenotype was very similar to that of the GMR flies.  S262A + B-WT flies had DC 
range of 0.22-0.39, demonstrating that these flies had a slight eye phenotype when 
compared to the GMR flies.  This was due to some disordered and fused ommatidia 
in the posterior section of the eye in the S262A + B-WT flies.  
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Figure 4.15: Scanning electron micrographs of flies expressing an S262A mutated 
isoform of tau with or without B-WT.   
Expression of S262A tau with or without B-WT caused no visible eye phenotype 
suggesting that S262 is an important residue for the establishment of both Tau and 
Tau + B-WT eye phenotypes.   Scale bar 100µm applies to all panels. 
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Figure 4.16: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies co-expressing human S262A tau with or 
without B-WT.   
In agreement with the SEM images, expression of S262A tau caused no eye 
phenotype – the curve for S262A tau overlies that of the GMR flies. Co-expression of 
B-WT and S262A tau had a small effect on the eye phenotype.  GMR n=10, Tau 
n=20, B-WT n=21, T + B-WT n=17, S262A n=12 and S262A + B-WT n=7.  
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Figure 4.17: Scanning electron micrographs of flies with the lowest and highest 
DCs expressing S262A tau with or without B-WT.   
DCs are shown on each image.  The range of DCs for the S262A flies overlapped 
with the range for the GMR flies (0.22-0.29 for GMR and 0.21-0.30 for S262A).  The 
range of the DCs for the S262A + B-WT flies overlapped with those of the GMR and 
the S262A flies but ended at a higher value; this was due to a number of disordered 
and fused ommatidia in the posterior of the eye.  Scale bar 100µm applies to all 
panels. 
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4.4.1 Co-expression of sgg S9A and S262A tau  
 
 
As there was no phenotype with the S262A tau and expression of S262A tau was 
lower than 0N4R tau (shown in Appendix 4, Figure 12.3), it was important to 
perform a positive control experiment in order to show that S262A tau could be 
modulated by kinase activity to produce an eye phenotype.  Shaggy (sgg) is the 
Drosophila homologue of human GSK3-β, a serine/threonine kinase which 
phosphorylates tau at many residues, but is not capable of phosphorylating tau 
directly at S262 (Kosuga et al., 2005).  sgg and PAR-1 appear to be in the same 
pathway, and phosphorylation of tau by PAR-1 has been shown to induce a cascade 
of phosphorylation of tau by other kinases including sgg (Nishimura et al., 2004; 
Kosuga et al., 2005).  Previous work showed that expression of sgg with S2A tau 
caused a rough eye phenotype and so I reasoned that expression of sgg with S262A 
tau should cause a similar eye phenotype (Chatterjee et al., 2009).   
 
For this experiment, a UAS-sgg S9A line was used which carries an S9A mutation 
enabling the sgg to be constitutively active (as phosphorylation at S9 deactivates sgg).  
Figure 4.18 shows that expression of sgg S9A alone caused a rough eye phenotype 
which was manifested as disordered bristles and some fused ommatidia.  Co-
expression of sgg S9A with S262A caused an enhancement of the phenotype seen 
with expression of sgg S9A alone, demonstrating that S262A tau was able to 
function and cause an eye phenotype. 
 
QED analysis (Figure 4.19) showed that sgg S9A expression caused an eye 
phenotype when compared to the GMR or S262A tau flies.  Co-expression of sgg 
S9A with S262A tau resulted in an enhanced phenotype that was robust, and had 
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little variation.  This data demonstrated that S262A tau was functional and was able 
to interact with sgg S9A to produce an eye phenotype.  This allowed me to draw the 
conclusion that the lack of phenotype in the S262A + B-WT flies was due to the 
S262A mutation, and not due to a lack of expression of S262A tau. 
 
Examination of the flies with the lowest and highest DCs (Figure 4.20) showed that 
the range of the DCs for the sgg S9A flies was higher than those for the GMR and 
S262A flies, demonstrating that expression of sgg S9A causes an eye phenotype.    
The DC range for the S262A + sgg S9A flies was higher than that of the sgg S9A 
flies, indicating that S262A tau was able to interact with sgg S9A and cause an eye 
phenotype which was distinct from the phenotype exhibited by the sgg S9A flies (DC 
ranges: 0.28-0.40 for sgg S9A and 0.44-0.57 for S262A + sgg S9A). 
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Figure 4.18: Scanning electron microscopy images of flies expressing a S262A 
mutated isoform of tau with or without sgg S9A.   
Expression of sgg S9A alone caused a mild rough eye phenotype whereas co-
expression of sgg S9A and S262A resulted in an enhanced eye phenotype, confirming 
that S262A could be modulated by kinase activity.  Scale bar 100µm applies to all 
panels. 
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Figure 4.19: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies co-expressing human S262A tau with or 
without sgg S9A.   
Expression of sgg S9A caused an eye phenotype.  Co-expression of S262A tau and 
sgg S9A enhanced this phenotype.  This confirmed that S262A was able to be 
modulated by kinase activity to produce an eye phenotype.  GMR n=10, S262A n= 
12, sgg S9A n=17 and S262A sgg S9A n=8. 
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Figure 4.20: Scanning electron micrographs of flies with the lowest and highest 
DCs expressing sgg S9A with or without S262A tau.   
DCs are shown on each image.  The range of DCs for the sgg S9A flies was higher 
than the range for the GMR and S262A tau flies (0.22-0.29 for GMR, 0.21-0.30 for 
S262A and 0.28-0.40 for sgg S9A) demonstrating that sgg S9A was capable of 
producing an eye phenotype.  The range of the DCs for the S262A + sgg S9A flies 
was higher than that of the sgg S9A flies, showing that S262A tau was capable of 
being modulated by sgg S9A and producing an eye phenotype despite the lack of 
phenotype seen in S262A tau flies.  Scale bar 100µm applies to all panels. 
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4.5 Phosphorylation of tau at S262 
 
 
Having identified S262 as an important residue for the B-WT enhancement of the tau 
phenotype I wished to explore whether B-WT was capable of phosphorylating tau at 
this residue.  Figure 4.21 shows that 0N4R tau was phosphorylated at S262 
(normalised to total tau, T46) and that co-expression of B-WT caused a significant 
increase in the intensity of phosphorylated S262 (pS262) signal (n=10, 0.32±0.03 for 
0N4R tau and n= 11, 0.62±0.05 for T + B-WT, p<0.001, one way anova).  No 
significant increase in pS262 signal was seen upon co-expression of B-NP or B-KD 
with 0N4R tau (n=8, 0.39±0.05 for T + B-NP and n=9, 0.33±0.05 for T + B-KD).  
The pS262 signal for T + B-NP and T + B-KD was significantly lower than the 
signal for T + B-WT (p<0.05 and p<0.01 respectively, one way anova).     
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Figure 4.21: Western blots for pS262 and total tau.   
Quantification of western blots from flies expressing tau, T + B-WT, T + B-NP or 
Tau + B-KD showed that co-expression of B-WT, but not B-NP or B-KD, with 0N4R 
tau caused a significant increase in tau phosphorylated at S262.  T + B-NP and T + 
B-KD were significantly different from T + B-WT but not from tau alone.  Mean ± 
SEM: 0.32±0.03 for tau (n=10), 0.62±0.05 for T + B-WT (n=11), 0.39±0.05 for T + 
B-NP (n=8) and 0.33±0.05 for T + B-KD (n=9). *** p<0.001, ** p<0.01, * p<0.05.  
Representative western blots shown.    
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4.6 S2A 
 
 
PAR-1 is a well characterised tau kinase that has been extensively studied in 
Drosophila.  It has been shown to phosphorylate tau at S262 and S356, residues that 
are within the KXGS repeat motifs in microtubule binding domains 1 and 4 
respectively (Nishimura et al., 2004).  Mutation of these residues to alanine in tau 
(hence S2A) prevented PAR-1 associated phosphorylation and PAR-1 enhancement 
of a tau-induced eye phenotype (Nishimura et al., 2004).   Due to the similarity of 
function between BRSKs and PAR-1, and the data presented in Figure 4.16 which 
was suggestive of there being another site on tau capable of being phosphorylated by 
B-WT, I decided to utilise S2A tau in order to assess if S356 could be involved in the 
enhancement of tau-induced eye phenotypes by B-WT.  In order to do this I used 
S2A and R406W tau flies (kind gifts of Dr Bingwei Lu), with R406W tau replacing 
0N4R tau as a control (as the S2A mutations were made in the R406W tau 
background). 
 
Figure 4.22 shows that expression of R406W tau under the control of the GMR 
driver caused a similar degenerative eye phenotype to that seen with expression of 
0N4R tau and that B-WT was capable of enhancing the R406W phenotype.  
However, the enhancement of R406W by B-WT was lethal – the fly shown was the 
only escaper from a number of crosses and as such SEM imaging and phenotypic 
analysis of R406W + B-WT flies using QED was not possible.  Expression of S2A 
tau, on the other hand, caused no phenotype.  Likewise, co-expression of S2A tau 
with B-WT caused no phenotype either.  This data suggests that the sites mutated in 
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S2A tau (S262/356A) are important for the establishment of both the tau phenotype 
and the enhancement seen upon co-expression of B-WT. 
 
Figure 4.23 shows SEM images of flies expressing S2A tau with or without B-WT 
and control eyes expressing GMR, R406W tau, 0N4R tau or 0N4R tau + B-WT.  In 
agreement with the observations made from the light microscope images in Figure 
4.22, expression of R406W tau caused a degenerative eye phenotype similar to that 
of flies expressing 0N4R tau.  However, it was evident from the SEM images that the 
eye phenotype of R406W tau flies was slightly enhanced when compared to the 
phenotype of 0N4R tau flies, an observation that was confirmed by QED analysis 
(Figure 4.24). 
  
Expression of S2A tau with or without B-WT did not cause an eye phenotype (Figure 
4.23) and this was confirmed by QED analysis (Figure 4.24), demonstrating that the 
S2A mutations were sufficient to fully rescue the B-WT enhancement of tau-induced 
eye phenotypes.  This suggests that in addition to phosphorylation at S262, 
phosphorylation at S356 is also involved in the establishment of the tau-BRSK eye 
phenotype.   
 
Figure 4.25 shows the range of DCs for the R406W, S2A and S2A + B-WT flies.  
R406W flies had a higher DC range than that of the 0N4R tau flies (0.39-0.63 for 
R406W and 0.31-0.55 for 0N4R tau) which was likely due to the slightly more toxic 
nature of R406W tau.  The range of the DCs for the S2A and S2A + B-WT flies was 
similar to that of the GMR flies (0.15-0.25 for S2A, 0.18-0.27 for S2A + B-WT and 
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0.22-0.29 for GMR), indicating that expression of S2A with or without B-WT did 
not cause an eye phenotype.  
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Figure 4.22: Light microscope images of flies expressing R406W or S2A mutated 
isoforms of tau with or without B-WT.   
Expression of R406W tau caused degenerative eye phenotype and B-WT was capable 
of enhancing the phenotype.  Expression of S2A tau, with or without B-WT, caused 
no eye phenotype suggesting that the S2A residues are important for the 
establishment of Tau and Tau + B-WT induced eye phenotypes.  Scale bar 100µm 
applies to all panels. 
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Figure 4.23: Scanning electron micrographs of flies expressing S2A mutated 
isoforms of tau with or without B-WT.   
Expression of R406W tau caused a slightly enhanced eye phenotype when compared 
to flies expressing 0N4R tau (Tau).  Expression of S2A tau, with or without B-WT, 
caused no eye phenotype suggesting that S356 is also an important residue for the 
establishment of Tau and Tau + B-WT induced eye phenotypes.  Scale bar 100µm 
applies to all panels. 
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Figure 4.24: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies co-expressing human S2A mutated tau with or 
without B-WT.   
Expression of R406W caused a slightly enhanced phenotype when compared to 0N4R 
tau (Tau).  Expression of S2A tau, with or without B-WT, caused no eye phenotype 
indicating that the S2A mutations were sufficient to fully rescue the tau-BRSK eye 
phenotype.  GMR n=10, Tau n=20, R406W n=6, T + B-WT n=17, S2A n= 6 and S2A 
+ B-WT n=8. 
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Figure 4.25: Scanning electron micrographs of flies with the lowest and highest 
DCs expressing R406W, S2A or S2A + B-WT.   
DCs are shown on each image.  The range of DCs for the R406W flies was higher 
than the range for the 0N4R tau flies (0.39-0.63 for R406W and 0.31-0.55 for 0N4R 
tau) demonstrating the slightly more toxic nature of R406W tau.  The range of the 
DCs for the S2A and S2A + B-WT flies was similar to that of the GMR flies (0.15-
0.25 for S2A, 0.18-0.27 for S2A + B-WT and 0.22-0.29 for GMR).  Scale bar 100µm 
applies to all panels. 
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4.7 Discussion 
 
 
Eyes expressing human BRSK2 isoforms did not have a distinct phenotype to those 
from GMR flies as assessed by SEM and QED.  Previous work in Drosophila using 
endogenous tau kinases over-expressed in the eye has shown that both sgg and PAR-
1 are capable of disrupting normal eye phenotypes when expressed in the absence of 
tau (Nishimura et al., 2004; Chatterjee et al., 2009).   On the other hand, not all tau 
kinases cause a phenotype when over-expressed in the eye; expression of checkpoint 
kinase 2 (Chk2) does not cause a rough eye phenotype despite it being capable of 
enhancing a tau-induced deleterious phenotype (Iijima-Ando et al., 2010).   
 
Co-expression of B-WT with 0N4R human tau caused a dramatic exacerbation of the 
tau-induced degenerative eye phenotype.  This was clearly visible in the SEM images, 
semi-thin resin sections and QED analysis.  As the BRSK2 expressed was WT, and 
as such required activation via phosphorylation at the T-loop T174 residue by an 
upstream kinase, this demonstrated the presence of upstream kinase(s) in Drosophila 
that could regulate human BRSK.  However, over-expression of the Drosophila 
BRSK homologue, CG6114, did not enhance the human tau-induced eye phenotype 
and in fact seemed to cause a slight amelioration of the human tau-induced 
phenotype.  In contrast to other work on tau kinases in Drosophila, this study uses 
human BRSKs with human tau (rather than endogenous kinases with human tau).  It 
is my belief that this is more relevant to human disease as the functions of 
Drosophila and human genes are not necessarily conserved: endogenous CG6114 
does not appear to be able to interact with human tau (as assessed by SEM and QED).  
This highlights the need to ensure that work with endogenous kinases that are shown 
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to be able to interact with or phosphorylate human tau is followed up and that the 
human genes are also validated to be tau kinases.  An alignment between the human 
BRSK isoforms and CG6114 showed that the two sites that were mutated in the 
human BRSK isoforms were conserved in CG6114.  This would suggest that the 
inability of CG6114 to enhance the human tau-induced eye phenotypes was not due 
to differential upstream regulation of human BRSKs and CG6144.  However, a 
weakness in the experiments using CG6114 is that the expression of CG6114 was not 
validated by western blot.  Thus it is possible that CG6114 was not being expressed 
properly or was unstable.   
 
There is a growing body of evidence in AD research showing that oxidative stress 
causes extensive damage to DNA, RNA and proteins in the brain (Lovell and 
Markesbery, 2007).  This is of interest because BRSK2 has been shown to be 
activated in response to UV- and methyl methane sulphonate-induced DNA damage 
in HeLa cells (Lu et al., 2004).  With regards to this, the phenotype exhibited upon 
co-expression of tau and B-WT is strikingly similar to that caused by co-expression 
of human tau with endogenous checkpoint kinase 2 (Chk2), a kinase which is 
activated primarily by ataxia telangectasia mutated (ATM) in response to double 
strand breaks in DNA (Iijima-Ando et al., 2010).  When activated by ATM, Chk2 
phosphorylates a number of proteins related to DNA damage responses including 
DNA repair and replication proteins and cell-cycle checkpoint regulators (Stracker et 
al., 2009).  Chk2 has been shown to be able to phosphorylate tau at S262 both in 
vitro and in vivo (Iijima-Ando et al., 2010).  Further work is required to elucidate the 
exact role BRSK2 may be playing in response to DNA damage, but at least two 
DNA damage response kinases (Chk1 and Chk2) have already been shown to 
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phosphorylate tau and this may infer that tau is implicated in the DNA damage 
response.         
 
Exacerbation was not seen when B-NP or B-KD was co-expressed with human tau, 
at similar levels to B-WT (shown in Chapter 3, Figure 3.7), demonstrating that two 
distinct point mutations that render the recombinant BRSK inactive prevent the 
genetic interaction with tau in this model.  This shows that it is BRSK kinase activity 
that modulates tau toxicity.  However, QED quantification indicated that B-NP was 
capable of producing an intermediate phenotype not obvious from visual 
examination of the SEM images.  LKB1, the master kinase of the AMPK family, 
phosphorylates a threonine in the T-loop of BRSKs and another 10 members of the 
AMPK family causing their activation (Lizcano et al., 2004).  The T-loop threonine 
residue in BRSK1, which is surrounded by the same amino acids as in BRSK2, has 
been shown to be targeted by CaMKKα in vitro (Fujimoto et al., 2008).  Mutation of 
the T-loop residue to alanine in B-NP should prevent B-WT from being activated 
through phosphorylation by LKB1 or CaMKKα.  Conversely, the data shown here 
for tau + B-NP suggests that either BRSK2 may have other functional interactions of 
tau independent of phosphorylation, or that mutation of the T-loop threonine to 
alanine is not sufficient to render the kinase fully inactive in this Drosophila model.   
 
Co-expression of B-CA with tau, which should have produced a similar phenotype to 
that seen in the tau + B-WT flies, did not cause an exacerbation of the tau phenotype.  
Mutation of the T-loop threonine to glutamic acid in BRSK1 creates a CA isoform of 
the kinase when expressed in E.coli cells (Lizcano et al., 2004).  However, it has 
been shown that the equivalent mutation in BRSK2 is not sufficient to render the 
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kinase constitutively active in mammalian cells, despite the sequence around the two 
residues being identical in both isoforms of BRSK (Bright et al., 2008).  The reason 
for differential effects of this mutation on BRSK isoforms is not known but it would 
seem that my phenotypic data is in agreement with the data of Bright et al (2008); 
mutation of T174 in BRSK2 is not sufficient to render the kinase constitutively 
active when expressed in Drosophila.  In order to test what effect the T174E 
mutation had on BRSK2 activity, I would co-transfect B-CA or B-WT with tau into 
HeLa cells in the presence of siRNA against CaMKK and measure the 
phosphorylation of tau at S262 by western blot.   As HeLa cells do not have LKB1, 
the use of siRNA against CaMKKα should down regulate the other major activator 
of BRSK2.  Thus, if B-CA activity was independent of its activation, then the pS262 
signal should be higher in the cells transfected with B-CA compared to B-WT.  
Although this approach would not enable me to determine the effect of the T174E 
mutation on BRSK2 activation when expressed in Drosophila, it would give an 
indication as to whether this mutation is sufficient to render BRSK2 constitutively 
active.  To further address whether the mutation can render BRSK2 constitutively 
active when expressed in Drosophila, I could perform a similar experiment in a 
Drosophila cell line such as Schneider 2 cells.  However, this would require siRNA 
targeting both LKB1 and CG17698 (the Drosophila homologue of CaMKKα).     
 
Expression of S262A tau prevented both the tau-induced phenotype and the B-WT 
exacerbation.  There was a small effect on ommatidial structure seen with co-
expression of S262A and B-WT, which could indicate that there may be other sites in 
tau that are important for the establishment of the Tau + B-WT phenotype.  The most 
likely candidate for another site would be S356, which is in the fourth microtubule 
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binding domain of tau and is part of a KXGS motif like the one surrounding S262.  
PAR-1 is capable of phosphorylating both sites, and due to the similarities in 
function of PAR-1 and BRSKs, it is likely that BRSKs are also capable of targeting 
both residues (Chatterjee et al., 2009).  That said, a large amelioration in phenotype 
was obtained by mutating S262, suggesting that S262 is an important residue for the 
formation of deleterious eye phenotypes caused by the co-expression of tau and B-
WT.  The production of the tau transgenic flies involves the random insertion of the 
human tau gene into the Drosophila genome.  This has led to a number of useful fly 
lines transgenic for various isoforms of human tau, but due to the nature of the 
transgenesis, the human genes are likely to have been inserted at different locations 
in the genome.  This is a problem as insertion at different locations leads to 
differential expression levels; an issue which should not be ignored.  When 
discussing the lack of phenotype produced by flies with mutations in tau (such as the 
S262A flies used here), the expression level must be taken into consideration as it 
may not necessarily be the mutations that prevent a phenotype, but a lower 
expression.  There is a way of circumnavigating this issue; it is now possible to 
perform targeted transgenesis in Drosophila where each transgene is inserted into the 
same genetic location.  However, this was not an option for the experiments 
performed in this thesis and so a positive control experiment using the Drosophila 
homologue of mammalian GSK3-β, sgg (constitutively active from) was conducted.  
This indicated that the lack of phenotype in the S262A flies was not due to the poor 
expression of S262A tau (shown in Appendix 4, Figure 12.3) as co-expression of 
S262A tau with sgg caused an eye phenotype which was worse than the phenotype 
caused by expression of either sgg or S262A tau alone, indicating that S262A tau 
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was capable of being modulated by kinase activity and that this modulation resulted 
in a detectable eye phenotype.      
 
Analysis of lysates from flies expressing 0N4R tau ± B-WT, B-NP or B-KD showed 
that 0N4R human tau was phosphorylated under basal conditions in the fly, and that 
co-expression of B-WT significantly elevated the level of phosphorylation.  
Phosphorylation of S262 has been shown to have a significant effect on the 
microtubule binding function of tau in both in vivo and in vitro experiments and is 
known to be elevated in pre-tangles using a pS262 antibody, and intra-neuronal 
NFTs using the 12E8 antibody, which also recognises pS356 (Sengupta et al., 1998; 
Augustinack et al., 2002; Fischer et al., 2009).  Pre-tangles and intra-neuronal NFTs 
are early forms of the extracellular NFTs which characterise AD.  Thus, 
phosphorylation of tau by B-WT may represent an important event in the early stages 
of AD pathogenesis.  Also relevant to this discussion is an experiment performed by 
a PhD student in the laboratories of Dr Moffat and Prof Frenguelli, demonstrating 
that co-expression of tau with B-WT causes a decrease in microtubule-bound tau 
when compared to flies expressing tau alone (personal communication, Mr Charlie 
Cameron).  Thus, it would seem that phosphorylation of tau at S262 by B-WT causes 
tau to dissociate from microtubules.  However, it is yet to be determined if the 
decrease in microtubule-bound tau is as a direct consequence of B-WT activity (by 
substituting B-WT for B-KD or B-NP) and whether there is a corresponding increase 
in tau phosphorylated at S262 in the soluble tau fraction of this assay (the tau which 
is not bound to microtubules).  Elevation of pS262 was not seen upon co-expression 
with the B-NP or B-KD isoforms of BRSK2 suggesting that the increase in pS262 
seen with B-WT expression is as a direct consequence of the kinase activity of B-WT.  
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The lack of pS262 phosphorylation in the flies co-expressing B-NP with tau does not 
correlate with the data produced using QED for these flies: QED analysis showed 
that B-NP slightly exacerbated the tau induced eye phenotype but western blots 
showed pS262 was not increased.  This would suggest that there may be other 
regulatory sites on BRSK (as shown by the B-NP QED data) and that there may be 
other residues in tau which are targeted by BRSK.  This is supported by the data that 
shows that co-expression of S262A tau with B-WT causes a slight eye phenotype.  
However, it should also be taken into consideration that western blotting is a semi-
quantitative technique and as such may not be sensitive enough to detect small 
differences in pS262.     
 
Mutation of two serine residues in S2A tau fully prevented the tau-induced 
degenerative phenotype and the B-WT enhancement, indicating that both S262 and 
S356 are important residues for the formation of these phenotypes.  With regards to 
this, an experiment performed recently by Dr Alessia Galasso, a post-doctoral 
researcher in the laboratories of Dr Moffat and Prof Frenguelli shows that co-
transfection of B-WT with human 2N4R tau in human embryonic kidney (HEK) 
cells increased tau phosphorylation at S356 (personal communication, Dr A. 
Galasso).  This supports the hypothesis that B-WT enhances tau toxicity through 
phosphorylation of tau at both S262 and S356, but this requires further study.  The 
data on S2A and B-WT is consistent with the observations made by Nishimura et al., 
(2004) who showed that S2A tau had no eye phenotype and that expression of PAR-
1 with S2A tau did not cause an enhancement (Nishimura et al., 2004).  Expression 
of B-WT with R406W tau was lethal; the reason for this lethality remains unknown - 
it could be due to the more toxic nature of R406W tau, or it could be as a result of 
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GAL4 toxicity (Wittmann et al., 2001; Kramer and Staveley, 2003; Dietzl et al., 
2007; Hua et al., 2010).  It was not possible to investigate the expression level of 
S2A tau as the stock became contaminated before the experiment was completed.  
However, I was able to show that the R406W tau flies expressed significantly less 
tau than the 0N4R tau flies, and it has been previously published that tau expression 
in the S2A flies is not significantly different from that of the R406W flies 
(Nishimura et al., 2004).  A positive control experiment for S2A tau (using 
constitutively active sgg) was not conducted as this has been previously published 
(Chatterjee et al., 2009).   
 
As an aside, it is interesting that it is very difficult to ameliorate the „basal‟ eye 
phenotype that is formed upon expression of human tau.  This raises the question of 
why does the human tau eye phenotype form?  There are a number of possible 
scenarios: it has been shown that expression of human tau in a Drosophila tau null (-
/-) background does not affect the human tau-induced eye phenotype, so it is unlikely 
that the phenotype arises due to sequestration of vital factors away from Drosophila 
tau by human tau, as a result of competition for microtubule binding between human 
and Drosophila tau or due to a simple „overload‟ of tau (Feuillette et al., 2010).  
Further to this, Feuillette et al. (2010) indicates that the majority of human tau 
expressed in the Drosophila eye exists as soluble cytosolic hyperphosphorylated 
species and that the accumulation of soluble cytosolic hyperphosphorylated species 
correlates with tau toxicity.  They draw this conclusion on the basis that expression 
of human tau
AP
 (in which 14 threonine and serine sites have been mutated to alanine 
to prevent phosphorylation), in their opinion, does not cause an eye phenotype 
whereas expression of human tau
E14
 (in which all of the serine sites have been 
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mutated to glutamic acid to mimic phosphorylation) causes a rough eye phenotype 
(Feuillette et al., 2010).  In contrast, my data shows that mutation of S356 and/or 
S262 to alanine is sufficient to prevent the human tau-induced eye phenotype, which 
would suggest that not only is phosphorylation at these residues vital, but that the 
formation of human tau-induced eye phenotypes may not have a direct relationship 
to the phosphorylation load of tau; the Feuillette study is based upon the mutation of 
a large number of residues, whereas I show that mutation of one or two residues (in 
the S262A and S2A tau respectively) is sufficient to render human tau non-toxic 
when expressed in the Drosophila eye despite all the other residues of tau being 
available for phosphorylation.  In support of this, is the data presented by Chatterjee 
et al., (2009) whereby S2A tau, which was still highly phosphorylated, was shown to 
be non-toxic and S11A tau (in which 11 serine residues that are known to be targeted 
by GSK-3β are mutated to alanine but S262 and S356 are not mutated), which was 
not highly phosphorylated, was shown to be toxic (Chatterjee et al., 2009).  
Therefore, it would appear that there is not a direct relationship between the toxicity 
of human tau and the phosphorylation load.  Instead, it may be the case that tau 
toxicity is more intricately linked to phosphorylation at individual sites and the effect 
that phosphorylation at each site has on the microtubule binding ability and solubility 
of tau.    
 
Taken together, the data in this chapter indicate that B-WT is capable of 
phosphorylating 0N4R human tau at S262.  This is the most convincing data to date 
of an in vivo interaction between human tau and BRSK2, although I have no 
evidence as to whether this interaction is direct or mediated by a third intermediary 
protein.  However, there is no evidence to date of BRSK forming a complex with 
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other proteins.  There is evidence that B-WT is able to interfere with the microtubule 
binding properties of tau, most likely through its role in phosphorylating tau at S262, 
a residue which is known to be important for microtubule binding (Sengupta et al., 
1998; Fischer et al., 2009) and that B-WT is also capable of phosphorylating tau at 
S356.  
 
Due to its brain-specific expression, especially in areas affected by AD such as the 
cortex and the hippocampus, BRSK2 is proving to be a potentially important tau 
kinase that has been previously overlooked.  In the next chapter I will address the 
regulation of human BRSK2 in the Drosophila model, and the possibility that the 
BRSK2-tau interaction is regulated in a calcium-dependent manner.   
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5| Upstream regulation of 
human BRSK2 in 
Drosophila. 
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5.1 Introduction 
 
 
Having demonstrated in the previous chapter that BRSK2 was capable of enhancing 
a tau-induced degenerative eye phenotype and phosphorylating tau at S262, I was 
interested in identifying endogenous Drosophila kinases that were capable of 
regulating this interaction.  According to the literature, there are two upstream 
regulators of BRSKs; LKB1 and CaMKKα (Lizcano et al., 2004; Fujimoto et al., 
2008).  As discussed in the Introduction, LKB1 is a master kinase that 
phosphorylates and regulates 14 members of the AMPK-related family of protein 
kinases and CaMKKα is a member of the Ca2+/calmodulin-dependent family of 
protein kinases.  Both kinases have been shown to activate BRSKs via 
phosphorylation at T174 in BRSK2 and T189 in BRSK1.  LKB1 and CaMKKα both 
have homologues in the Drosophila genome - LKB1 (referred to as DmLKB1 in 
order to distinguish between the human and Drosophila genes) and CG17698 
respectively.    
 
Experiments were conducted in order to elucidate whether DmLKB1 and/or 
CG17698 were required for the interaction between human tau and human BRSK2 in 
the Drosophila eye.  To do this, RNAi lines (obtained from the Vienna Drosophila 
RNAi Collection, VDRC) targeting endogenous DmLKB1 and CG17698 were 
utilised. To address the specificity of the RNAi, flies transgenic for human CaMKKα 
(hCaMKKα) were utilised as hCaMKKα is not targeted by the CG17698 RNAi.  Due 
to time constraints it was not possible to do the same rescue experiment using 
DmLKB1 RNAi and human LKB1.  To elucidate whether enhancement of tau-
induced eye phenotypes by B-WT occurred in a calcium dependent manner, UAS-
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cacophony1 flies (obtained from the Bloomington Stock Center) were used to over-
express cacophony1 (Drosophila calcium channel α subunit) in the eye along with 
tau and B-WT.    
 
Due to the apparent overlap between BRSK and PAR-1 functions, I was interested to 
ascertain whether endogenous PAR-1 (referred to DmPAR-1 in order to distinguish 
between the human and Drosophila genes) was contributing to B-WT exacerbation 
of the tau phenotype.  To address this, I used a DmPAR-1 RNAi line (obtained from 
VDRC) to down-regulate the expression of endogenous DmPAR-1 in flies co-
expressing tau with B-WT.  Finally, western blots on lysates from flies expressing 
tau and B-WT together with DmLKB1 RNAi, CG17698 RNAi or DmPAR-1 RNAi 
were performed in order to elucidate the effect of down-regulation of the genes 
targeted by the RNAi on B-WT induced phosphorylation of tau at S262. 
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5.2 Results 
 
 
5.2.1 Co-expression of DmLKB1 RNAi with human tau and human B-WT  
 
 
In order to ascertain whether endogenous DmLKB1 was required for regulation of 
human B-WT in Drosophila, RNAi targeting DmLKB1 was utilised.  Visual 
examination of flies expressing two copies of DmLKB1 RNAi, with or without tau, 
showed that DmLKB1 RNAi expression did not have an effect on eye phenotype 
(Figure 5.1).  This was confirmed by QED analysis.  GMR flies (shown in Chapter 4, 
Figure 4.4) had a DC range of 0.22-0.29 whilst flies expressing two copies of 
DmLKB1 RNAi had a range of 0.19-0.33.  Flies expressing Tau (shown in Chapter 4, 
Figure 4.7) had a DC range of 0.31-0.55 whilst flies expressing two copies of 
DmLKB1 RNAi with Tau had a range of 0.31-0.65 (data not shown).  
 
Expression of one or two copies of DmLKB1 RNAi in fly eyes expressing human tau 
with human B-WT resulted in a phenotype which was in-between that of the Tau and 
Tau with B-WT flies (Figure 5.2).  QED analysis confirmed that expression of 
DmLKB1 RNAi with Tau and B-WT rescued the phenotype, resulting in a 
phenotype similar to that of flies co-expressing tau and B-NP.  This rescue did not 
appear to be dose-dependent as the curves produced for flies with one copy of the 
RNAi was very similar to the curve produced for flies with two copies (Figure 5.3). 
 
Figure 5.4 shows that the DC range for flies expressing one copy of DmLKB1 RNAi 
with Tau and B-WT (0.39-0.62) was intermediate to the ranges of flies expressing 
Tau alone (0.31-0.55, shown in Chapter 4, Figure 4.7) or Tau with B-WT (0.40-0.99, 
shown in Chapter 4, Figure 4.7).  The DC range of flies expressing two copies of 
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DmLKB1 RNAi with Tau and B-WT (0.36-0.99) appeared very similar to the range 
of the Tau + B-WT flies, but this was not the case; it can be seen from figure 5.3 that 
there is only one fly that had a high DC (0.99) and that the rest of the flies fell in-
between the Tau and Tau + B-WT curves. 
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Figure 5.1: SEM images and QED analysis of flies expressing two copies of 
DmLKB1 RNAi with or without 0N4R tau. 
A: Expression of two copies of DmLKB1 RNAi had no visible effect on the eye 
phenotype when expressed either alone (compared to GMR) or with tau (compared 
to tau).   Scale bar 100µm applies to all panels. B: Quantitative analysis of flies 
expressing two copies of DmLKB1 RNAi, with or without tau, shows that down-
regulation of endogenous DmLKB1 had no effect on eye phenotype in flies either 
expressing DmLKB1 RNAi alone (compare with GMR) or with Tau (compare with 
tau).  GMR n=11, 2xDmLKB1 RNAi n=12, Tau n=20 and T + 2xDmLKB1 RNAi 
n=10. 
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Figure 5.2: SEM images of flies expressing 0N4R tau, B-WT and DmLKB1 RNAi. 
Scanning electron micrographs showing that expression of DmLKB1 RNAi (one or 
two copies) rescues the phenotype caused by co-expression of tau with B-WT (T/B + 
1xDmLKB1 RNAi and T/B + 2xDmLKB1 RNAi).  Scale bar 100µm applies to all 
panels. 
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Figure 5.3: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies co-expressing 0N4R tau, B-WT and DmLKB1 
RNAi.   
Quantitative analysis of flies expressing one or two copies of DmLKB1 RNAi shows 
that down-regulation of endogenous DmLKB1 rescues the phenotype caused by co-
expression of Tau with B-WT (T/B + 1xDmLKB1 RNAi and T/B + 2xDmLKB1 RNAi).  
The rescue did not appear to be dose-dependent as one copy of DmLKB1 RNAi had 
the same effect as two copies.  GMR n=11, Tau n=20, B-WT n=21, T + B-WT n=17, 
T/B + 1xDmLKB1 RNAi n=8 and T/B + 2xDmLKB1 RNAi n=9. 
 
 
 
 
 
 
 
 
 
 
 
187 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4: SEM images of flies expressing tau, B-WT and one or two copies of 
DmLKB1 RNAi with the lowest and highest DCs.   
Images of flies expressing either one or two copies of DmLKB1 RNAi with 0N4R tau 
and B-WT.  The range of DCs is very similar.  DCs are shown on the images.     
Scale bar 100µm applies to all panels. 
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5.2.2 Co-expression of CG17698 RNAi with tau and B-WT 
 
 
In order to ascertain whether endogenous CG17698 was capable of regulating human 
B-WT in Drosophila, RNAi targeting CG17698 was utilised.  Visual examination of 
flies expressing CG17698 RNAi, with or without Tau, showed that CG17698 RNAi 
expression did not have an effect on eye phenotype when expressed alone, but that it 
slightly enhanced the phenotype when expressed with Tau (Figure 5.5).  This was 
confirmed by QED analysis: the curve for flies expressing CG17698 RNAi with Tau 
was shifted to the right of the curve for flies expressing Tau alone (Figure 5.5).  The 
DC range for GMR flies (shown in Chapter 4, Figure 4.4) was 0.22-0.29 whilst flies 
expressing CG17698 RNAi had a range of 0.22-0.27.  Flies expressing Tau (shown 
in Chapter 4, Figure 4.7) had a DC range of 0.31-0.55 whilst flies expressing 
CG17698 RNAi with Tau had a higher DC range of 0.46-0.77 (data not shown). 
 
Expression of CG17698 RNAi in fly eyes expressing human tau with human B-WT 
rescued the Tau-BRSK phenotype (Figure 5.6), resulting in a phenotype that was 
similar to that of flies co-expressing tau and CG17698 RNAi or tau and B-NP.  
Further to this, expression of human CaMKKα (hCaMKKα rescue), which was not 
targeted by the RNAi, reversed the rescue seen upon expression of CG17698 RNAi 
in the Tau + B-WT background.  However, due to the complex genetics involved in 
producing this fly, the n number is low.  Co-expression of hCaMKKα and tau did not 
alter the tau-induced eye phenotype (assessed using a light microscope, data not 
shown); this is likely to be due to CG6114 not being able to act on human tau 
(Chapter 4, Figures 4.11, 4.12 and 4.13).     
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QED analysis confirmed the results seen upon visual examination of the SEMs; 
expression of CG17698 RNAi with Tau and B-WT rescued the phenotype and 
expression of hCaMKKα in this background returned the phenotype to one similar to 
that of the flies expressing Tau with B-WT (Figure 5.7).   
 
Figure 5.8 shows that the DC range for flies expressing CG17698 RNAi with Tau 
and B-WT (0.38-0.59) was intermediate to the ranges of flies expressing Tau alone 
(0.31-0.55, shown in Chapter 4, Figure 4.7) or Tau with B-WT (0.40-0.99, shown in 
Chapter 4, Figure 4.7).  The DC range of flies expressing hCaMKKα in the Tau, B-
WT and CG17698 RNAi background (0.48-0.99) was very similar to the DC range 
of the flies expressing Tau with B-WT. 
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Figure 5.5: SEM images of flies expressing CG17698 RNAi with or without 0N4R 
tau.  
Expression of CG17698 RNAi had no effect on eye phenotype when expressed alone 
(compare with GMR) but appeared to enhance the eye phenotype when expressed 
with tau (compare with tau).   Scale bar 100µm applies to all panels.  Quantitative 
analysis of flies expressing CG17698 RNAi, with or without tau, shows that down-
regulation of CG17698 had no effect on eye phenotype in flies expressing CG17698 
RNAi alone (compare with GMR) but that it enhanced the phenotype in flies 
expressing the RNAi with 0N4R tau (compare with tau).  GMR n=11, CG17698 
RNAi n=12, Tau n=20 and T + CG17698 RNAi n=11. 
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Figure 5.6: SEM images of flies expressing 0N4R tau, B-WT and CG17698 RNAi 
with or without hCaMKKα.   
Scanning electron micrographs showing that expression of CG17698 RNAi can 
rescue the enhancement seen with co-expression of tau and B-WT.  Expression of 
human CaMKKα in the tau, B-WT, CG17698 RNAi background (hCaMKKα rescue) 
can over-ride the effect of the RNAi and return the phenotype to something similar to 
what was seen with expression of tau and B-WT.  Scale bar 100µm applies to all 
panels. 
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Figure 5.7: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies expressing 0N4R tau, B-WT and CG17698 
RNAi with or without hCaMKKα.   
Quantitative analysis of flies expressing CG17698 RNAi shows that down-regulation 
of endogenous CG17698 rescues the phenotype caused by co-expression of 0N4R tau 
with B-WT.  Expression of hCaMKKα in the tau, B-WT, CG17698 RNAi background 
(hCaMKKα rescue) over-rides the rescue seen with the RNAi.  GMR n=11, Tau 
n=20, B-WT n=21, T + B-WT n=17, T/B + CG17698 RNAi n=8 and hCaMKKα 
rescue n=4. 
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Figure 5.8: SEM images of flies expressing tau, B-WT and CG17698 RNAi with or 
without hCaMKKα, with the lowest and highest DCs.   
The range of DCs for flies expressing tau, B-WT and CG17698 RNAi is in-between 
the DC ranges of flies expressing tau or tau with B-WT.  The range of flies 
expressing tau, B-WT, CG17698 RNAi and hCaMKKα (hCaMKKα rescue) is similar 
to the DC range of flies expressing tau with B-WT.   DCs are shown on the images.     
Scale bar 100µm applies to all panels. 
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5.2.3 Co-expression of both CG17698 and DmLKB1 RNAi with tau and B-WT 
 
 
Expression of either DmLKB1 RNAi or CG17698 RNAi with tau and B-WT caused 
a rescue of the eye phenotype.  Thus, it could be hypothesised that expression of both 
RNAi with tau and B-WT could rescue the phenotype to a larger extent (if both 
RNAi were not 100% effective).  However, expression of both RNAi with tau and B-
WT did not appear to further rescue the eye phenotype.  Instead the phenotype 
appeared worse than when the RNAi were used individually and the phenotype was 
returned to something similar to the phenotype seen upon co-expression of tau with 
B-WT (Figure 5.9).   
 
QED analysis (Figure 5.10) demonstrated that although the n number was quite low 
(n=5), the eye phenotypes of eyes expressing both RNAi with tau and B-WT were 
largely similar to the eye phenotypes of flies expressing tau and B-WT but no RNAi.  
The DC range of the flies expressing both RNAi with tau and B-WT (Figure 5.10) 
was 0.45-0.72, a range which ended at a lower figure than that of the flies expressing 
tau and B-WT (0.44-0.99, shown in Chapter 4, Figure 4.7).  This could indicate that 
expression of both RNAi together caused a rescue of the flies with the most severe 
eye phenotype.  However, it is also possible that if more flies were analysed, flies 
with the more severe eye phenotype would be observed.  Unfortunately this was not 
possible due to difficulties producing flies of this genotype. 
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Figure 5.9: SEM images of flies expressing both RNAi with tau and B-WT. 
Expression of CG17698 RNAi or two copies of DmLKB1 RNAi with tau and B-WT 
rescued the eye phenotype.  Expression of both RNAi with tau and B-WT did not 
rescue the phenotype to the same extent as when the single RNAi were utilised.   
Scale bar 100µm applies to all panels. 
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Figure 5.10: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software and images of flies with the lowest and highest DC for 
flies co-expressing both RNAi with tau and B-WT.   
Quantitative analysis of flies co-expressing both RNAi with 0N4R tau and human B-
WT under the control of the GMR-GAL4 driver showed that expression of both RNAi 
did not rescue the eye phenotype.  GMR n=11, Tau n=20, T + B-WT n=17, T/B + 
2xDmLKB1 RNAi n=9, T/B + CG17698 RNAi n=8 and T/B + both RNAi n=5.  The 
range of DC for T/B + both RNAi flies was 0.45-0.72.  Scale bar 100µm applies to 
all panels. 
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5.2.4 Co-expression of CG17698 RNAi or DmLKB1 RNAi with tau and B-CA 
 
 
Co-expression of either CG17698 RNAi or two copies of DmLKB1 RNAi with tau 
and B-CA showed that B-CA was unable to „over-ride‟ the rescue effect of either of 
the RNAi (data not shown).   This is in agreement with the data presented in Chapter 
4 (Figures 4.9 and 4.10), which suggested that B-CA was not capable of enhancing 
the tau-induced eye phenotype, either because it was not constitutively active or 
because the protein was unstable.   
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5.2.5 Co-expression of a calcium channel subunit with tau and B-WT 
 
 
The potential regulation of BRSKs through CaMKK is interesting as it would 
provide a mechanistic link between the calciumopathy model for AD and tau 
phosphorylation.  The calciumopathy model for AD states that as humans age their 
capacity for buffering calcium becomes impaired leading to a dysregulation of 
calcium homeostasis: such changes, if sustained, could trigger age-associated 
modifications in the brain (Khachaturian, 1987; LaFerla, 2002).  In order to 
investigate whether a rise in intracellular calcium would have an effect on tau and B-
WT induced eye phenotypes, I used UAS-cacophony1 flies (obtained from the 
Bloomington Stock Center).  cacophony1 (cac1) is the Drosophila homologue of the 
human voltage-dependent calcium channel alpha-1 subunit.  It is predominantly 
expressed in neuronal tissue and is known to be involved in neurotransmitter release, 
synaptic transmission and nerve terminal growth (Dason et al., 2009; Gu et al., 2009).  
Although there is currently no data indicating that expression of cac1 in the eye leads 
to an increase in intracellular calcium, it has been shown that cac1 mediates slow-
inactivating calcium currents in neurons cultured from late stage pupal brains (Gu et 
al., 2009).    
 
Over-expression of cac1 under the control of the GMR driver with or without human 
tau did not cause a visible eye phenotype (Figure 5.11).  However, over-expression 
of cac1 in the presence of both human tau and B-WT caused a dramatic exacerbation 
of the eye phenotype. This exacerbation was human B-WT dependent, suggesting 
that B-WT enhancement of tau-induced deleterious eye phenotypes is a process that 
could be regulated in a calcium-dependent manner. 
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QED analysis of cac1 flies confirmed that over-expression of cac1 alone, or with tau, 
caused no eye phenotype and that over-expression with tau and B-WT exacerbated 
the tau-BRSK phenotype (Figure 5.12).  The cumulative curve for flies expressing 
cac1 with tau and B-WT showed a large shift to the right of the curve for flies 
expressing tau and B-WT but no cac1.  
 
Figure 5.13 shows the cac1 over-expressing flies with the lowest and highest DCs.  
GMR cac1 flies had a DC range of 0.21-0.33.  T + cac1 flies had a DC range of 0.39-
0.52.  T/B + cac1 flies had a DC range of 0.70-0.99 and the enhanced phenotype was 
clearly visible – flies of this genotype had little eye structure, patches of necrosis and 
smaller eyes than flies expressing tau and B-WT without cac1.  
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Figure 5.11: SEM images of flies over-expressing cac1 with 0N4R tau and B-WT. 
Over-expression of cac1 alone or with tau did not affect the eye phenotype.  Over-
expression of cac1 with tau and B-WT caused an exacerbation of the eye phenotype.  
Scale bar 100µm applies to all panels. 
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Figure 5.12: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies over-expressing cac1 with tau and B-WT.   
Quantitative analysis of flies over-expressing cac1 with or without tau shows that 
this had no effect on eye phenotype.  Over-expression of cac1 with tau and B-WT 
caused a shift of the cumulative curve to the right of that of the tau + B-WT flies, 
indicating a more severe phenotype..  GMR n=11, Tau n=20, GMR cac1 n=5, T + 
B-WT n=17, T + cac1 n=11 and T/B + cac1 n=8. 
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Figure 5.13: SEM images of flies over-expressing cac1 with the lowest and highest 
DCs.   
Images of flies expressing cac1 alone, with 0N4R tau or with 0N4R tau and B-WT.  
Over-expression of cac1 alone or with tau gives a DC range which is similar to that 
of the appropriate control (GMR for GMR cac1 and Tau for T + cac1).  Co-
expression of cac1 with tau and B-WT gives a DC range that is indicative of a more 
severe eye phenotype that the T + B-WT flies.  DCs are shown on the images.     
Scale bar 100µm applies to all panels. 
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5.2.6 Co-expression of DmPAR-1 RNAi with tau and B-WT 
 
 
PAR-1 and BRSKs are members of the AMPK-related family of protein kinases.  
PAR-1 can phosphorylate tau at two residues in the KXGS motifs; Serine 262 and 
Serine 356 (Nishimura et al., 2004), and was originally described as a „major KXGS 
kinase‟ (Drewes et al., 1997).  Like BRSKs, PAR-1 also has roles in the 
establishment of neuronal polarity and neurite outgrowth (Biernat et al., 2002; Kishi 
et al., 2005). 
 
Expression of DmPAR-1 RNAi (obtained from the VDRC) under the control of the 
GMR driver had no effect on eye phenotype (Figures 5.14 and 5.15).  However, 
expression of DmPAR-1 RNAi with human tau appeared to enhance the tau-induced 
eye phenotype to some extent (Figure 5.14 and 5.15).  This enhancement produced 
an eye phenotype which was not as severe as that of flies expressing tau with B-WT, 
but was similar to that of flies expressing tau with CG17698 RNAi (Figures 5.6 and 
5.7).  Expression of DmPAR-1 RNAi with tau and B-WT resulted in a very variable 
phenotype (Figure 5.15).  QED analysis (Figure 5.15) showed that the phenotype 
ranged from similar to tau flies at the lower end of the scale, right up to worse than 
Tau + B-WT flies at the higher end.  Figure 5.16 shows that expression of DmPAR-1 
RNAi alone gave a DC range of 0.22-0.31, co-expression with tau gave a range of 
0.39-0.65 and co-expression with tau and B-WT gave a wide range of 0.32-0.99.            
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Figure 5.14: SEM images of flies expressing DmPAR-1 RNAi with 0N4R tau and 
B-WT.   
Expression of DmPAR-1 RNAi alone (DmPAR-1 RNAi) did not cause an eye 
phenotype.  Co-expression of DmPAR-1 RNAi with tau (T + DmPAR-1 RNAi) 
appeared to enhance the tau phenotype.  Co-expression of DmPAR-1 RNAi with tau 
and B-WT caused a variable phenotype; the example shown here is of an eye 
exhibiting a similar phenotype to a T + B-WT fly.  Scale bar 100µm applies to all 
panels. 
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Figure 5.15: Cumulative distribution plot of ommatidial distortion measures (DCs) 
produced by QED software for flies expressing DmPAR-1 RNAi with 0N4R tau 
and B-WT.   
Quantitative analysis of flies expressing DmPAR-1 RNAi, with or without tau, shows 
that down-regulation of endogenous DmPAR-1 had no effect on eye phenotype in 
flies expressing DmPAR-1 RNAi alone (compare with GMR) but that it enhanced the 
phenotype in flies expressing the RNAi with 0N4R tau (compare with tau).  Co-
expression of the RNAi with tau and B-WT produced a very variable phenotype.  
GMR n=11, DmPAR-1 RNAi n=10, Tau n=20 and T + DmPAR-1 RNAi n=10, T + 
B-WT n=17 and T/B + DmPAR-1 RNAi n=14. 
 
 
 
 
 
 
 
 
 
 
206 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.16: SEM images of flies expressing DmPAR-1 RNAi with the lowest and 
highest DCs.  
Images of flies expressing DmPAR-1 RNAi alone, with tau or with tau and B-WT.  
Expression of DmPAR-1 RNAi alone gives a DC range which is very similar to that 
of the GMR flies.  Co-expression of DmPAR-1 RNAi and tau gives a DC range that is 
higher than that of the tau flies, demonstrating that expression of DmPAR-1 RNAi 
enhances the tau-induced phenotype.  Expression of DmPAR-1 RNAi with tau and B-
WT gives a wide range of DCs; in some flies the phenotype was ameliorated and in 
some flies the phenotype was enhanced.  DCs are shown on the images.     Scale bar 
100µm applies to all panels. 
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5.2.7 Phosphorylation of pS262 in RNAi expressing flies 
 
 
Figure 5.17 shows representative western blots carried out on lysates of flies 
expressing tau, T + B-WT or T/B with each of the three RNAi lines used in this 
chapter (CG17698, DmLKB1 and DmPAR-1).  The data for tau and T + B-WT flies 
was originally shown in Chapter 4, Figure 4.21, but has been included here for 
comparison.  Co-expression of B-WT with tau caused a significant increase in the 
amount of pS262 signal (normalised to total tau, T46) n=10, 0.32±0.03 for 0N4R tau 
and n= 11, 0.62±0.05 for T + B-WT, p<0.001, one way anova.  Expression of 
DmPAR-1 RNAi or CG17698 RNAi with tau and B-WT had no significant effect on 
the pS262 when compared to flies expressing tau with B-WT, but neither was the 
pS262 in these flies significantly different from the tau flies (n=7, 0.54±0.08 for T/B 
+ DmPAR-1 RNAi and n=10, 0.50±0.04 for T/B + CG17698 RNAi).  Expression of 
DmLKB1 RNAi with tau and B-WT resulted in pS262 that was not significantly 
different to pS262 in tau + B-WT flies, but pS262 in the DmLKB1 RNAi flies was 
significantly elevated when compared to the tau flies (n=9, 0.56±0.05 for T/B + 
2xDmLKB1 RNAi, p<0.05, one way anova). 
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Figure 5.17: Western blots for pS262 and total tau.   
Quantification of western blots from flies expressing tau, T + B-WT, T/B + DmPAR-
1 RNAi, T/B + 2xDmLKB1 RNAi or T/B + CG17698 RNAi show that co-expression 
of B-WT with 0N4R tau caused a significant increase in tau phosphorylated at S262.  
Expression of DmPAR-1, DmLKB1 or CG17698 RNAi with tau and B-WT had no 
effect on the increased pS262.  Flies expressing DmLKB1 RNAi with tau and B-WT 
had significantly elevated pS262 when compared to flies expressing tau alone. Mean 
± SEM: 0.32±0.03 for tau (n=10), 0.62±0.05 for T + B-WT (n=11), 0.54±0.08 for 
T/B + DmPAR-1 RNAi (n=7), 0.56±0.05 for T/B + 2xDmLKB1 RNAi (n=9) and 
0.50±0.04 for T/B + CG17698 RNAi (n=10). *** p<0.001, * p<0.05, one way anova.  
Representative western blots shown. 
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5.3 Discussion 
 
Expression of RNAi targeting endogenous DmLKB1 had no effect on control eyes, a 
finding that is consistent with the literature (Wang et al., 2007a).  In addition, there 
was no effect of DmLKB1 RNAi expression on tau-induced eye phenotypes.  The 
DmLKB1 RNAi has been previously shown to be effective at knocking-down 
DmLKB1 expression and so the lack of effect on the tau-induced eye phenotypes 
would suggest that none of the endogenous kinases which are regulated by DmLKB1 
(such as PAR-1) contribute significantly to the establishment of „basal‟ tau-induced 
eye phenotypes (Wang et al., 2007a).   
 
Co-expression of DmLKB1 RNAi with tau and B-WT resulted in a rescue of the eye 
phenotype, as shown by SEM and QED, with flies exhibiting an eye phenotype 
similar to that of flies co-expressing tau and B-NP.  This confirms that DmLKB1 is 
capable of regulating human B-WT.  In mammals, LKB1 is known to regulate 14 
members of the AMPK-related family of protein kinases (including BRSKs and 
PAR-1) and in Drosophila DmLKB1 has been shown to regulate endogenous PAR-1 
(Lizcano et al., 2004; Wang et al., 2007a).  Thus, it would appear that the regulatory 
pathway from DmLKB1 to members of the AMPK-related kinases has been 
conserved in Drosophila.  
 
Expression of CG17698 RNAi alone had no effect on eye phenotypes.  When co-
expressed with human tau, there was a slight exacerbation of the tau-induced eye 
phenotype.  The mechanism for this enhancement is unknown; it could be related to 
the phosphorylation status of tau, indeed it has been suggested that an optimal level 
of tau phosphorylation is essential to the physiological function of tau (Chatterjee et 
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al., 2009), but without any evidence for this hypothesis, this interpretation is purely 
speculative.  Equally possible is that the enhancement is due to off target effects of 
the RNAi.     
 
Co-expression of CG17698 RNAi with tau and B-WT resulted in a rescue of the eye 
phenotype similar to that seen with DmLKB1 RNAi, confirming that CG17698 is 
also required for the enhancement of the tau phenotype by human B-WT in vivo.  
Preliminary work in the laboratories of Dr Moffat and Prof Frenguelli has shown that 
the CG17698 RNAi line knocks-down expression of CG17698 by approximately 
70% (personal communication, Mr Sharad Mennon).  The similar rescues exhibited 
upon expression of CG17698 or DmLKB1 RNAi raises the question of whether both 
genes are acting upon BRSK as part of a linear pathway.  It would be relatively 
straightforward to address this by performing in vitro phosphorylation assays, 
however, in the absence of any evidence for this scenario, it is equally likely that the 
system is not fully quantitative or that the RNAi are having off target effects that 
complicate the analysis.   
 
Over-expression of human CaMKKα, which is known to regulate human BRSKs and 
was not targeted by the RNAi (Fujimoto et al., 2008), prevented the rescue seen with 
CG17698 RNAi expression, indicating that the RNAi was specific for CG17698.  
Due to the complex genetics involved in producing this fly, the n number is low 
(n=4), but QED analysis indicates that the phenotype was not very variable; each of 
the flies has a phenotype similar to that of tau + B-WT flies.  Assessment of flies co-
expressing hCaMKKα and tau using a light microscope indicated that hCaMKKα did 
not alter the tau-induced eye phenotype, providing more evidence that CG6114 is not 
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able to act on human tau.  There is another member of the AMPK family that is 
regulated by CaMKKs; AMPK, the prototypical member of the AMPK-related 
family of protein kinases.  However, AMPK is mainly regulated by the β-isoform of 
CaMKKs (Hawley et al., 2005).  Thus, the data supports the conclusion that the 
hCaMKKα „over-ride‟ of the CG17968 RNAi was due to a direct activation of 
human BRSK.  Conversely, expression of both RNAi (CG17698 and DmLKB1) 
simultaneously with tau and B-WT resulted in a phenotype that was more similar to 
that of flies expressing tau with B-WT than flies expressing tau alone.  This could be 
due to additive off target effects of the RNAi, or because the down regulation of at 
least 14 kinases in the AMPK family (that are targeted by these two regulators) is in 
itself toxic.  In order to test for toxicity related to the joint use of the CG17698 and 
DmLKB1 RNAi, I would express the RNAi simultaneously with the GMR driver 
and with tau (without BRSK).  Unfortunately, due to time constraints I was unable to 
perform these experiments.        
 
In order to elucidate whether BRSKs were activated in a calcium-dependent manner, 
I over-expressed cac1, a calcium channel α subunit, in an attempt to increase 
intracellular calcium levels from extracellular sources (rather than via release from 
the endoplasmic reticulum).  Over-expression of cac1 with tau and B-WT 
dramatically enhanced the eye phenotype, indicating that an increase in intracellular 
calcium was sufficient to enhance the tau-BRSK eye phenotype.  Importantly, the 
enhancement was human BRSK dependent; no enhancement was seen when cac1 
was over-expressed with tau alone, neither did over-expression of cac1 by itself in 
the eye cause any disruption to the wild type eye phenotype.  This experiment 
provides the first tentative in vivo link between increased intracellular calcium, a tau 
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kinase and increased tau toxicity.  Unfortunately I was unable to pursue this further, 
but it will now be important to demonstrate that tau phosphorylation at S262 and 
BRSK2 phosphorylation at T174 is increased upon over-expression of cac1 with tau 
and B-WT, that the calcium induced exacerbation of tau-BRSK eye phenotypes is 
dependent on CG17698, whether the S262A/S2A mutants are insensitive to cac1 
expression with B-WT, that over-expression of cac1 in the eye causes a rise in 
intracellular calcium and that over-expression of cac1 has no effect when B-NP or B-
KD is substituted for B-WT.  If this is the case, it would categorically show that 
BRSKs are activated in response to calcium, leading to tau phosphorylation and an 
increase in tau toxicity in the Drosophila model, as indicated in the summary 
diagram in Figure 5.18.   
 
This would be highly relevant for AD as perturbed calcium homeostasis has been 
implicated in the pathogenesis of AD for a number of decades (Khachaturian, 1987; 
LaFerla, 2002).  As discussed in the Introduction, the calciumopathy model for AD 
proposes that as humans age calcium regulation becomes impaired due to a decrease 
in buffering capacity and if sustained, dysregulated calcium homeostasis may 
provide a trigger for age-associated changes in the brain (Khachaturian, 1987).  
There is a large amount of evidence supporting this theory: calcium signalling has 
been shown to be impaired before the manifestation of symptoms in familial and 
sporadic AD patients, increased Aβ and presenilin mutations can increase 
intracellular calcium and increased cytosolic calcium directly and indirectly activates 
tau kinases leading to increased tau phosphorylation (Arispe et al., 1993; Ito et al., 
1994; Litersky et al., 1996; Etcheberrigaray et al., 1998; Leissring et al., 1999a; 
Leissring et al., 1999b; Kusakawa et al., 2000; Ferreiro et al., 2004; Zempel et al., 
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2010).  There is also data suggesting that increasing the cytosolic calcium 
concentration increases the production of intracellular Aβ (Querfurth and Selkoe, 
1994; Pierrot et al., 2004; Pierrot et al., 2006).  However, this remains a contentious 
issue as it has also been demonstrated that increasing cytosolic calcium by a different 
mechanism leads to decreased Aβ production (Buxbaum et al., 1994).  Nevertheless, 
in AD, the production of Aβ - whether as a result of rising intracellular calcium or 
not, would serve to greatly exacerbate this process.          
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Figure 5.18: Summary schematic of BRSK regulation.   
BRSK is regulated by two distinct upstream pathways; LKB1 and CG17698.  
Calcium influx through plasma membrane calcium channels leads to a rise in 
intracellular calcium and activation of CG17698 (CaMKKα in humans).  CG17698 
and LKB1 activate BRSK by phosphorylating at T174 (BRSK2) or T189 (BRSK1).  
BRSK phosphorylates tau at S262, and possibly at S356. 
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Due to the similarities in function of PAR-1 and BRSKs, it was important to attempt 
to establish whether DmPAR-1 and BRSK were in the same pathway to tau that 
generates the eye phenotype.  Experiments were conducted using DmPAR-1 RNAi 
but the results were mixed and did not allow me to draw any firm conclusions.  
Expression of DmPAR-1 RNAi under the control of the GMR driver had no effect on 
eye phenotype.  However, co-expression of DmPAR-1 RNAi with human tau led to 
an exacerbation of the tau-induced eye phenotype.  This is an important result as 
PAR-1 is a potential S262 kinase (Biernat et al., 2002).  Thus down regulation of 
DmPAR-1 may be expected to decrease the toxicity of human tau in the eye if it was 
the only important S262 kinase and S262 phosphorylation was responsible for the 
toxicity of human tau in the eye (as is suggested by the S262A data).  Co-expression 
of DmPAR-1 RNAi with tau and B-WT resulted in a very varied phenotype; the 
RNAi appeared to rescue the phenotype in some flies and to enhance it in others.  
Due to the degree of variation in the phenotype, no firm conclusions can be drawn as 
to any interactions between DmPAR-1 and BRSK based on this data; further work is 
required, beginning with characterisation of the RNAi line.  Alternatively, it may be 
simpler to investigate the potential for interactions between BRSK and PAR-1 using 
a cellular model. 
 
Analysis of tau phosphorylation in lysates from the various flies showed that none of 
the RNAi used in this chapter significantly altered pS262 (as detected by western 
blot).  This links back to a point made in the Discussion of Chapter 4; western 
blotting is a semi-quantitative method and so it is difficult to rank samples with small 
differences in phosphorylation levels.  In addition, it is not known to what extent 
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phosphorylation and phenotype correlate – it is possible that a small difference in the 
phosphorylation status of tau (which would be very difficult to detect using a semi-
quantitative method) would be sufficient to produce a rescue such as that seen upon 
expression of DmLKB1 or CG17698 RNAi.  This question awaits the development 
of more sensitive and quantitative approaches, such as an ELISA assay or Mass 
Spectrometry method to specifically quantify the stoichiometry of tau 
phosphorylated at S262.   
 
In summary, two upstream regulators of human BRSKs have been identified in the 
Drosophila genome; DmLKB1 and CG17698.  Expression of RNAi targeting either 
gene resulted in rescue of the tau-BRSK phenotype, suggesting a linear regulatory 
pathway.  There is no evidence for this in the literature and as such this warrants 
further investigation.  Whilst the data showing that endogenous DmLKB1 can 
regulate human BRSKs is interesting, LKB1 is already accepted as a regulator of 14 
members of the AMPK family of protein kinases (Lizcano et al., 2004).  CaMKKα 
has previously only been shown to regulate BRSKs in vitro and thus my data is the 
most convincing evidence to date that there is functional regulation of BRSKs by 
CaMKKα in vivo (Fujimoto et al., 2008).  In addition, the potentially calcium-
dependent nature of the eye phenotype suggests an interesting novel pathway from 
deregulated intracellular calcium to tau phosphorylation at a disease relevant residue 
(S262), potentially via CaMKK and BRSKs.  In support of this, I have shown that 
over-expression of a calcium channel results in an enhanced tau-BRSK eye 
phenotype, providing the first in vivo evidence that human BRSKs can be regulated 
in a calcium-dependent manner and a link between the calciumopathy model for AD 
and tau phosphorylation.  Further work will be required in order to confirm that this 
217 
 
process is mediated by CaMKK and that S262 and B-WT phosphorylation is 
increased upon co-expression of cac1 with tau and B-WT.     
 
In the following chapter, I extend the present data from flies to humans, in a study 
conducted using human post-mortem brain tissue to investigate the expression and 
activation levels of human BRSKs and the two upstream regulators, LKB1 and 
CaMKK (human homologue of CG17698).     
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6| Analysis of samples 
from post-mortem 
human brain tissue. 
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6.1 Introduction 
 
 
The experiments contained in this chapter were conducted in the lab of Dr Diane 
Hanger, King‟s College, London, under the supervision of Dr Diane Hanger and Dr 
Wendy Noble.  Post-mortem frontal cortex tissue from clinically and histologically 
confirmed human AD patients and age-matched control subjects was provided by the 
MRC Neurodegenerative Diseases Brain Bank at the Institute of Psychiatry, King‟s 
College, London.  Clinical information on the subjects whose samples were used in 
this study is shown in Tables 6.1 and 6.2.  Written consent was obtained from each 
subject and/or their family members for the purpose of this study and the study was 
conducted according to the principles expressed by the Declaration of Helsinki. 
 
The analysis of human samples is a unique opportunity to investigate the expression 
and/or activity of proteins of interest in disease and control subjects.  Although 
Drosophila is an excellent model for basic protein interactions, once proteins of 
interest have been identified, it is useful to investigate their expression in the tissue 
and organism affected.  The aim of this study was to elucidate if expression of BRSK 
and/or either of its upstream regulators, LKB1 and CaMKK, was altered in AD 
samples as this may provide a mechanistic link between the work presented in the 
previous chapters and the molecular pathology of AD.   
   
Samples were subjected to analysis by Western Blot as described in the Methods 
section.  Membranes were probed with various antibodies and the signals were 
quantified using Odyssey software (version 3).  The strength of signal with each 
probe was compared between AD and control and analysed for statistical 
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significance using the student‟s t-test (for normally distributed data) or the Mann 
Whitney test (for data with a non-normal distribution).  Also tested was the effect of 
post-mortem delay (PMD) and age using Spearman (for non-normally distributed 
data) and Pearson tests (for normally distributed data), and sex using t-tests.  
However, most of the tests for PMD, age and sex were not statistically significant for 
the antibodies used. Therefore for clarity, statistically significant correlations are 
shown in the relevant section, and correlations that are not significant are 
summarised in tabular form at the end of the results section (Table 6.3).  In addition, 
analysis is performed on AD samples grouped according to increasing Braak stage 
(where that data was available).  None of this data was significant (tested by one way 
anova) and so it was interpreted as „positive trend‟, „negative trend‟ or „no trend‟.  
Data which showed a trend is presented in the relevant section and data which didn‟t 
show a trend is summarised in Table 6.3 at the end of the results section. 
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6.2 Results 
 
 
Tables 6.1 and 6.2 show the clinical information supplied by the MRC 
Neurodegenerative Diseases Brain Bank on the control and AD subjects whose 
samples were used in these experiments respectively, sorted according to sex and age.  
AD cases were histologically confirmed using the original method described by 
Braak and Braak (1997), and more recently a Brain Net Europe Consortium Scheme 
method which also takes into account the presence of amyloid plaque pathology 
(Braak and Braak, 1997; Alafuzoff et al., 2008).  All AD cases were Braak stage IV-
VI.  In the control subjects, cause of death is listed instead of pathological diagnosis.  
Control subjects had a wide variety of causes of death, however the brain bank 
attempted to avoid any subjects who had suffered a traumatic brain injury as this can 
result in the formation of AD pathology in both the acute and chronic phases (Smith 
et al., 2003; Ikonomovic et al., 2004).  In fact, it is well documented that there is a 
link between a history of traumatic brain injury and subsequent development of AD 
(Lye and Shores, 2000; Plassman et al., 2000). 
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Autopsy 
Number 
Sex Age Post 
Mortem 
Delay 
(hours) 
Cause of Death 
A042/01 F 52 44 Carcinoma of the lung 
A155/95 F 63 34 Myocardial infarction 
A170/00 F 68 9 Systemic lupus 
erythematosus 
A278/96 F 77 29 Pulmonary embolism 
A239/95 F 79 38 Chronic obstructive 
airway disease 
A094/95 F 80 31 Left ventricular 
failure/Bronchopneumonia 
A047/02 F 87 22 Carcinoma of the breast 
A135/95 M 65 24 Coronary artery occlusion 
A077/00 M 68 53 Ischemic heart disease 
A223/96 M 80 11 Carcinoma of the prostate 
A346/95 M 85 16 Ruptured aortic aneurism 
A401/97 M 85 42 Gastrointestinal 
haemorrhage 
A133/95 M 85 48 Left ventricular failure 
A134/00 M 86 6 Myocardial infarction 
A149/01 M 95 44 Gastrointestinal bleed 
 
Table 6.1: Clinical information on control subjects sorted according to sex and age 
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Autopsy 
Number 
Sex Age Post Mortem 
Delay (hours) 
Pathological Diagnosis 
A188/00 F 64 10 Alzheimer‟s disease: Definite 
A010/06 F 67 56 Alzheimer's disease:  Braak VI 
A074/06 F 69 25 Alzheimer's disease:  Braak VI with 
diffuse neocortical Lewy body disease 
A157/00 F 75 9 Alzheimer‟s disease: Definite 
A232/00 F 79 8 Alzheimer‟s disease: Definite 
A221/03 F 81 37 Alzheimer‟s disease: probable Braak V 
A169/05 F 82 43 Alzheimer's disease :  Braak V/VI 
A309/07 F 83 7 Alzheimer's disease:  Braak V with 
amyloid angiopathy type II and mild 
neocortical Lewy body disease 
A210/05 F 84 <24 Alzheimer's disease:  Braak V 
A168/05 F 84 36 Alzheimer's disease:  Braak V/VI 
A203/04 F 84 37 Alzheimer's disease:  Braak V with mild 
amyloid angiopathy 
A074/05 F 89 29 Alzheimer's disease:  Braak V/VI 
A240/06 F 97 12 Alzheimer's disease:  Braak V 
A186/04 M 71 5 Alzheimer's disease:  Braak V/VI 
A176/01 M 71 41 Alzheimer‟s disease: Definite 
A249/07 M 74 69 Alzheimer's disease: Braak VI with 
amyloid angiopathy 
A206/07 M 81 47 Alzheimer‟s pathology: Braak IV 
A122/04 M 86 26 Alzheimer's disease:  Braak V with 
moderate amyloid angiopathy 
 
Table 6.2: Clinical information on Alzheimer’s disease patients sorted according to 
sex and age 
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6.2.1 Tau 
 
 
Human tau produces a number of bands on western blots due in part to the slight 
differences in molecular weight of the various isoforms, combined with the range of 
post-translational modifications of this protein; for the purpose of this study all bands 
in the molecular weight range of 45-65kDa were quantified (see Figure 6.1 for an 
example).  The boxes for the quantification were of uniform size, and an attempt was 
made to ensure that they were aligned.  However, in the case of the outer lanes of 
some gels, it was necessary to move the box (e.g. the far right hand lane in Figure 
6.1); due to characteristics of the gel, bands in outer lanes may migrate slightly 
differently, this phenomenon is commonly known as smiling.   
 
Figure 6.2 A(i) shows that there was no difference in the intensity of total tau signal 
(normalised to neuron specific enolase (NSE) to control for the loss of neurons in 
AD) between AD and control samples (n=12, 4.67±1.08 for control and n=18, 
4.87±1.22 for AD, p=0.45 unpaired t-test).   
 
Consistent with the literature, there was a significant increase in the intensity of the 
signal for tau phosphorylated at S262
 
(normalised to total tau), as shown in Figure 
6.2 B(i) (n=12, 0.0085±0.0016 for control and n=18, 0.035±0.011 for AD, p=0.031 
unpaired t-test), a residue which is known to be important for the microtubule 
binding properties of tau (Hanger et al., 2007; Fischer et al., 2009).  There was no 
correlation between the pS262 signal and PMD, age or sex (Table 6.3).  
 
Figure 6.3 A(i) shows a significantly higher intensity for the PHF-1  (pS396/pS404) 
antibody (normalised to total tau) in AD subjects when compared to controls (n=12, 
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0.29±0.23 for control and n=18, 4.17±0.96 for AD, p=0.0016 unpaired t-test).  The 
PHF-1 antibody recognises two phosphorylated serines which are found in paired 
helical filament tau (pS396/pS404) and so is generally accepted to be a marker for 
tau tangles (Otvos et al., 1994).  The linear regression in Figure 6.3 B(i) shows a 
positive correlation between the intensity of PHF1 and pS262 signals in the AD 
subjects and a Pearson r test for correlation shows that this is significant (n=18, 
p=0.0012). 
 
Recently a move has been made by the MRC Neurodegenerative Diseases Brain 
Bank during post-mortem examinations to incorporate assessment of immuno-
histochemical staining of brain sections with the AT8 antibody.  AT8 is a phospho-
specific antibody for tau which recognises pS202/pT205 and it has been suggested 
that Braak staging of AD brains according to AT8 staining (with more AT8 immuno-
reactivity giving a higher Braak stage) is more accurate and reproducible than the 
traditional Gallyas staining (Alafuzoff et al., 2008).   
 
Figure 6.4 shows graphs grouping the pS262 and PHF1 signals according to the 
Braak stage of the patients, where that information was available.  Despite there 
being a visible trend for increased pS62 and PHF1 according to Braak stage, this was 
not significant for either antibody (pS262: n=6, 0.012±0.0074 for stage V, n=4, 
0.038±0.031 for stage V/VI and n=3, 0.048±0.027 for stage VI, p=0.43, one way 
anova PHF1: n=6, 1.65±1.30 for stage V, n=4, 4.48±1.82 for stage V/VI and n=3, 
6.49±3.20, for stage VI, p=0.23, one way anova).  Data for Braak stage IV was 
excluded from the statistical analysis due to this group only having one data point. 
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Figure 6.1: An example of quantification for tau western blots.   
For tau western blots (total, pS262 and PHF1 antibodies), bands in the molecular 
weight range of 45-65 kDa were quantified in order to ensure quantification of all 
tau species.  Each box was the same size and an attempt was made to keep the boxes 
aligned - unless there were lanes on the edges of the gel in which the bands were not 
straight (e.g. the far right hand lane). 
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Figure 6.2: Total tau and pS262 tau in Alzheimer brain and aged-matched control 
brain.   
A(i): There is no difference in the level of total tau found in Alzheimer brain (n=18, 
4.87±1.22) when compared to age-matched control brain (n=12, 4.67±1.08), p=0.45 
unpaired t-test.  B (i): Tau phosphorylated at S262 is significantly elevated in 
Alzheimer brain (n=18, 0.035±0.011) when compared to age-matched control brain 
(n=12, 0.0085±0.0016), p=0.0315 unpaired t-test.  A (ii) and B (ii): Representative 
western blots for total tau, NSE and pS262 antibodies. 
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Figure 6.3: PHF1 tau and correlation between PHF1 and pS262 tau in Alzheimer 
patients and aged-matched controls.   
A (i): Tau phosphorylated at residues recognised by the PHF1 antibody 
(pS396/pS404) is significantly elevated in Alzheimer brain (n=18, 4.17±0.96) when 
compared to aged-matched control brain (n=12, 0.29±0.23), p=0.0016 unpaired t-
test.  B (i): There is a significant correlation between the amount of tau 
phosphorylated at the PHF1 residues and at S262 in Alzheimer brain, p=0.0012 
Pearson r test of correlation.  A (ii) and B (ii): Representative western blots for 
PHF1, total tau and pS262 antibodies. 
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Figure 6.4: PHF1 and pS262 antibody signals grouped according to Braak stage. 
Data for stage IV was discounted in the statistical analysis due to only one data 
point. (i): There is a trend for increased pS262 signal with increasing Braak stage 
but this was not significant (n=6, 0.012±0.0074 for stage V, n=4, 0.038±0.031 for 
stage V/VI and n=3, 0.048±0.027 for stage VI, p=0.43, one way anova).  (ii): There 
is a trend for increased PHF1 signal with increasing Braak stage but this was not 
significant (n=6, 1.65±1.30 for stage V, n=4, 4.48±1.82 for stage V/VI and n=3, 
6.49±3.20, for stage VI, p=0.23, one way anova).  
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6.2.2 LKB1 
 
 
LKB1 is the master regulator of 14 members of the AMPK-related family of kinases, 
including BRSKs (Lizcano et al., 2004).  As seen in figure 6.5, there was no 
significant difference in the intensity of the signal for total LKB1 (normalised to 
NSE) in the AD samples when compared to the control samples (n=10, 0.08±0.008 
for control and n=17, 0.11±0.01 for AD, p=0.12 unpaired t-test).   
 
LKB1 requires phosphorylation at threonine 189 (T189) in order to become active 
and phosphorylation at this residue is thought to occur through an auto-catalytic 
property of LKB1 itself.  Looking at the phosphorylated (and thus activated) kinase 
to total kinase ratio gives an indication of the portion of total kinase which is 
activated at a point in time; the pool of total kinase may not be altered but the amount 
of that pool which is in the activated state might be.  Figure 6.6 shows that there was 
no significant difference in the ratio of pT189 LKB1 to total LKB1 in AD samples 
when compared to control samples (n=10, 0.12±0.02 for control and n=17, 0.26±0.11 
for AD, p=0.29 Mann Whitney test).   
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Figure 6.5: Total LKB1 in Alzheimer patients and aged-matched controls.   
(i): There is no difference in the intensity of total LKB1 in Alzheimer brain (n=17, 
0.11±0.01) when compared to age-matched control brain (n=10, 0.08±0.008) 
p=0.12 unpaired t-test.  (ii): Representative western blots for total LKB1 and NSE 
antibodies. 
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Figure 6.6: Ratio of phosphorylated (T189) LKB1 to total LKB1 in Alzheimer 
patients and aged-matched controls.   
(i): Comparison of the ratio of pLKB1 (T189) to total LKB1 in Alzheimer brain 
(n=17, 0.26±0.11) and age-matched control brain (n=10, 0.12±0.02) p=0.29 Mann 
Whitney test.  (ii): Representative western blots for pLKB1 (T189), total LKB1 and 
NSE antibodies. 
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6.2.3 CaMKK 
 
 
CaMKKα is a second important regulator of BRSKs (Fujimoto et al., 2008).  As 
shown in figure 6.7, there was no significant difference in the expression of CaMKK 
in the AD samples when compared to the control samples (using a pan-CaMKK 
antibody which recognises both the α and β isoforms of CaMKK) (n=11, 1.74±0.22 
for control and n=18, 1.58±0.15 for AD, p=0.27 unpaired t-test).  Unfortunately, it 
was not possible to look at the relative activity of CaMKK as there are currently no 
phospho-specific antibodies available to either isoform of CaMKK.    
 
There was an age-related increase in the expression of the CaMKK in the AD 
samples (figure 6.8), but this was not present in the control samples (n=11, p=0.8027 
for controls and n=18, p=0.02 for AD, Pearson r test).   
 
However, in order to make a fair comparison between the control and AD data sets, 
the data should be compared over the same age range.  This necessitated the removal 
of one data point from the AD graph; this patient died at the age of 97 and there were 
no samples from subjects who had an age over 90 in the control data.  Removal of 
this data point from the AD samples rendered the correlation between age of death 
and CaMKK expression in the AD samples insignificant (n=17, p=0.21 Pearson r 
test).  Removal of this sample from the initial analysis of control and AD groups had 
no effect on the results; there was no significant difference in the expression of 
CaMKK between the two groups (n=11, 1.74±0.22 for control and n=17, 1.49±0.12 
for AD, p=0.14 unpaired t-test).  
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Figure 6.7: Total CaMKK in Alzheimer patients and aged-matched controls.   
(i): There is no difference in total CaMKK in Alzheimer brain (n=18, 1.58±0.15) 
when compared to age-matched control brain (n=11, 1.74±0.22) p=0.27 unpaired t-
test.  (ii): Representative western blots for total CaMKK and NSE antibodies. 
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Figure 6.8: Total CaMKK expression and age of Alzheimer patients and aged-
matched controls.   
(i): There is no correlation between total CaMKK and age in control brain (n=11, 
p=0.8027 Pearson r test). (ii): There is a significant correlation between total 
CaMKK and age in AD brain (n=18, p=0.02 Pearson r test). (iii): Removal of the 97 
year old patient also removes any significant correlation (n=17, p=0.21 Pearson r 
test).  
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6.2.4 BRSK2 
 
 
Figure 6.9 shows that there was no difference in the expression of BRSK2 as 
measured by a C-terminal antibody (normalised to NSE) in AD samples when 
compared to control samples (n=11, 0.37±0.068 for control and n=18, 0.38±0.059 for 
AD, p=0.42 unpaired t-test).  It was not possible to measure phosphorylated (and 
thus activated) BRSK in each group, since I was unable to detect BRSK 
phosphorylation in the brain lysates by Western blot.   
 
However, when BRSK was visualised with the antibody raised to the C-terminus of 
BRSK, a prominent low molecular weight multi-band species running at 
approximately 44kDa was detected in addition to the full length BRSK (88kDa), 
(figure 6.10).  The novel complex potentially represents fragments of BRSK and is 
highlighted in the green box (fragment 1) and red box (fragment 2).  There has been 
one previous report of such low molecular weight BRSK species on immunoblots of 
rat brain probed with affinity purified anti-BRSK2 antibodies isolated from the 
serum of a patient with limbic encephalitis and small-cell lung cancer (Sabater et al., 
2005).   
 
Quantification of individual species (figure 6.11) revealed that fragment 1 is 
significantly more represented in the AD patient group compared to controls (n=11, 
0.02±0.0072 for controls and n=18, 0.16±0.055 for AD, p=0.0278 unpaired t-test).  
There was no correlation between the expression of fragment 1 and PMD, age or sex 
(Table 6.3).  However, although fragment 1 is significantly elevated in the AD group 
compared to the control group, it would appear that it is only elevated in a subset of 6 
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patients (1/3
rd
) from the 18 AD cases.  Further analysis of these six samples showed 
no correlation between PMD, age or sex.   
 
Figure 6.12 shows that there was no significant difference in the intensity of 
fragment 2 in AD samples when compared to controls (n=11, 0.57±0.17 for control 
and n=18, 3.66±2.61 for AD, p=0.33 Mann Whitney test).  
 
There was no correlation between full length BRSK and fragment 1 or fragment 2 in 
either of the groups, neither was there any correlation between fragment 1 and 
fragment 2 (Table 6.4). 
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Figure 6.9: Total BRSK2 (C-terminal) in Alzheimer patients and aged-matched 
controls.   
(i): There was no difference in the level of total BRSK2 in Alzheimer brain (n=18, 
0.38±0.059) when compared to age-matched control brain (n=11, 0.37±0.068) 
p=0.42 unpaired t-test.  (ii): Representative western blots for total BRSK2 (C-
terminal) and NSE antibodies. 
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Figure 6.10: Low molecular weight BRSK2 (C-terminal) fragments.   
BRSK2 protein usually runs at approximately 88kD (purple box) on a western blot.  
Using a BRSK2 C-terminal antibody there are also prominent low molecular weight 
species at approximately 44kDa, termed fragment 1 (green box) and fragment 2 (red 
box) in future analyses. 
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Figure 6.11: BRSK2 (C-terminal) fragment 1 in Alzheimer patients and aged-
matched controls.   
(i): BRSK2 C-terminal fragment 1 is significantly elevated in Alzheimer brain (n=18, 
0.16±0.055) when compared to age-matched control brain (n=11, 0.02±0.0072), 
p=0.0278 unpaired students t-test.  (ii): Representative western blots for BRSK2 C-
terminal and NSE antibodies. 
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Figure 6.12: BRSK2 (C-terminal) fragment 2 in Alzheimer patients and aged-
matched controls.   
(i): There is no difference in the level of BRSK2 C-terminal fragment 2 in Alzheimer 
brain (n=18, 3.66±2.61) when compared to age-matched control brain (n=11, 
0.57±0.17) p=0.33 Mann Whitney test.  (ii): Representative western blots for BRSK2 
C-terminal and NSE. 
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6.2.4.1 Calpain Assay 
 
Calpain is a calcium dependent cysteine protease which has been shown to be 
activated upon treatment of neuronal cultures with fibrillary Aβ peptide (Lee et al., 
2000).  Due to its calcium dependent nature, I was interested in whether calpain may 
be the protease responsible for the BRSK fragments seen in the AD samples. 
 
In order to address this, I performed a calpain cleavage assay (adapted from Patze 
and Tsai, 2002).  Figure 6.13 shows natural degradation of recombinant His-tagged 
BRSK2 protein which had been incubated in a 37°C water bath for a number of 
hours, as detected with the C-terminal BRSK2 antibody.  Although BRSK2 was 
somewhat degraded during the longer incubation times, the most prominent species 
was still full-length BRSK2 (88kDa) and there were no specific degradation products 
visible on the gel. 
 
Figure 6.14 shows a representative western blot (using the BRSK2 C-terminal 
antibody) of the calpain cleavage assay which was conducted in triplicate.  
Degradation of BRSK2 by calpain produced a band running at approximately 35kDa, 
which was not present in the lane with no calpain (visible in the lanes where the 
calpain inhibitor was used).  Although this band is of a lower molecular weight than 
those seen on the western blots from post-mortem brain, it cannot be ruled out that if 
this assay were to be performed in a cellular system, post-translational modifications 
of BRSK may cause the fragment to run at a higher molecular weight. 
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Figure 6.13:  Western blot of recombinant His-BRSK2 protein using the C-
terminal antibody.   
BRSK2 protein is degraded during incubation at 37°C, however the most prominent 
species is still full-length BRSK (88kDa).  There don’t appear to be any specific 
degradation products. 
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Figure 6.14:  m-calpain degradation of BRSK2.   
Western blot showing the degradation of his-tagged BRSK2 by m-calpain at three 
different concentrations, in the presence or absence of 2µM of the m-calpain 
inhibitor, calpeptin.  Degradation of BRSK2 by calpain produced a band of 
approximately 35kDa which was most prominent in the lanes where the calpain 
inhibitor was used.   
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6.2.5 Results of statistical analyses for correlations of antibody signals with 
PMD, age and sex and trend analysis for AD samples in relation to 
Braak stage 
 
 
 
Table 6.3: Results for correlation of antibody signals in control and AD tissue with 
post mortem delay, age and sex and trend analysis for AD samples in relation to 
Braak stage.   
‘ns’ indicates non-significant data, ‘s’ indicates significant data (p-values are shown 
in brackets for significant data).  Correlations were tested using Pearson r or 
Spearman r tests of correlation for normally and non-normally distributed data 
respectively (PMD and age) and parametric or non-parametric t-tests for normally 
and non-normally distributed data respectively (sex).  None of the antibody signals 
correlated with PMD in either of the groups.  CaMKK showed a significant age-
dependent increase in signal in the AD samples.  Sex had no influence over the 
antibody signals in either of the groups.  It was not possible to analyse the effect of 
sex on the samples with high pS262 as the n number for the males was too low.  For 
the Braak stage data, none of the antibodies showed a significant correlation (one 
way anova) and so the data was interpreted as positive trend, negative trend or no 
trend.   
 
 
 
Antibody Correlation with Trend with 
Braak stage 
(AD samples) 
PMD Age Sex 
Control AD Control AD Control AD 
Total tau ns ns ns ns ns ns None 
pS262 ns ns ns ns ns ns Positive 
pS262 subset - ns - ns - n 
too 
low 
- 
PHF-1 ns ns ns ns ns ns Positive 
PHF1 subset - ns - ns - ns - 
Total LKB1 ns ns ns ns ns ns None 
pLKB1/Total 
LKB1 
ns ns ns ns ns ns None 
CaMKK ns ns ns s 
(0.02)  
ns ns None 
BRSK2 C ns ns ns ns ns ns None 
BRSK2 C  
Fragment 1 
ns ns ns ns ns ns None 
BRSK2 C 
Fragment  
1 subset 
- ns - ns - ns - 
BRSK2 C  
Fragment 2 
ns ns ns ns ns ns None 
246 
 
 
6.2.6 Results of statistical analyses for correlations of full length BRSK, 
fragment 1 and fragment 2. 
 
 
 
Correlation Result 
Full length BRSK to fragment 1 AD ns 
Full length BRSK to fragment 1 Control ns 
Full length BRSK to fragment 2 AD ns 
Full length BRSK to fragment 2 Control ns 
Fragment 1 to fragment 2 AD ns 
Fragment 1 to fragment 2 Control ns 
 
 
Table 6.4: Results for correlation of antibody full length BRSK, fragment 1 and 
fragment 2.   
Correlations of full length BRSK to fragment 1 or fragment 2 (AD and Control) were 
not significant.  Correlations of fragment 1 and fragment 2 (AD and Control) were 
not significant.  Correlations were tested using Pearson r or Spearman r tests of 
correlation for normally and non-normally distributed data respectively. 
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6.3 Discussion 
 
 
The work in this chapter examines the expression levels of protein kinases involved 
in the regulation of BRSKs in human post mortem brain tissue from AD and control 
subjects.  There was no difference in the level of total tau between the two groups, a 
finding which is consistent with current literature (Causevic et al., 2010).  However 
there was an increase in tau phosphorylation in the AD samples at the epitopes 
recognised by the pS262 and PHF1 antibodies.  The three sites recognised by these 
phospho-specific antibodies were known to be phosphorylated in AD brain tissue 
(Hanger et al., 2007), but this is the strongest evidence to date of a significant 
increase in phosphorylation of S262 of tau associated with AD.  In addition, I found 
a trend toward increased tau phosphorylation at these residues with increasing Braak 
stage but this was not significant.  Braak staging is based upon the tau tangle load in 
the brain and tangles are largely composed of hyperphosphorylated tau (Augustinack 
et al., 2002), hence it is plausible that phosphorylation of tau at S262 by BRSK 
contributes to this association but larger sample sizes will be required to confirm this 
hypothesis. 
 
I was unable to detect any differences in the expression, or phosphorylation of 
threonine 189, of LKB1 between the two groups, suggesting that LKB1 activity is 
not altered in AD. Neither was there any correlation with PMD, age or sex, or any 
trend associated with Braak stage.  Therefore the increase in phosphorylation of tau 
at S262 in these samples cannot be related to induction of BRSK by abnormally 
activated LKB1.  
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Similarly, there was no significant difference in the expression of CaMKK between 
the AD and control groups and no correlation of CaMKK expression with PMD, sex 
or Braak stage.  However, there was a positive correlation between CaMKK 
expression and age in the AD samples which was not present in the control samples, 
suggesting an age-dependent increase in CaMKK expression in AD subjects. Having 
said this, removal of one data point from the AD data set in order to conduct the 
control and AD correlations over the same age range rendered the AD data not 
significant (removal of the same point from the original analysis of CaMKK 
expression in AD and control subjects had no effect on the results).  This suggests 
that in order to perform such correlations, it would be better to have a larger data set 
where there is a greater spread of data points.  It also highlights the need to perform 
such comparisons fairly and over the same scale in order to draw conclusions that are 
not biased by the presence of one data point.    
  
The calciumopathy model for AD states that as humans age their capacity for 
buffering calcium becomes impaired, leading to a dysregulation of calcium 
homeostasis which if sustained, may provide a trigger for age-associated changes in 
the brain (Khachaturian, 1987; LaFerla, 2002).  Indeed, in 2001 it was shown that 
amyloid proteins cause a rise in intracellular calcium in neurons (Kawahara and 
Kuroda, 2000).  More recently, it has been shown that treatment of neurons with 
amyloid proteins led to missorting of tau from axons to dendrites, local elevation of 
intracellular calcium levels, tau phosphorylation at a number of residues and 
increased expression and/or activation of tau kinases such as PAR-1 and BRSK1 
(Zempel et al., 2010).  The calmodulin kinases (CaMKs) are a family of kinases that 
are regulated in a calcium and calmodulin dependent manner.  Many CaMKs are 
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capable of phosphorylating and activating calcium-responsive transcription factors 
such as CREB and ATF-1 and so it could be hypothesised that a rise in intracellular 
calcium (if sustained) may cause an up-regulation of the expression of many genes 
via the calcium dependency of such transcription factors, and their activation by 
CaMKs (Wayman et al., 2008).  Thus, increased activation of BRSK in response to 
increased calcium is likely to be mediated through CaMKKα which is a member of 
the CaMKs and has been shown to regulate BRSKs in vitro (Fujimoto et al., 2008).    
 
Unfortunately, the antibody that I had for CaMKK was pan-CaMKK and as such did 
not differentiate between the α isoform, which does regulate BRSKs, and the β 
isoform which does not (Bright et al., 2008; Fujimoto et al., 2008).  Possibly more 
importantly, I was unable to establish the activation status of the CaMKK as 
currently there are no phospho-CaMKK antibodies (to either isoform).  There are two 
ways of circumnavigating the lack of phospho-CaMKK antibodies; I could have 
investigated the downstream targets of CaMKKs, however, it would appear that none 
of the downstream targets of CaMKKs, such as CaMKI and CaMKIV, are targeted 
specifically by either isoform (Wayman et al., 2008).  Alternatively, I could have 
performed immunoprecipitation kinase assays for CaMKK activity using a synthetic 
peptide as a substrate for CaMKKs.  This was not pursued due to insufficient brain 
lysate material for such an approach.   
 
There was no significant increase in BRSK expression in the AD samples.  Neither 
was there any effect of PMD or sex on BRSK expression.  In addition there was no 
correlation with age and BRSK2 expression and neither was there any trend toward 
abnormal BRSK2 expression associated with Braak stage. 
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Of potential interest were prominent low molecular weight species visible on the 
Western blots for BRSK2.  One of the low molecular weight species (termed 
fragment 1), was significantly elevated in AD samples compared to control.  There 
was no correlation between fragment 1 and PMD, age or sex.  Neither was there any 
trend associated with Braak stage.  This fragment seemed to be highly represented in 
a subset of the patients (1/3
rd
 of the AD cases), but further analysis of these six 
samples showed that there was no correlation with PMD, age or sex.  It would have 
been interesting to see if there was a correlation with the age of onset of the disease 
(age of onset may give an indication as to the type of AD the patients had e.g. 
familial or sporadic; familial AD, which has a genetically inherited cause, usually 
has a lower age of onset) but unfortunately this clinical data was not held by the 
brain bank and so this comparison was not possible. 
 
It was tempting to hypothesise that the low molecular weight fragments were 
fragmented BRSK proteins, indeed similar low molecular weight fragments have 
been reported in immunoblots of rat brain probed with affinity purified anti-BRSK2 
antibodies isolated from the serum of a patient with limbic encephalitis and small-
cell lung cancer (Sabater et al., 2005).   However, it is possible that the fragments 
were due to non-specific binding of the antibodies.  Non-specific binding of 
antibodies to proteins (which are not the targeted antigen) often occurs, especially 
when using polyclonal antibodies.  A relatively simple experiment which would 
address this would be to perform a peptide blocking experiment.  Briefly, the BRSK 
antibody would be neutralized with the immunizing peptide (the peptide which 
corresponds to the epitope that the antibody recognises).  The blocked antibody 
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would then no longer be available to bind to the protein immobilised on the 
membrane and by comparing the results obtained from blocked and non-blocked 
antibody, the portion of staining which was specific could be determined as this 
would be absent from the membrane incubated with the blocked antibody. 
 
Before performing any further studies on this fragment it would be important to 
establish exactly what proteins were present in the 44kDa region and which of these 
were over-expressed in the 6 AD patients. Proteins present in a BRSK 
immunoprecipitation from one of the patient samples could be identified by Mass 
fingerprinting after separation by SDS-PAGE. This would give a clear indication if 
BRSK was truly the major component of fragment 1 or fragment 2, and indicate the 
likely region of cleavage. Alternatively a novel potential marker of AD may be 
identified.  
 
Assuming that the fragments were BRSK proteins, I attempted to generate the 
fragments from recombinant BRSK.  Calpain was an interesting possible protease 
due to its calcium-dependent nature and the fact that it is activated in neurons treated 
with fibrillar Aβ peptide (Lee et al., 2000).  An in vitro calpain cleavage assay 
(adapted from Lee et al., 2000) showed that calpain degraded BRSK protein with the 
appearance of a band of approximately 35kDa.  However, it was not possible to 
identify the degradation products under the conditions used in my assay.  Further 
work on this was not possible due to time constraints, but if it were to be re-visited it 
may be more sensible to take a bioinformatics approach, possibly by scanning the 
BRSK sequence for known protease motifs and then using in vitro cleavage assays to 
further assess any candidate proteases.  It would also be worth examining whether 
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this fragment is generated in cells exposed to amyloid or calcium, and if it is found in 
any models of AD or tauopathy where pS262 of tau is increased as post-translational 
modifications of BRSK in a cellular system may well cause the fragment to run at a 
higher molecular weight. 
 
As with CaMKK, it was not possible to investigate the phosphorylated BRSK by 
western blot.  Unfortunately there was only one phospho-BRSK antibody available 
and I was unable to observe a signal using this antibody.  It was not clear if this was 
because there was little or no phospho-BRSK signal in the samples, or because the 
antibody wasn‟t good enough.  It is likely to be the latter situation as I was also 
unable to detect a signal when using this antibody on lysates from Drosophila 
expressing human BRSK2.  One way to address the lack of sensitive phospho-
specific antibodies for many proteins would be to utilise a technology called 
PhosTag™ (Kinoshita et al., 2006).  This is based on the retardation of 
phosphorylated proteins in SDS-PAGE gels using alkoxide-bridged dinuclear metal 
complexes as phosphate binding molecules.  Incorporation of Mn
2+
 phos-tags into 
acrylamide gels enables the preferential binding of phosphate molecules bound to 
Serine, Threonine or Tyrosine residues, causing the phosphorylated proteins to 
migrate slower than the corresponding non-phosphorylated proteins.  This allows the 
detection of phosphorylated proteins using a total antibody for the protein of interest.  
However, the weakness of this technology is that it would only show if a particular 
protein was phosphorylated at a Serine, Threonine or Tyrosine residue; it would not 
indicate phosphorylation of a specific residue in the protein.  
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During the analysis, I noticed that on many of the blots there were points which were 
obviously above the mean (for an example see figure 6.5).  Further analysis of such 
points showed no particular pattern between most antibody signals, for example the 6 
samples with the highest pS262 signal were not the same samples that had the 
highest BRSK2 C-terminal fragment 1 signal and there was no relationship between 
the expression of full length BRSK and either of the fragments.  The only pattern I 
was able to observe was that 5 of the samples that had high pS262 signal also had 
high PHF1 signal.  It was important to investigate the pattern of the samples with 
obviously high signals as this could potentially have revealed subsets of patients with 
a specific pattern of pathological markers.  Unfortunately, it would seem that the data 
sets I used were too small for this kind of analysis; samples which seemed to have 
unusually high signal in this study may not be so striking in a larger data-set due to a 
greater spread of data points or alternatively a larger data set may reveal subsets of 
patients with varying expression levels (as seen with pS262, PHF1 and BRSK2 C-
terminal fragment 1).   
 
Currently, there are no other studies investigating the expression of the kinases 
upstream of tau phosphorylation at S262, as described here.  Unfortunately, lack of 
response to the phospho-specific antibody for BRSK available to me and a lack of 
phospho-specific antibodies for CaMKK prevented the assessment of activity of 
BRSK or CaMKK.  However, there have been many other studies that have 
successfully identified altered signalling pathways linked to AD (for example MAP 
kinases (in particular p38 and SAPK), calpain (a calcium dependent protease), 
cAMP-dependent protein kinase, CRMP2 and GSK-3β) using the same approach that 
was utilised in this study (Swatton et al., 2004; Liu et al., 2005b; Cole et al., 2007; 
254 
 
Liang et al., 2007; Causevic et al., 2010).  Further challenges to studying the 
expression and activation level of proteins in post-mortem tissue, beyond those of 
obtaining reagents, are those posed by the nature of the tissue.  The variability seen 
in post-mortem tissue may arise from several factors; PMD, storage temperature 
(before post-mortem and the associated sampling) and tissue fixation methods have 
all been documented to have an effect on the preservation of proteins, DNA and 
RNA in post-mortem samples (Ferrer et al., 2008).  In terms of proteins, PMD and 
temperature of storage are the most important factors and it has been shown that 
kinases are particularly sensitive to such variables (Ferrer et al., 2008).  Having said 
this, I found no correlation between PMD and the expression level of any of the 
kinases in this study, suggesting that for the samples I used, PMD was not a 
contributing factor to the lack of relationship to AD reported.  I did not have any 
information regarding the storage temperature before post-mortem and so cannot 
draw any conclusions with regards to this factor.      
 
In conclusion, I have been able to show that there is no difference in the expression 
of total LKB1, pT189 LKB1, CaMKK and BRSK2 C-terminal between AD and 
control groups.  There was an age-dependent increase in CaMKK expression in the 
AD samples but I have been unable to elucidate if this was the α isoform or the β 
isoform.  There was no age dependent increase in the signal from the BRSK2 
antibody neither was there any trend between the antibody signal and Braak stage.  
There was a significant increase in a low molecular weight species detected by the 
BRSK2 antibody in the AD group, suggesting that BRSK2 may be cleaved in AD 
brain.  However, it remains to be elucidated if these fragments are actually BRSK 
proteins and if so, what effect cleavage may have.   
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The data I have presented in the previous chapters show that human BRSKs are 
capable of interacting with and phosphorylating human tau in a Drosophila 
expression model.  I show that these interactions are regulated by at least two 
endogenous upstream kinases, LKB1 and CG17698 and due to the calcium sensitive 
nature of CaMKKα (the human homologue of CG17698) and the data showing that 
over-expression of a calcium channel subunit (cac1) enhances the tau-BRSK eye 
phenotype; I suggest that BRSKs may prove to be important and previously largely 
unstudied tau kinases.  It was important for my thesis to attempt to link the data 
attained in the Drosophila model with the situation in human disease.  The data 
presented in this chapter is as comprehensive as possible - taking into account the 
limited reagents available and the time constraints.  Whilst I was able to show there 
was no difference in the activation of LKB1 between control and AD samples, I was 
unable to reach a solid conclusion for BRSK and CaMKK in terms of activation, 
although their expression was not altered.  As such I must conclude that it is still 
possible that the activity of these kinases is elevated in AD.  It should also be taken 
into consideration that it is feasible that the pathological profile of these kinases may 
be different according to disease, for example, kinases may play a more important 
role in the pathogenesis of the tauopathies as these are a spectrum of diseases in 
which it would appear that tau is the main pathological species (as opposed to AD 
where amyloid-beta also plays an important role) and so it could be expected that 
kinases (and/or phosphatases) may play a more pivotal role in the tauopathies.      
    
 
 
256 
 
7| Concluding remarks 
and perspectives for 
future work 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
257 
 
At the beginning of this project, little was known about BRSKs and their importance 
to tau phosphorylation in AD.  This study provides the first in vivo evidence and the 
most convincing data to date that human BRSKs are able to phosphorylate human tau, 
exacerbating a human tau-induced degenerative eye phenotype.  Importantly, and in 
contrast to previous studies in Drosophila, here I have utilised the human BRSKs in 
concert with human tau in my experiments.  It is my opinion that this approach is 
more disease relevant, in comparison with studies where human tau and endogenous 
Drosophila kinases were used.  However, there is currently no information on the 
physiological role of BRSK-induced phosphorylation of tau.  It would be useful to 
expand this study in an attempt to determine this, and also to address how the 
phosphorylation of tau by BRSK fits in with phosphorylation of tau by other kinases.  
 
I have shown, by use of RNAi lines, that human BRSK2 can be regulated by 
Drosophila LKB1 and CG17698.  However, data obtained using B-NP, which carries 
a T174A mutation to prevent activation by phosphorylation at T174 by an upstream 
kinase, indicates that there may be other regulatory sites on BRSK that act 
independently of the T-loop T174 residue targeted by LKB1 and CG17698, or that 
BRSKs possess weak activity in the absence of T-loop T174 phosphorylation.  It has 
been suggested that BRSKs are also regulated by PKA via phosphorylation of 
threonine 260 (Guo et al., 2006).  However this is contradicted by Bright et al. (2008) 
who indicated that PKA was unable to activate BRSKs (Bright et al., 2008). 
Drosophila provides a powerful unbiased model to address this discrepancy, and to 
identify other regulators of BRSKs.  In order to achieve these objectives, a deficiency 
screen could be performed on B-WT and B-NP, to rapidly isolate enhancers or 
suppressors of the tau-BRSK eye phenotype.  Deficiency stocks have been produced 
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for all four Drosophila chromosomes and are freely available from the stock centres 
(Thibault et al., 2004; Ryder et al., 2007).  Deficiency screens have long been used to 
successfully identify components of signalling pathways and the eye is by far the 
most popular tissue in which to conduct such screens because it is not essential for 
viability or fertility and is easy to score (St Johnston, 2002).  Each deficiency is fully 
mapped to the genome and as such, the genes contained within a deletion can be 
identified.  Using a deficiency screen, in addition to resolving whether PKA is 
capable of regulating BRSK, new positive and negative regulators of human BRSKs 
could be identified.  Importantly, LKB1 and CG17698 could be used as positive 
controls in a screen as I have already shown them to be regulators of human BRSK2. 
 
An important observation from my thesis is the apparent calcium-dependent 
regulation of tau through BRSKs.  Here I provide the first direct in vivo evidence 
between an increase in intracellular calcium, a tau kinase and increased tau toxicity; 
over-expression of cac1, a calcium channel α subunit (in order to increase 
intracellular calcium levels from extracellular sources), with tau and B-WT 
dramatically exacerbated the tau-BRSK eye phenotype in a human BRSK2-
dependent manner.  Although there is much work to be done to characterise this 
calcium-dependent enhancement of tau toxicity by BRSKs, it is a process that is 
highly relevant for AD due to the link between AD and perturbed calcium 
homeostasis.  To date, the only other evidence directly linking calcium to tau 
phosphorylation is the calcium-dependence of another tau kinase, CaMKII, and the 
cleavage of p35 to p25 (which activates the tau kinase cdk5) by the calcium-activated 
protease calpain (Litersky et al., 1996; Lee et al., 2000).  It will now be important to 
demonstrate an increase in intracellular calcium levels and in tau phosphorylation at 
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S262 and BRSK2 phosphorylation at T174 upon over-expression of cac1 with tau 
and B-WT in the eye.  This would provide a biochemical link between the 
exacerbated eye phenotype and BRSK activation, leading to increased tau 
phosphorylation at a disease relevant site.  In addition, it will be important to 
elucidate whether the calcium-induced exacerbation of tau-BRSK eye phenotypes is 
dependent on CG17698, whether the S262A/S2A mutants are insensitive to cac1 
expression with B-WT and whether over-expression of cac1 has an effect when B-
NP or B-KD are substituted for B-WT.  These experiments would give an indication 
as to whether the exacerbated eye phenotype observed upon over-expression of cac1 
in the presence of tau and B-WT is truly mediated by BRSK, through CG17698, and 
whether S262 and/or S356 are the important residues for this interaction.  This seems 
most likely as the effect of cac1 on the eye phenotypes was only apparent in the 
presence of B-WT, but the precise details of the interaction require further evidence. 
 
To date, three members of the AMPK-related family of protein kinases have been 
demonstrated to be tau kinases; PAR-1, AMPK and BRSK2 (Drewes et al., 1997; 
Nishimura et al., 2004; Vingtdeux et al., 2010a; Thornton et al., 2011).  I have shown 
by phenotypic scoring that BRSK1 is able to enhance a tau-induced degenerative eye 
phenotype and so it is likely that BRSK1 is also able to phosphorylate tau.  Indeed, in 
the mouse, knockout of each BRSK individually has no effect whereas the double 
knockout mice have a very severe phenotype, demonstrating redundancy between the 
two mammalian genes (Kishi et al., 2005).  This raises the question of whether any 
other members of the AMPK-related family of protein kinases are capable of 
phosphorylating tau.  In addition, there are four isoforms of PAR-1/MARK in 
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humans and two isoforms of AMPK; it would be useful to elucidate whether all of 
these isoforms also phosphorylate tau or whether it is an isoform-specific activity.  
  
Whilst BRSKs have undoubtedly been demonstrated to be essential during 
development, there is currently little data on their function in mature organisms.  I 
have shown by western blots on lysates from post-mortem human brain that BRSKs 
and their upstream regulators are expressed in aged humans (AD and control) and 
this suggests that their function extends beyond the vital developmental stages.  
Indeed it has been demonstrated that BRSKs are involved at the synapse in the 
release of neurotransmitters through the phosphorylation of the active zone protein 
RIM1 (Inoue et al., 2006).  However, it would be interesting to ascertain whether the 
continued expression of BRSKs beyond developmental stages is also linked to the 
phosphorylation of tau. 
 
I was able to conclude that the expression of BRSKs was unaltered between post-
mortem human brain samples from AD patients and control subjects.  However, it 
was unfortunate that due to insufficient reagents I was unable to investigate the 
activation of BRSKs in the samples.  Thus I was unable to draw any firm conclusions 
with regards to BRSK activity in AD.  With the advent of more sophisticated 
techniques for measuring phosphorylated proteins such as Mass Spectrometry or 
ELISAs, it may be possible to readdress this unresolved and clearly vital issue.  It 
may also be worthwhile extending the study to encompass some of the non-AD 
tauopathies as arguably the pathology in this collection of diseases appears to arise 
only as a result of tau tangles and as such, phosphorylation of tau may play a more 
pivotal role in the pathogenesis of the tauopathies as opposed to AD.  
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The use of Drosophila as a model in this study allowed me to take advantage of 
established genetic techniques, such as the production of recombinant chromosomes, 
in order to conduct complex experiments where multiple proteins were co-expressed. 
With the development of more sophisticated genetic tools (such as the recently 
developed gene-switch system or the temperature-sensitive inhibitor of GAL4, 
GAL80ts) for temporal control of gene expression, Drosophila is rapidly becoming a 
useful model organism for aging studies (Osterwalder et al., 2001; McGuire et al., 
2003; Nicholson et al., 2008; Sofola et al., 2010). This is an attractive 
benefit as over-expression of human BRSK (and down regulation of CG6114, the 
Drosophila homologue, via RNAi) in the CNS was lethal at the embryonic stage; 
these new techniques could be utilised for the study of human tau and BRSK 
expression in neuronal tissue and in aged animals.  Although a number of 
neurodegenerative diseases apart from AD such as ALS, Parkinson's and 
Huntington's have been modelled in Drosophila, new tools such as the gene-
switch system enable temporal and spatial control of gene expression, greatly 
enhancing the appeal of Drosophila as a model for AD and other neurodegenerative 
diseases (Marsh et al., 2003; Liu et al., 2008; Ratnaparkhi et al., 2008).   
 
Phosphorylation of tau is highly complex with currently 45 identified phosphorylated 
residues
3
 and little information on the importance of each to tau toxicity, not to 
mention the signalling pathways that control them.  Similar studies to those described 
in my thesis could be used to map the contribution of every tau phosphorylation site 
to neurotoxicity, as well as to establish the potential regulatory kinases and 
phosphatases.  This could help clarify the role that specific phosphorylation sites play 
                                                 
3
 http://cnr.iop.kcl.ac.uk/hangerlab/tautable 
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in tau pathology and identify targets for modulating tau phosphorylation at an early 
stage in vivo.  
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Label Description Full Genotype Source 
Canton S Wild type + ; + ; + Lab stock 
GMR::GAL4 
Driver of GAL4 
in eye 
photoreceptors 
w
[1118] 
; 
{w[
+
mc],UAS-
GMR::GAL4} ; + 
Lab stock 
0N4R tau 0N4R human tau 
w
[1118] 
; + ; 
{w[
+
mc],UAS-4R 
tau} 
Kind gift of Mel 
Feany 
0N3R tau 0N3R human tau 
w
[1118] 
; w[
+
mc],UAS-
3R tau}; + 
Kind gift of Mel 
Feany 
R406W tau 
0N4R R406W 
human tau 
w
[1118] 
; + ; 
{w[
+
mc],UAS-0N4R 
R406W} 
Kind gift of Bingwei 
Lu 
S2A tau 
0N4R R406W 
S2A human tau 
w
[1118] 
;  
{w[
+
mc],UAS-0N4R 
R406W S2A}; + 
Kind gift of Bingwei 
Lu 
S262A tau 
0N4R S262A 
human tau 
w
[1118] 
; +; 
{w[
+
mc],UAS-0N4R 
S262A} 
Kind gift of Koichi 
Iijima 
B2WT1 
Wild type (WT) 
human BRSK2 
w
[1118] 
; 
{w[
+
mc],UAS- 
B2WT1}/Cyo ; + 
This work 
B2WT2 
WT human 
BRSK2 
w
[1118] 
; 
{w[
+
mc],UAS- 
B2WT2}/CyO ; + 
This work 
B2WT3 
WT human 
BRSK2 
w
[1118] 
; + ; 
{w[
+
mc],UAS- 
B2WT3}/TM3 
This work 
B2WT4 
WT human 
BRSK2 
w
[1118] 
; + ; 
{w[
+
mc],UAS- 
B2WT4}/TM3 
This work 
B2WT5 
WT human 
BRSK2 
w
[1118] 
; + ; 
{w[
+
mc],UAS- 
B2WT5}/TM3 
This work 
B2NP1 
Non-
phosphorylatable 
(NP) human 
BRSK2 
w
[1118] 
; 
{w[
+
mc],UAS- 
B2NP1}/CyO ; + 
This work 
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Label Description Full Genotype Source 
B2NP2 
NP human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2NP2}/CyO ; + 
This work 
B2NP3 
NP human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2NP3}/TM3 
This work 
B2NP4 
NP human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2NP4}/TM3 
This work 
B2NP5 
NP human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2NP4}/TM3 
This work 
Stock died 
B2NP6 
NP human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2NP6}/TM3 
This work 
B2NP7 
NP human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2NP7}/CyO ; + 
This work 
Stock died 
B2NP8 
NP human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2NP8}/CyO ; + 
This work 
B2KD1 
Kinase dead 
(KD) human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2KD1}/CyO ; + 
This work 
B2KD2 
KD human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2KD2}/CyO ; + 
This work 
Stock died 
B2KD3 
KD human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2KD3}/CyO ; + 
This work 
B2KD4 
KD human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2KD4}/TM3 
This work 
B2KD5 
KD human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2KD5}/CyO ; + 
This work 
B2KD6 
KD human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2KD6}/CyO ; + 
This work 
Stock died 
B2KD7 
KD human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2KD7}/TM3 
This work 
B2KD8 
KD human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2KD8}/TM3 
This work 
Stock died 
B2KD9 
KD human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2KD9}/TM3 
This work 
B2KD10 
KD human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2KD10}/CyO ; + 
This work 
Stock died 
B2CA1 
Constitutively 
active (CA) 
human BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA1}/ CyO; + 
This work 
Stock died 
B2CA2 
CA human 
BRSK2 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B2CA2}/TM3 
This work 
Stock died 
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Label Description Full Genotype Source 
B2CA3 
CA human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA3}/ CyO; + 
This work 
Stock died 
B2CA4 
CA human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA4}/ CyO; + 
This work 
B2CA6 
CA human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA6}/ CyO; + 
This work 
Stock died 
B2CA7 
CA human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA7}/ CyO; + 
This work 
B2CA8 
CA human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA8}/ CyO; + 
This work 
B2CA9 
CA human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA9}/ CyO; + 
This work 
Stock died 
B2CA10 
CA human 
BRSK2 
w
[1118] 
; {w[
+
mc],UAS- 
B2CA10}/ CyO; + 
This work 
B1WT1 
WT human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1WT1}/CyO ; + 
This work 
Stock died 
B1WT2 
WT human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1WT2}/CyO ; + 
This work 
 
B1WT3 
WT human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1WT3}/CyO ; + 
This work 
 
B1WT4 
WT human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1WT4}/CyO ; + 
This work 
Stock died 
B1WT5 
WT human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1WT5}/CyO ; + 
This work 
 
B1WT6 
WT human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1WT6}/TM3 
This work 
 
B1WT7 
WT human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1WT7}/CyO ; + 
This work 
 
B1WT8 
WT human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1WT8}/TM3 
This work 
 
B1WT9 
WT human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1WT9}/TM3 
This work 
Stock died 
B1WT10 
WT human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1WT10}/CyO ; + 
This work 
 
B1KD1 
KD human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1KD1}/TM3 
This work 
Stock died 
B1KD2 
KD human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1KD2}/TM3 
This work 
Stock died 
B1KD3 
KD human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1KD3}/CyO ; + 
This work 
Stock died 
B1KD4 
KD human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1KD4}/CyO ; + 
This work 
Stock died 
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Label Description Full Genotype Source 
B1KD5 
KD human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1KD5}/TM3 
This work 
Stock died 
B1KD6 
KD human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1KD6}/CyO ; + 
This work 
B1NP1 
NP human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1NP1}/TM3 
This work 
Stock died 
B1NP2 
NP human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1NP2}/CyO ; + 
This work 
Stock died 
B1NP3 
NP human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1NP3}/TM3 
This work 
 
B1NP4 
NP human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1NP5}/TM3 
This work 
 
B1NP5 
NP human 
BRSK1 
w
[1118] 
; {w[
+
mc],UAS- 
B1NP6}/CyO ; + 
This work 
 
B1CA1 
CA human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1CA1}/TM3 
This work 
 
B1CA2 
CA human 
BRSK1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
B1CA2}/TM3 
This work 
 
hCaMKKα1 
human 
hCaMKKα 
isoform 
w
[1118] 
; {w[
+
mc],UAS- 
hCaMKKα1}/CyO ; + 
This work 
hCaMKKα2 
human 
hCaMKKα 
isoform 
w
[1118] 
; + ; {w[
+
mc],UAS- 
hCaMKKα2}/TM3 
This work 
hCaMKKα3 
human 
hCaMKKα 
isoform 
w
[1118] 
; {w[
+
mc],UAS- 
hCaMKKα3}/CyO ; + 
This work 
hCaMKKα4 
human 
hCaMKKα 
isoform 
w
[1118] 
; + ; {w[
+
mc],UAS- 
hCaMKKα4}/TM3 
This work 
hCaMKKα5 
human 
hCaMKKα 
isoform 
w
[1118] 
; {w[
+
mc],UAS- 
hCaMKKα5}/CyO ; + 
This work 
hCaMKKα6 
human 
hCaMKKα 
isoform 
w
[1118] 
; + ; {w[
+
mc],UAS- 
hCaMKKα6}/TM3 
This work 
hCaMKKα7 
human 
hCaMKKα 
isoform 
w
[1118] 
; + ; {w[
+
mc],UAS- 
hCaMKKα7}/TM3 
This work 
hCaMKKα8 
human 
hCaMKKα 
isoform 
w
[1118] 
; {w[
+
mc],UAS- 
hCaMKKα8}/CyO ; + 
This work 
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Label Description Full Genotype Source 
hCaMKKα9 
human hCaMKKα 
isoform 
w
[1118] 
; + ; {w[
+
mc],UAS- 
hCaMKKα9}/TM3 
This 
work 
GMR ; tau 
0N4R human tau 
driven by 
GMR::GAL4 
w
[1118] 
; {w[
+
mc],UAS-
GMR::GAL4}/CyO ; 
{w[
+
mc],UAS-4R tau}/TM6B 
This 
work 
GMR ; tau, 
B2WT5 
Recombinant 
0N4R human tau 
and B2WT5 driven 
by GMR::GAL4 
w
[1118] 
; {w[
+
mc],UAS-
GMR::GAL4}/CyO ; 
{w[
+
mc],UAS-
B2WT5},{w[
+
mc],UAS-4R 
tau}/TM6B 
This 
work 
CG17698 RNAi 
RNAi to CG17698 
(Drosophila 
homologue of 
CaMKK) 
w
[1118] 
; {w[
+
mc],UAS-
CG17698 RNAi} ; + 
VDRC 
LKB1 RNAi 
RNAi to 
Drosophila LKB1 
w
[1118] 
; {w[
+
mc],UAS-LKB1 
RNAi} ; {w[
+
mc],UAS-LKB1 
RNAi} 
Kind gift 
of 
Bingwei 
Lu 
PAR-1 RNAi 
RNAi to 
Drosophila PAR-1 
w
[1118] 
; +; {w[
+
mc],UAS- 
PAR-1 RNAi} 
VDRC 
CG6114 RNAi 
RNAi to CG6114 
(Drosophila 
homologue of 
BRSK) 
w
[1118] 
; {w[
+
mc],UAS-CG6114 
RNAi} ; + 
VDRC 
LKB1;LKB1,tau 
0N4R and LKB1 
RNAi recombinant 
w
[1118] 
; {w[
+
mc],UAS-LKB1 
RNAi}/CyO ; {w[
+
mc],UAS-
LKB1 RNAi}, {w[
+
mc],UAS-
4R tau}/TM6B 
This 
work 
UAS-CG6114-2 
CG6114 
(Drosophila 
homologue of 
BRSK) 
w
[1118] 
; + ; {w[
+
mc],UAS- 
CG6114-2}/TM3 
This 
work 
UAS-LKB1-2 human LKB1 
w
[1118] 
; + ; {w[
+
mc],UAS- 
LKB1-2}/TM3 
This 
work 
 
CG17698; 
B2WT5 
CG17698 RNAi 
and B2WT5 
w
[1118] 
; {w[
+
mc],UAS-CG6114 
RNAi}/+ ; {w[
+
mc],UAS-
B2WT5}/TM6B 
This 
work 
GMR, 
CG17698; 
hCaMKKα6 
CG17698 RNAi 
and hCaMKKα6 
driven by 
GMR::GAL4 
w
[1118] 
; {w[
+
mc],UAS-
GMR::GAL4}/{w[
+
mc],UAS-
CG6114 RNAi} ; 
{w[
+
mc],UAS- 
hCaMKKα6}/TM6B 
This 
work 
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Label Description Full Genotype Source 
CyO/If; Tau, 
B2WT5 
Recombinant 
0N4R human tau 
and B2WT5 
w
[1118] 
; If /CyO ; 
{w[
+
mc],UAS-
B2WT5},{w[
+
mc],UAS-4R 
tau}/TM6B 
This work 
sgg S9A Shaggy S9A 
w[1118] ; P{w[+mC]=UAS-
sgg.S9A}MB14  
Bloomington 
sgg; B2WT5 
Shaggy S9A and 
B2WT5 
w
[1118] 
; {w[
+
mc],UAS-sgg 
S9A}/CyO ; {w[
+
mc],UAS- 
B2WT5}/TM6B 
This work 
sgg; S262A 
Shaggy S9A and 
0N4R S262A tau 
w
[1118] 
; {w[
+
mc],UAS-sgg 
S9A}/CyO ; {w[
+
mc],UAS- 
0N4R S262A}/TM6B 
This work 
GMR, 
CG17698; 
B2WT5 
CG17698 RNAi 
and B2WT5 
driven by 
GMR::GAL4 
w
[1118] 
; {w[
+
mc],UAS-
GMR::GAL4}/{w[
+
mc],UAS-
CG6114 RNAi} ; 
{w[
+
mc],UAS- 
B2WT5}/TM6B 
This work 
GMR, 
CG17698; 
TM6B/MKRS 
CG17698 RNAi 
driven by 
GMR::GAL4 
w
[1118] 
; {w[
+
mc],UAS-
GMR::GAL4}/{w[
+
mc],UAS-
CG6114 RNAi} ; 
MKRS/TM6B 
This work 
CG17698; 
B2CA5 
CG17698 RNAi 
and B2CA5 
w
[1118] 
; {w[
+
mc],UAS-
CG6114 RNAi}/+ ; 
{w[
+
mc],UAS-
B2CA5}/TM6B 
This work 
GMR; 
B2CA5 
B2CA5 driven by 
GMR::GAL4 
w
[1118] 
; {w[
+
mc],UAS-
GMR::GAL4}/CyO; 
{w[
+
mc],UAS-
B2CA5}/TM6B 
This work 
DB Double Balancer w
[1118] 
; CyO/If; TM6B/MKRS Lab stock 
CyO/If; 
B2WT5, 
hCaMKKα 
Recombinant 
hCaMKKα and 
B2WT5 
w
[1118] 
; If /CyO ; 
{w[
+
mc],UAS-
B2WT5},{w[
+
mc],UAS-
hCaMKKα}/TM6B 
This work 
cac1 
cacophony 1 
(calcium channel 
α subunit) 
w
[1118] 
; + ; P{w[+mC]=UAS-
cac1-EGFP}786C  
Bloomington 
 
 
 
 
 
 
 
 
 
 
296 
 
10| Appendix 2 – QED 
Documentation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
297 
 
 
 
 
 
 
 
 
 
Quantitative Edge Detection 
Q E D 
 
http://go.warwick.ac.uk/qcaudron/qed 
 
 
 
 
 
 
 
 
Quentin CAUDRON 
q.caudron@warwick.ac.uk 
http://go.warwick.ac.uk/qcaudron 
 
 
 
 
 
 
Centre for Complexity Science 
The University of Warwick 
 
January 21, 2010 
298 
 
Contents  
 
1 Introduction  2 
1.1 About QED . . . . . . . . . . . . . . . . . . . . . . . . . . . . 
 2
1.2 Acknowledgements . . . . . . . . . . . . . . . . . . . . . . . .  2 
 
2 Installation  3 
2.1 First Installation . . . . . . . . . . . . . . . . . . . . . . . . .  3 
 
 
3 Running QED  4 
3.1 Image Preparation . . . . . . . . .  . . . . . . . . . . . . . . .   4 
3.2 Launching QED . . . . . . . . . . .  . . . . . . . . . . . . . . .   4 
3.3 Runtime Output . . . . . . . . . .  . . . . . . . . . . . . . . .   4 
    3.4 Selecting the Directory to Analyse .  . . . . . . . . . . . . . . .   4 
    3.5 Entering Genotypes . . . . . . . . .  . . . . . . . . . . . . . . .   4 
    3.6 Defining the Eye Region . . . . . .  . . . . . . . . . . . . . . .   5 
    3.7 Optimising the Edgeset . . . . . . .  . . . . . . . . . . . . . . .   5 
    3.8 Selecting the Image Genotype . . .  . . . . . . . . . . . . . . .   6 
    3.9 Collating Edgesets . . . . . . . . .  . . . . . . . . . . . . . . .   6 
 
 
4 Results  7 
4.1 Generated Files . . . . . . . . . . . . . . . . . . . . . . . . .  7  
4.2 Repeat Analyses . . . . . . . . . . . . . . . . . . . . . . . . .  7 
 
5 Code  8 
5.1 File Breakdown . . . . . . . . . . . . . . . . . . . . . . . . . .  8 
 
6 Help  9 
6.1 Contact Details . . . . . . . . . . . . . . . . . . . . . . . . . .  9 
 
 
 
 
 
 
 
 
 
 
 
 
1 
299 
 
1 Introduction  
 
Quantitative Edge Detection (QED) is a software package, written in Matlab, that 
assesses the extent of structural diferences in biomedical images. QED's  
website is located at http://go.warwick.ac.uk/qcaudron/qed.  
 
 
1.1  About QED  
 
This package is geared towards analysing phenotypic differences in Drosophila 
melanogaster eyes, caused by genetic manipulations such as the expression of Tau 
protein, or in the general use of fruit ﬂies as neurodegenerative disease models. 
QED uses implementations of the edge detection algorithms to extract information 
from images, namely the Marr-Hildreth and Sobel edge detectors. It accounts, to 
some extent, for the curvature of the eye by a perspective transformation and uses 
morphological operations on the resulting images to obtain connected edgesets - a 
pixel-thin net that defines the location of all edges (of a specific width) on the 
original image. From these edgesets, information is extracted and metrics are 
defined. Comparing these between genotypes with statistical tests leads to a 
quantitative evaluation of the difference between physical features of the two 
genotypes.  
 
 
1.2  Acknowledgements  
 
QED was written by Quentin Caudron, with contributions from John Aston of the 
Department of Statistics, and from Bruno Frenguelli, Kevin Moffat and Ceri Lyn-
Adams of the Department of Biological Sciences, all at the University of Warwick.  
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2 Installation  
 
QED can be downloaded, both in the form of a standalone Windows executable 
and of the source code. The Windows installer contains both the QED executable 
and the Matlab Component Runtime libraries (MCR). The MCR libraries are 
essential for the running of QED on your system, as they contain all of the 
functions required for QED to work if Matlab is not installed on your computer.  
 
 
2.1  First Installation  
 
The Windows installer is available for download on QED's website. Whilst the 
installer itself is less than 50 KB, please note that in order to maintain QED up-to-
date, all installation components are downloaded upon installation. You will 
therefore need an internet connection to install QED. Please note that this is a 
relatively large download (approximately 150 MB) and that installation of the 
MCR component may take some time. Once the MCR libraries have been 
installed, QED will be downloaded and installed into your Program Files directory.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3 
301 
 
3 Running QED  
 
 
3.1  Image Preparation  
 
QED will analyse the contents of a folder on your computer. This folder should 
contain only the images you wish to process, in greyscale .tif or  
.tiff format, and no other files or folders. You should copy images from  
both the control genotype and the genotype of interest into this folder. The  
more images present, the more accurate the results.  
 
 
3.2  Launching QED  
 
QED can be run from the Start Menu or Desktop shortcut. Because QED is written 
in Matlab and uses a large number of external runtime components, it may appear 
to run relatively slowly. Please be patient and only run the program once ! Whilst 
graphical elements are demanding on system resources, the information processing 
and analysis, once underway, is fast.  
 
 
3.3  Runtime Output  
 
A black terminal window will appear. This window is purely used for verbose 
output, and in fact, the vast majority can be ignored. Only in the case of a program 
crash should the contents of this window be studied.  
 
 
3.4  Selecting the Directory to Analyse  
 
When QED has loaded all of its functions, you will be prompted to select a folder 
to analyse. Browse through your system, select the relevant folder, and click OK.  
 
 
3.5  Entering Genotypes  
 
The first time a folder is processed, you will be asked to enter the names of the two 
genotypes. You should ideally enter plain text, though spaces, dashes and 
underscores are acceptable. Examples are, GMR, GMR-Tau or Control Eyes. 
Press OK when done.  
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3.6  Defining the Eye Region  
 
QED will begin processing images alphabetically. You are first told what the 
filename of the current image is, and asked to cut around the eye. This is done by 
clicking around the eye. Each time you click, a point is placed on the image. Points 
automatically connect to the last point, so you should click around the eye to draw 
a polygon, following the contour as closely as possible. Once you are finished, 
either click on the first point you placed to close the shape, or double-click while 
placing your final point.  
At this stage, all points can be moved by clicking and dragging them, and the 
entire shape can be moved by clicking in the middle of the polygon and dragging. 
You can delete a point by right-clicking on it and selecting Delete. If you wish to 
add a point, hover the mouse over the edge of the polygon and press the A key on 
your keyboard, and then click to insert a new point. Once you are satisfied with the 
cutout, double-click inside the shape to confirm your selection.  
 
 
3.7  Optimising the Edgeset  
 
Once you have defined the eye region, you will be shown the original image, 
alongside an edgeset. You can then modify two parameters and one setting in order 
to obtain a better edgeset.  
The first is the width of the Gaussian kernel, which defines the width of edges 
that are extracted from the image. As an example, a 650 x 650-pixel image, close-
cropped onto the eye of a wild-type ﬂy, may have edge widths between four and six 
pixels. The default value, in this case, is five pixels. The selected value must be in 
the correct edge width range, or the algorithm will begin to pick up features that are 
not true edges.  
The second parameter is the Sobel threshold. This defines how sharp changes 
in luminosity should be in order to be considered edges. The default, for the above 
image dimensions, is four. Lowering this tends to bring out more edges, but also 
more noise, whereas increasing it will break up edges. Because it is very important 
to have connected edgesets, this parameter should be set to remove as much noise 
as possible, but not be set so high as to begin breaking up edges. The lower bound 
for this threshold is zero, but  
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it does not necessarily have to take integer values. If extreme sensitivity is  
required, the Sobel threshold can be dropped to 0.001, for example. On the other 
end of the scale, if the edges are very well-defined, a higher threshold may be better, 
and can be increased to values in the tens or above.  
You can apply Contrast-Limited Adaptive Histogram Equalisation to the image, 
by using the checkbox below the parameter modification area. You will see the 
original image on the left change, such that contrast is enhanced. This is good if the 
original image contains a shadow, for example, but is not appropriate for all 
images. If you select this contrast enhancement, the luminosity values of the image 
will change, and the above parameters will thus need to be altered. The important 
parameter to modify, in the case of a contrast-adapted image, is the Sobel threshold, 
which should generally be increased to account for the increased contrast in the 
image.  
Modifying these parameters is possibly equal parts science and art, and will 
require a large amount of trial and error. For the example image dimensions listed 
above, it could be found that decreasing the Gaussian kernel width to four, and 
increasing the Sobel threshold to approximately fifteen, can provide an 
improvement on the default values, though these can often remain superior for a 
majority of images.  
If an adequate edgeset cannot be found, the option to reject the image exists. 
The image will simply be moved to another folder, an edgeset will not be 
generated, and QED will ignore its existence during the analysis.  
 
 
3.8  Selecting the Image Genotype  
 
After accepting the edgeset for an image, you will be asked to specify the genotype 
of that image, and will be presented with a list of the two genotypes you entered 
earlier. Make your selection, and click OK.  
 
 
3.9  Collating Edgesets  
 
Once all images in the directory have been processed, QED will gather all edgeset 
data into memory and begin extracting structural information from them. This 
information is used in the metrics that are used to compare between genotypes : 
roundness of ommatidia, distances between ommatidia  
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and angles between ommatidia around the centre of the eye. You are then  
presented with a results graph window, which is automatically saved in both  
.eps and .tif formats in the Results directory, created in the folder being  
analysed.  
 
 
 
4 Results  
 
 
4.1  Generated Files  
 
The graphs that appear on your screen show the dispersion coefficients for each 
metric. A dispersion coefficient is a measure of how wide a distribution is, and 
thus, the lower it is, the more regular and ordered a measure is. Dispersion 
coefficients are calculated for ommatidial roundness and for interommatidial 
distances and angles. For a control genotype, dispersion coefficients are expected 
to be small, as we expect hexagonal packing (60◦ and equal distances between 
ommatidia) of ommatidia, which should all be round. When ommatidia begin to 
fuse, they lose their roundness (they are now oval or more "blob"-shaped) and the 
regularity of the hexagonal lattice is reduced, leading to higher dispersion 
coefficients.  
Each graph shows two sets of points. Blue points are the first genotype, which 
should be your control. Points in red are from the second genotype. Each point 
represents the dispersion coefficient for a particular image, and the three graphs 
show these for the three different measures.  
Numerical results are also saved in the Results folder, as .csv files.  
Dispersion coefficients are saved in three files - one per metric - with the left  
column containing the first (control) genotype. Full results for metrics are also 
saved in the Results directory, under Raw Data.  
Images showing the progress of edge detection are also generated, in folders 
created for each image.  
 
 
4.2  Repeat Analyses  
 
If you wish to add or remove images, or simply attempt to improve an edgeset, you 
should be aware of the files created by QED. The folder you have just  
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analysed will now contain the following :  
• The .tif or .tiff images you placed there for analysis  
 
• A .qed file for each image, containing genotype and edgeset information  
 
• genotypes.qed, a file containing information regarding the genotypes  
being analysed  
 
• A Rejected folder, containing any images which had their edgesets  
rejected  
 
• A Results folder, containing numerical and graphical results from the  
analysis  
The second item in this list determines whether or not an image will be  
analysed. Any image in the directory without an associated .qed file will be  
analysed, and you will be prompted to create an edgeset for it. Any image  
with an associated .qed file will be analysed, but its edgeset will have been  
already created, allowing repeat analyses of a directory to be done much  
more rapidly. If you wish to recreate the edgeset for an image, simply delete  
its .qed file and rerun the program. Likewise, to add images to be analysed,  
simply copy the image into the directory along with the other images, and  
an edgeset will be created for it when you run QED. If you believe an image  
should not be being analysed, delete its .qed and move the .tif or .tiff  
into the Rejected folder.  
 
 
5 Code  
 
 
The code for QED is available for download on its website.  
 
 
5.1  File Breakdown  
 
• qed.m is the central file. It prompts for a directory and genotype in- 
formation, collates edgeset results, and calculates the metrics from the  
extracted information. It also computes the p-values from the Mann- 
Whitney test and generates the results plot as well as saving all results to file.  
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• qextract.m opens an image, prompts the user to cut out the eye region  
and opens the GUI for generating the edgeset. It applies the perspective  
transform to the edgeset and searches for boundaries.  
 
• QGUI.m is the functionality behind the edgeset creation. It defines the  
behaviour of buttons on the GUI.  
 
• qedgeset.m returns the edgesets from an image, given the Gaussian  
kernel width and Sobel threshold values.  
 
• qdispersion.m calculates a dispersion coefcient given a distribution.  
 
• qgauss2D.m computes the 2D derivates of a Gaussian.  
 
• qsurface.m generates a semiellipsoidal surface based on x and y di-  
mensions, with an empirically-defined curvature.  
 
• qresult.m generates CSV files containing results.  
 
• QGUI.fig contains information on what the GUI looks like.  
 
• itriu.m extracts half of a diagonal matrix.  
 
 
6 Help  
 
 
Please contact the author with any questions or queries.  
 
 
6.1  Contact Details  
Email:  q.caudron@warwick.ac.uk 
Address:   Quentin CAUDRON  
Centre for Complexity Science D2.05,  
Mathematics Institute  
University of Warwick  
Coventry, CV4 7AL  
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1. Sequencing pUAST.BRSK1 clones: 
 
a) Sense primer: 5’ TAGACGTCGTGGAGCTTGAG 3’ 
 
b) M (sequences over the mutation sites): 5’ CGCCATCCTGAAGCTCATAG 3’ 
 
c) Anti-sense primer: 5’ TGGTTCGGGAACTTCATCTC 3’ 
 
 
2. Sequencing pUAST.BRSK2 clones: 
 
a) Sense primer: 5‟ GGTAGGGCCCAACATACTGC 3‟ 
 
b) M (sequences over the mutation sites): 5’ TTCTTCCGGCAGATCATCTC 3’ 
 
c) Anti-sense primer: 5’ GTCACCTTCACCCTGCTCTC 3’ 
 
 
3. BRSK1 genotyping PCR primers (also used for sequencing the PCR 
products): 
 
a) Sense primer: 5‟ TGCTCCAGACTGAGCCTTTT 3‟ 
 
b) Anti-sense primer: 5‟ GTTCTTCCGCCAGATTGTGT 3‟ 
 
 
4. BRSK2 genotyping PCR primers: 
 
a) Sense primer: 5‟ CAGCAGCTTGTTGCGGTCTC 3‟ 
 
b) Anti-sense primer: 5‟ CGCCACCATGTACCCATACG 3‟ 
 
5. BRSK2 genotyping sequencing primer 
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a) Antisense primer: 5‟ TGTCAGGTGGTGAGCTCTTC 3‟ 
 
 
6. CaMKKα cloning primers (PCR primer pair)  
 
a) Sense primer: 5‟ TTCACCGTCATCACCGAAAC 3‟  
 
b) Anti-sense primer: 5‟ GAATTC GCC CTT GGA TTC GCC ACC ATG GAG 
                                   GGG GGT CCA GCT GT 3‟ 
 
 
7. pUAST.CaMKKα sequencing primers  
 
a) Sense primer: 5‟ CGCAGCTGAACAAGCTAAAC 3‟ 
 
b) Antisense primer: 5‟ CTGCTCCCATTCATCAGTTC 3‟  
 
 
8. LKB1 cloning primers (PCR primer pair) 
 
a) Sense primer:  
5‟ ATAAGAATGCGGCCGCTAAACTATCGCCCTTTCACTGCTGCTGT 3‟   
 
b) Anti-sense primer:  
5‟ CCGGAATTCCGGGCCCTTGGATCCGCCACCATGGAGGTGGACCCGCA 
3‟ 
 
 
9. pUAST.LKB1 sequencing primers  
 
a) Sense primer: 5‟ GCCGGTTCGTACTCAAGCATCC 3‟ 
 
b) Anti-sense primer: 5‟ GTTCATCCACCGCATCGACTCC 3‟ 
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10. pUAST.CG 6114 sequencing primers  
 
a) Sense primer: 5‟GTCACACCACAGAAGTAAGG 3‟ 
 
b) Anti-sense primer: 5‟ GCGATGTGTACGAGAACAAG 3‟ 
 
11. Tau genotyping PCR primers (also used for sequencing the PCR products) 
 
N terminal: 
 
a) Sense primer: 5‟ CAGAGCTGGGTGGTGTCTTTGG 3‟ 
 
b) Anti-sense primer: 5‟ AAGATCACGCTGGGACGTACGG 3‟ 
 
C terminal: 
 
c) Sense primer: 5‟ CCCGTGGTCTGTCTTGGCTTTG 3‟ 
 
d) Anti-sense primer: 5‟ AAGGTGGCAGTGGTCCGTACTC 3‟ 
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12.1 Genotyping tau flies by PCR and sequencing 
 
 
In this work, a number of Drosophila stocks transgenic for human tau isoforms 
which were generously donated form other laboratories were utilised.  There are six 
different isoforms of human tau, ranging from 352 to 441 amino acids in length, 
differing by the presence of three (3R tau) or four (4R tau) 31-35 amino acid C-
terminal repeats encoding microtubule binding domains combined with zero, one or 
two N-terminal inserts caused by alternative splicing of exons 2 and 3.  We had 
transgenic flies carrying the 0N3R, 0N4R, R406W, S2A and S262A isoforms and so 
I decided to genotype the tau stocks in order to confirm that the flies carried the 
stated isoform and/or mutations.  
 
This was done via PCR from genomic DNA using PCR primers 11 a) and 11 b) for 
the N-terminal and 11 c) and 11 d) for the C-terminal.  N-terminal primers were 
designed so that 0N isoforms would yield a 348bp fragment, 2N isoforms a 435bp 
fragment and 3N isoforms a 521bp fragment.  The C-terminal primers were 
positioned such that 3R tau would yield a 402bp fragment and 4R tau a 494bp 
fragment.   
 
It was possible to clearly genotype each tau stock from the PCR fragments (Figure 
12.1).  The S356A and/or S262A mutations in the S2A and S262A stocks were 
checked by direct sequencing of the PCR products (Figure 12.2) using primers 11 b) 
and 11 c). 
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Figure 12.1 Tau Fly genotyping PCRs 
Loading of genomic DNA: Lanes 1+6 – 0N3R.  Lanes 2+7 – 0N4R.  Lanes 3+8 – 
0N4R (R406W).  Lanes 4+9 – 0N4R (R406W S2A).  Lanes 5+10 – 0N4R (S262A).  
N-terminal primers were designed so that 0N isoforms would yield a 348bp fragment, 
2N isoforms a 435bp fragment and 3N isoforms a 521bp fragment.  The C-terminal 
primers were positioned such that 3R tau would yield a 402bp fragment and 4R tau a 
494bp fragment.   All of the N-terminal primers yielded a band of ~344bp and so all 
of the isoforms are 0N (lanes 1-5).  Lane 6 yielded a band of ~396bp with the C-
terminal primers and so this lane contains 3R tau.  Lanes 7-10 yielded bands of 
~500bp with the C-terminal primers and so these lanes contain 4R tau.     
 
 
 
 
 
 
 
 
 
 
 
314 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12.2 Genotyping tau flies  
Highlighted in red are the relevant nucleotides which form the codons for S262 and 
S356.  Both S2A and S262A tau carry a TCC to GCC (serine to alanine) mutation of 
the codon for S262.  S2A tau carries a TCC to GCT (serine to alanine) mutation of 
the codon for S356 whilst S262A tau is wild type for this codon. 
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12.2 Tau expression 
 
 
Having confirmed the genotypes of the flies, western blots were performed on lysates 
from flies expressing the 4R tau isoforms (3R was not included as it has not been 
used in this study) as described in the Methods section.  Densitometric quantification 
of the bands was performed using Scion image software.  Figure 12.3 shows that 
expression of S262A tau and R406W tau was significantly lower when compared to 
the control of 0N4R tau (normalised to actin) (n=3 2.91±0.14 for 0N4R tau, n=3 
1.94±0.06 for S262A tau and n=3 1.54±0.05 for R406W tau, p<0.01, Dunnett‟s 
multiple comparison test).  Unfortunately it was not possible to investigate the 
expression of the S2A flies as the stock became contaminated before the experiment 
could be completed.  However, it has been shown previously that the expression of 
tau in the S2A tau flies was not significantly different from that of the R406W tau 
flies (Nishimura et al., 2004).  
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Figure 12.3: Western blots for total tau (T46) and actin.   
Quantification of western blots from flies expressing 0N4R tau, S262A tau and 
R406W tau show that expression of tau was significantly lower in S262A tau and 
R406W tau flies than in the control 0N4R tau flies.   Mean ± SEM: 2.91±0.14 for 
0N4R tau (n=3), 1.94±0.06 for S262A tau (n=3) and 1.54±0.05 for R406W tau (n=3). 
** p<0.01, Dunnett’s multiple comparison test.  Representative western blots shown. 
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